Oncology Clinical Development
Ribociclib (LEE011)
Protocol CLEE011XUS29 / [STUDY_ID_REMOVED]  
TRINITI- 1: A Phase I/II, single arm , open -label study of 
Ribociclib in Combination w ith Ev erolimus + Exemestane 
in the Treatment of Men and P ostmenopausal Women w ith 
HR+, HER2 - Locally Advanced or Metastatic Breast Cancer 
Follow ing Progression on a CDK 4/6 Inhibitor
Triplet with R ibociclib, A fINitor® and AI posT CDK 4/6 Inhibitor
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]Authors
Document type Amend ed Protocol Version
Version number 03 (Clean )
Development phase I/II
Document status Final
Release date 15-Feb-2019

[COMPANY_001] Confidential Page 2
Amended Protocol v03 ( clean ) CLEE011XUS29
Table of contents
Table of contents ..................................................................................................................................... [ADDRESS_159897] cancer ........... 35
1.2 Introduction to investigational treatment(s) and other study treatment(s) ............................... 39
1.2.1 Overview of riboc iclib (LEE011) ......................................................................... 39
1.2.2 Summary of results from patients treated with the combination of ribociclib 
600 mg and letrozole 2.5 mg daily from study CLEE011A2301 
(MONALEES A-2)................................................................................................ 45
1.2.3 Overview of everolimus (RAD001/ Afinitor®) .................................................... 49
1.2.4 Overview of exemestane ....................................................................................... 52
1.2.5 Ribociclib in combination with everolimus .......................................................... 53
2 Rationale ............................................................................................................................................... 59
2.1 Study rationale and purpose .................................................................................................... 59
2.1.1 Rationale for Continuous Dosing -Phase I -Dose Escalation ................................ 60
2.1.2 Rational for stomatitis prevention mouthwash ..................................................... 62
2.2 Risks and benefits .................................................................................................................... 62
2.2.1 Potential benefits to clinical trial participation ..................................................... 63
2.2.2 Potential risks to clinical trial par ticipants ............................................................ 63
3 Study objectives and endpoints ............................................................................................................. 63
3.1 Objectives and related endpoints -Phase I ................................................................................ 63
3.2 Objectives and related endpoints -phase II ............................................................................... 64
4 Study design .......................................................................................................................................... 66
4.1 Description of study design ..................................................................................................... 66
4.1.1 Screening phase (Phase I and II) .......................................................................... 68
4.1.2 Treatment phase .................................................................................................... 69
4.1.3 Treatment discontinuation .................................................................................... 69
4.1.4 Safety  follow -up ................................................................................................... 69

[COMPANY_001] Confidential Page 3
Amended Protocol v03 ( clean ) CLEE011XUS29
4.2 Timing of interim analyses ...................................................................................................... 69
4.3 Definition of end of study........................................................................................................ 70
4.4 Early study termination ........................................................................................................... 70
5 Population ............................................................................................................................................. 70
5.1 Patient population .................................................................................................................... 70
5.1.1 Screening for Hepatitis B ...................................................................................... 71
5.1.2 Screening for Hepatitis C ...................................................................................... 71
5.2 Inclusion criteria ...................................................................................................................... 72
5.3 Exclusion criteria ..................................................................................................................... 74
6 Treatment .............................................................................................................................................. 77
6.1 Study treatment ........................................................................................................................ 77
6.1.1 Dosing regimen ..................................................................................................... 77
6.2 Dose escalation and de -escalation guidelines: Phase I Safety Run -in..................................... 78
6.2.1 Criteria for dose escalation and determination of MTD(s)/RP2D ........................ 79
6.2.2 Definitions of dose limiting toxicities (DLTs) ..................................................... 80
6.2.3 Follow up for dose limiting toxicities ................................................................... 81
6.2.4 Doses for Phase II ................................................................................................. 82
6.3 Overview of Dexamethasone oral solution ............................................................................. 83
6.4 Dose modification ................................................................................................................... 84
6.4.1 Dose cohort modification ..................................................................................... 84
6.4.2 Anticipated Risks and safety considerations of the study drug c ombination ........ 87
6.4.3 Dose modifications for ribociclib+everolimus+exemestane combination ............ [ADDRESS_159898] .............. 99
6.4.6 Guidance for all other adverse reactions ............................................................. 100
6.5 Concomitant medications ...................................................................................................... 101
6.5.1 Permitted concomitant therapy for all treatment groups ..................................... 101
6.5.2 Prohibited concomitant therapy du ring combined ribociclib + everolimus + 
exemestane .......................................................................................................... 102
6.5.3 Permitted concomitant therapy requiring caution and/or action while on 
study ................................................................................................................... 103
6.5.4 Drugs with QTc prolongation ............................................................................. 103
6.6 Patient numbering, treatment assignment or randomization ................................................. 104
6.6.1 Patient numbering ............................................................................................... 104
6.6.2 Treatment blinding ............................................................................................. 104
6.6.3 Study drug preparation and dispensation ............................................................ 104
6.6.4 Study drug packaging and labeling ..................................................................... 104
6.6.5 Drug supply and storage ..................................................................................... 105
6.6.6 Study drug compliance and accountability ......................................................... 105

[COMPANY_001] Confidential Page 4
Amended Protocol v03 ( clean ) CLEE011XUS29
6.6.[ADDRESS_159899] abnormalities ............................................................................. 132
8.2 Serious adverse events ........................................................................................................... 133
8.2.1 Definitions .......................................................................................................... 133
8.2.2 Reporting ............................................................................................................ 133
8.3 Pregnancy .............................................................................................................................. 134
8.4 Data Monitoring Committee .................................................................................................. 134
8.5 Steering committee ................................................................................................................ 135
9 Data collecti on and management ........................................................................................................ 135
9.1 Data confidentiality ............................................................................................................... 135
9.2 Site monitoring ...................................................................................................................... 135
9.3 Data collection ....................................................................................................................... 136
9.4 Data management and quality control ................................................................................... 136
10 Statistical methods and data analysis .................................................................................................. 137
10.1 Analysis sets .......................................................................................................................... 138
10.1.1 Full analysis set .................................................................................................. 138

[COMPANY_001] Confidential Page 5
Amended Protocol v03 ( clean ) CLEE011XUS29
10.1.2 Safety  set............................................................................................................ 138
10.1.3 DLT-determining analysis set ............................................................................. 138
10.1.4 Pharmacokinetic analysis set .............................................................................. 138
10.1.5 Per-protocol set ................................................................................................... 138
10.2 Patient demographics/other baseline characteristics ............................................................. 138
10.3 Treatments (study treatment, concomitant therapi[INVESTIGATOR_014], compliance) ....................................... 139
10.3.1 Study treatment ................................................................................................... 139
10.3.2 Concomitant therapi[INVESTIGATOR_014] ........................................................................................ 139
10.3.3 Compliance ......................................................................................................... 139
10.4 Statistical hypothesis, model, and method of analysis .......................................................... 139
10.4.1 Study Design ...................................................................................................... 139
10.4.2 Sample size and accrual ...................................................................................... 139
10.5 Objectives .............................................................................................................................. 140
10.5.1 Primary objectives .............................................................................................. 140
10.5.2 Secondary objective(s) ........................................................................................ 140
10.5.3 Pharmacokinetics ................................................................................................ 142
143
143
144
10.7 Interim analysis ..................................................................................................................... 145
11 Ethical considerations and administrative procedures ........................................................................ 145
11.1 Regulatory and ethical compliance ........................................................................................ 145
11.2 Responsibilities of the investigator and IRB/IEC/REB ......................................................... [ADDRESS_159900] keepi[INVESTIGATOR_140892] n of documents ....................................... 146
11.7 Confidentiality of study documents and patient records ....................................................... 147
11.8 Audits and inspections ........................................................................................................... 147
11.9 Financial disclosures ............................................................................................................. 147
12 Protocol adherence .............................................................................................................................. 147
12.1 Amendments to the protocol ................................................................................................. 147
13 References (available upon request) ................................................................................................... 147
14 Appendices .......................................................................................................................................... 154
14.1 Appendix 1 -Concomitant medication ................................................................................... 154
14.2 Appendix 2 - Guidelines for response, duration of overall response, TTF, TTP, 
progression -free survival and overall survival (based on RECIST 1.1) ................................ 157
14.2.1 Introduction ........................................................................................................ 158
14.2.2 Efficacy assessments .......................................................................................... 158

[COMPANY_001] Confidential Page 6
Amended Protocol v03 ( clean ) CLEE011XUS29
14.2.[ADDRESS_159901] overall response .......................................................................................... 167
14.2.18 Time to event variables ....................................................................................... 169
14.2.19 Progression -free survival .................................................................................... 169
14.2.20 Overall survival ................................
.................................................................. 169
14.2.21 Time to progression ............................................................................................ 169
14.2.22 Time to treatment failure .................................................................................... 170
14.2.23 Duration of response ........................................................................................... 170
14.2.24 Time to response ................................................................................................. 171
14.2.25 Definition of start and end dates for time to event variables .............................. 171
14.2.26 Handling of patients with non -measurable disease only at baseline ................... 172
14.2.27 Sensitivity analyses ............................................................................................. 173
14.2.28 Data handling and programming rules ................................................................ 175
14.2.29 Study/project specific decisions ......................................................................... [ADDRESS_159902] -treatment follow -up (study phase comp letion) ................................ 176
14.2.32 Medical validation of programmed overall lesion response ............................... 176
14.2.33 Programming rules ............................................................................................. 177
14.2.34 Calculation of ‘time to event’ variables .............................................................. [ADDRESS_159903] known date patient alive or d eath............................... 177
14.2.37 Non-target lesion response ................................................................................. 177
14.2.38 Study/project specifi c programming ................................................................... 177
14.2.39 Censoring reason ................................................................................................ 177
14.2.40 References (available upon request) ................................................................... 178

[COMPANY_001] Confidential Page 7
Amended Protocol v03 ( clean ) CLEE011XUS29
14.3 Appendix 3 - Bone Marrow Reserve in Adults ..................................................................... 179

[COMPANY_001] Confidential Page 8
Amended Protocol v03 ( clean ) CLEE011XUS29
List of tables
Table 1-[ADDRESS_159904] generation AIs in metastatic premenopausal BC patients .....37
Table 1-2 Serious adverse events with a suspected causal relationship with ribociclib 
single agent ........................................................................................................... 43
Table 1-3 Patient Demographic and baseline characteristics in study (CLEE011A2301) ....46
Table 1-4 Adverse events with suspected relationship to study treatment in study 
(CLEE011A2301) ................................................................................................. 47
Table 1-5 Pharmacokinetic Parameters of Ribociclib and Everolimus at Steady State 
(Cycle 1, Day 15) .................................................................................................. 55
Table 1-6 LEE011X2106: Adverse Events (All -grade greater than or equal to 15% in 
All Patients Receiving Triplet Therapy) Suspected to Be Related to 
Treatments ............................................................................................................ 56
Table 1-7 LEE011XUS29: Adverse Events (cohort A and B) Suspected to Be Related 
to Treatments ........................................................................................................ 58
Table 3-1 Objectives and related endpoints -Phase I ............................................................. 63
Table 3-2 Objectives and related endpoints -phase II ............................................................ 64
Table 6-1 Dose and treatment schedule for the following combination: ribociclib + 
everolimus +exemestane (Phase II) ...................................................................... 77
Table 6-2 Dose levels for ribociclib, everolimus and exemestane in Phase I dose 
escalation (cohort A and B) .................................................................................. 78
Table 6-3 Dose levels for ribociclib, everolimus and exemestane in Phase I dose de -
escalation (cohort C) ............................................................................................. 78
Table 6-4 Criteria for defining Dose Limiting Toxicities ..................................................... 80
Table 6-5 Phase I dose escalation (cohort A and B) and Phase II group 1: Dose 
modification guidelines for Ribociclib + everolimus + exemestane ..................... 85
Table 6-6 Phase I dose de- escalation (cohort C) and Phase II cohort 2: Dose 
modification guidelines for Ribociclib + everolimus + exemestane ..................... 85
Table 6-7 Dose modification guidelines for ribociclib (if everolimus is held longer than 
3 weeks for pneumonitis) ...................................................................................... 86
Table 6-8 Dose modifications and management recommendations for hematologic 
adverse reactions ................................................................................................... 87
Table 6-9 Ribociclib/everolimus dose modification and management for QTcF 
prolongation .......................................................................................................... 89
Table 6-10 Ribociclib/everolimus dose modification and management for cardiac 
dysfunction ........................................................................................................... 92
Table 6-11 Ribociclib/everolimus dose modification and management for hepatotoxicity ....[ADDRESS_159905] ....................................... 99
Table 6-15 Guidelines for management of hepatitis B ........................................................... 99
Table 6-16 Ribociclib/everolimus dose adjustment and management recommendation 
for all other adverse reactions ............................................................................. 100

[COMPANY_001] Confidential Page 9
Amended Protocol v03 ( clean ) CLEE011XUS29
Table 7-[ADDRESS_159906] of medications to be used with caution during study drug treatment .......... 155
Table 14-3 Response criteria for target lesions ..................................................................... 163
Table 14-4 Response criteria for non- target lesions .............................................................. 165
Table 14-5 Overall lesion response at each assessment ........................................................ 166
Table 14-6 Overall lesion response at e ach assessment: patients with non- target disease 
only ..................................................................................................................... 173
Table 14-7 Options for event dates used in PFS, TTP, duration of response ........................ 174
Table 14-8 Marrow distribution of the adult ......................................................................... 179

[COMPANY_001] Confidential Page 10
Amended Protocol v03 ( clean ) CLEE011XUS29
List of figures
Figure 1 -1 Kaplan -Meier plot of PFS based on Investigator assessment (Full Analysis 
Set)........................................................................................................................ [ADDRESS_159907] -
1 xenograft models ............................................................................................... 54
Figure 4 -1 Study design ......................................................................................................... 68

[COMPANY_001] Confidential Page 11
Amended Protocol v03 ( clean ) CLEE011XUS29
List of abbreviations
aBC
AEAdvanced Breast Cancer
Adverse Event
ALT Alanine aminotransferase/glutamic pyruvic transaminase /GPT
ANC Absolute Neutrophil Count
AST Aspartate aminotransferase/glutamic oxaloacetic transaminase/GOT
AUC Area Under the Curve
BC Breast Cancer
BCRP Breast Cancer Resistance Protein
IRC Independent Review Committee
BSEP Bile Salt Export Pump
BUN Blood Urea Nitrogen
CBR Clinical Benefit Rate
CCND1 Cyclin D1
CDK4/6 Cyclin -Dependent Kinases 4 and 6
Cmax Peak blood concentration
Cmin Minimum concentration
CR Complete Response
CRF Case Report/Record Form; the term CRF can be applied to either EDC or Paper
CRO Contract Research Organization
CSR Clinical study report
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DCR Disease Control Rate
DDI Drug -Drug Interaction
DILI Drug -Induced Liver Injury
DLT Dose Limiting Toxicity
DNA Deoxyribonucleic Acid
DOR Duration of Response
DS&E Drug Safety and Epi[INVESTIGATOR_140893] -Fixed, Paraffin -Embedded
FIH First-in-human
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GGT Gamma -glutamyl transferase
GI Gastrointestinal
HDL High Density Lipoprotein
HER2 Human Epi[INVESTIGATOR_14907] 2
HIV Human Immunodeficiency Virus

[COMPANY_001] Confidential Page 12
Amended Protocol v03 ( clean ) CLEE011XUS29
HR+ Hormone Receptor Positive
IB Investigator Brochure
IC50 Inhibitory Concentration, where 50% inhibition is observed
ICF Informed Consent Form
ICH International Conference on Harmonization
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IHC Immunohistochemistry
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
LDH Lactate Dehydrogenase
LDL Low Density Lipoprotein
LFT Liver Function Test
LLN Lower Limit of Normal
LLOQ Lower Limit of Quantification
LVEF Left Ventricular Ejection Fraction
MAP Master Analysis Plan documents project standards in the statistical methods which will be 
used within the individual clinical trial RAP documentation
MBC Metastatic Breast Cancer
MTD Maximum To lerated Dose
MUGA Multiple Gated Acquisition
NCRNPD Non-Complete Response Non -Progressive Disease
NSAI Nonsteroidal Aromatase Inhibitors
NSCLC Non-Small Cell Lung Cancer
ORR Overall Response Rate
OS Overall survival
PAS Pharmacokinetic Analysis Set
Pd Pharmacodynamics
PD Progressive Disease
PFS Progression free survival
P-gP Permeability -glycoprotein
PgR Progesterone receptor
PHI Protected Health Information
PK Pharmacokinetics
PPS Per Protocol Set
PR Partial Response
pRb Retinoblastoma Protein
PS Performance Status
PT Prothrombin time
QD Quaque Die (every day)
RAP Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
RDE Recommended dose of expansion

[COMPANY_001] Confidential Page 13
Amended Protocol v03 (clean) CLEE011XUS29
REB Research Ethics Board
RECIST Response Evaluation Criteria in Solid Tumors
R Value ALT/ALP in x ULNSAE Serious Adverse EventSC Steering Committee
SD Stable Disease
SEC Safety Event CategoriesSERM Selective ER ModulatorsS-ICF Study ICFSMT [COMPANY_001] Safety Management Team
SmPC Summary of Product Characteristics
S[LOCATION_003]R Suspected Unexpected Serious Adverse ReactionT1/2 The elimination half-life associated with the terminal slope (z) of a semi logarithmic 
concentration-time curve (time).
TBIL Total BilirubinULN Upper Limit of Normal
[COMPANY_001] Confidential Page 14
Amended Protocol v03 ( clean ) CLEE011XUS29
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, tissue, urine, 
stool, etc. taken from a study subject or study patient
Control drug A study treatment used as a comparator to reduce assessment bias, preserve blinding of 
investigational drug, assess internal study validity, and/or evaluate comparative effects of 
the investigational drug
Cohort A group of newly enrolled patients treated at a specific dose and regimen (i.e. treatment 
group) at the same time
Cycles Number and timing or recommended repetitions of therapy are usually expressed as 
number of days (e.g.: q28 days)
Dose level The dose of d rug given to the patient (total daily or weekly etc.)
Enrollment Point/time of patient entry into the study; the point at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Investigational 
drugThe study treatment whose properties are being tested in the study; this definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with “investigational new 
drug.”
Investigational 
treatmentDrug whose properties are being tested in the study as well as their associated placebo 
and active treatment controls (when applicable). This also includes approved drugs used 
outside of their indication/approved dosage, or that are tested in a fixed combination. 
Investigational treatment generally do es not include other study treatments administered 
as concomitant background therapy required or allowed by [CONTACT_140945]/dosage
Medication 
numberA unique identifier on the label of each study treatment package whic h is linked to one of 
the treatment groups of a study
Other study 
treatmentAny drug administered to the patient as part of the required study procedures that was not 
included in the investigational treatment
Subject Number A unique identifying number as signed to each patient/subject/healthy volunteer who 
enrolls in the study
Randomization 
numberA unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stage related to 
study timelin eA major subdivision of the study timeline; begins and ends with major study milestones 
such as enrollment, randomization, completion of treatment, etc.
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the tumor, 
whether lymph nodes contain cancer, and whether the cancer has spread from the original 
site to other parts of the body
Stop study 
participationPoint/time at which the patient came in for a final evaluation visit or when study treatment 
was discon tinued whichever is later
Study treatment Includes any drug or combination of drugs in any study arm administered to the patient 
(subject) as part of the required study procedures, including placebo and active drug run -
ins.
In specific examples, it is im portant to judge investigational treatment component 
relationship relative to a study treatment combination; study treatment in this case refers to 
the investigational and non -investigational treatments in combination.
Study treatment 
discontinuationPoint/time when a patient permanently discontinues study treatment for any reason
Supportive 
treatmentRefers to any treatment required by [CONTACT_140946] a study treatment, e.g. premedication 
of vitamin supplementation and corticosteroid for pemetrexed disodium.

[COMPANY_001] Confidential Page 15
Amended Protocol v03 ( clean ) CLEE011XUS29
Treatment group A treatment group defines the dose and regimen or the combination, and may consist of 1 
or more cohorts. Cohorts are not expanded, new cohorts are enrolled.
Variable Identifier used in the data analysis; derived directly or indirectly from data collected using 
specified assessments at specified time points
Withdrawal of 
Consent Withdrawal of consent occurs only when a patient does not want to participate in the study 
any longer, and does not want any further visits or asses sments, and does not want any 
further study related contact

[CONTACT_18619] 16
Amended Protocol v03 ( clean ) CLEE011XUS29
Amendment 3 
Study  CLEE011XUS29 (TRINITI- 1) was initiated in June 2016. As of 14-Nov-18, a total of 
104patients hav e been enrolled in the study  (25 patients in Phase I , 79 patients in Phase II).
The purpose of this amendment is to:
(i) Update the dose adjustment and management recommendations for QTcF prolongation.
Analy ses of preclinical and clinical data with ribociclib have demonstrated that ribociclib
prolongs the QT interval in a concentrat ion-dependent manner. Moreover, based on the
ribociclib exposure -ΔQTcF relationship and the clinical experience in studies CLEE011A2301 
(MONALEESA -2), CLEE011F2301 (MONALEESA -3) and CLEE011E2301 
(MONALEESA -7), ribociclib dose reduction is an effective strategy formanaging ribociclib 
therap y in patients experiencing QTcF prolongation. Therefore, inorder to reduce the risk of 
subsequent QTcF prolongation in patients experiencing a QTcF between 481-[ADDRESS_159908] occurrence of QTcF ≥ 481 
msec. As a result, this amendment includes an update to the dosage management guidance for 
patients who experience QTcF prolongation.
(ii) Update the prohibited concomitant medications based on drug-drug interactio n and 
comedication considerations.
(iii). Update End of Study  to be defined as 15months follow up from the last patient enrolled 
in the study
(iv). Minor additional updates as summarized below
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Section 4.1 and 6.2.4: RP2D for Phase II Group 2 was added
Section 4.1.3: Updated treatment discontinuation tofollow patients through 
progression or follow up for up to 15months after last patient enrolled in the study
Section 4.3: Updated definition of end of st
udy to follow up for at least [ADDRESS_159909] patient enrolled in the study
Section 4.4: updated the language regarding the reasons why the study  may be 
terminated early  by [CONTACT_140947]
Section 5.1: updated inclusion criteria to add estimated glomerular filtration rate
Section [IP_ADDRESS] and 6.5.2: updated to clarify  that herbal or dietary  supplements with a 
known risk of QT prolongation are not permitted
Section [IP_ADDRESS]: added to include guidance on use of antiemet ic medications

[COMPANY_001] Confidential Page 17
Amended Protocol v03 ( clean ) CLEE011XUS29
Section 6.5.3: clarified the information provided regarding renal transporters MATE1, 
OCT2 and BCRP.
Section [IP_ADDRESS]: added to include guidance on use of corticosteroids with caution
Section 7.1.5: updated language regarding actions needed when a patient withdraws 
their consent to participate in the trial
Section 7.1.7 and 7.1.8: updated to define end of follow up 
Table 6-4: updated with instructions on how to define hepato -biliary  criteria for Dose 
Limiting Toxicities
Table 6- 9: updated wit h instructions on how to manage QTcF prolongation
Table 14- 1: updated with the most current prohibited medications
Table 14-2: updated with the most current medications to be used with caution
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 18
Amended Protocol v03 ( clean ) CLEE011XUS29
Amendment 2
Amendment 2 rationale
Study  CLEE011XUS29 (TRINITI- 1) was initiated in June 2016. As of 22-May-17, a total of 
[ADDRESS_159910] been enrolled in the study  (18 patients in Phase I , 45 patients in Phase II). 
The current amendment is intended to update the trial design to remove th e Simon Two -Stage 
analysis of the phase II since cohort A, of Phase 1 demonstrated a CBR of 50% at 6 months in 
the patients that progressed on a CDK 4/6 inhibitor and a CBR of 100% at 6 months in those 
patients that were CDK 4/6 naïve (based on local assessment).  One interim analy sis was done 
after the completion of the phase I portion of this trial, and one final analysis will be done after 
the completion of the phase II portion. 
Additionally  this amendment will re-open the phase I portion of this trial to introduce a dose 
de-escalation in efforts to explore a new dosing regimen that would be safe and better tolerated 
with maximum exposure of everolimus. This will be referred to as Cohort C. Cohort C will be 
a 3+3 design to determine safet y and tolerabili ty. If proven safe and tolerable, an expansion 
phase will be added to phase II, referred toasGroup 2 to look at Clinical Benefit Rate at 24 
weeks. 
The current phase II expansion phase (300mg qd + 2.5mg qd +25mg qd, will be referred to as 
Group 1).
A sum mary  of the key  changes proposed in this amendment is listed below:
Removed the Simon Two-stage design from the phase II portion of this trial. 
oThe phase II will now move forward with a standard phase II design and analy sis.
oThe initial study  design required approximately  39 evaluable patients for this 
Phase of the study . Now retaining the same assumptions using a one
-sided alpha 
level of 0.05% to detect a power of at least 8 0%, a minimum of approximately 
60 evaluable patients are required for the study ,(30 evaluable patients per group, 
Group 1 & Group 2)
Phase II sample size increased to 60 evaluable patients. Accounting for 10% drop out 
rate, approximately  66 patients will be enrolled, (33 patients per group, group 1 & group 
2)
o8 or more patients need to show 
clinical benefit at 24 weeks for group 1 and 8 
patients in group 2 of the phase II part of this study  to be considered a success 
based on the statistical changes.
Removed the term “key ” from secondary  endpoints for the phase II portion of this trial
Inclusion criteria #15 was updated to allow any endocrine therapy  for up to 28 days 
prior to enrollment, rather than only allowing exemestane, so long as the patient does 
not progress on this therapy .

[COMPANY_001] Confidential Page 19
Amended Protocol v03 ( clean ) CLEE011XUS29
Exclusion Criteria #9 was updated to further clarify  drugs with overlappi[INVESTIGATOR_140894].
Exclusion Criteria #16 was updated to remove: “ Clinically  and radiographically  stable 
CNS tumor at the time of screening and not receiving steroids and/or enzyme inducing 
anti-epi[INVESTIGATOR_140895].” This change was based on supporting 
preclinical data demonstrating that ribociclib crosses the blood brain barrier.
Amendment 02 also includes minor editorial changes a nd additional clarifications to addre ss
investigators’ questions as described in the list of changes below.  
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underli ne for insertions.
The changes being made to the protocol due to this amendment are incorporated in the following 
sections:
Throughout the document: Language stating, or relating to the Simon Two-Stage design 
was removed.
Section [IP_ADDRESS].1: Safety  data fro m the interim analy sis of TRINITI -1 was added
Section 3.2: Removed the term “Key ” from Secondary  Endpoints so all Secondary 
endpoints are looked at equally .
Section 4.1: Updated to reflect new trial design
Figure 4.1: Updated to reflect new trial design
Section 5.2: Inclusion Criteria #15 was updated to allow any endocrine therapy  for up 
to 28 day s prior to enrollment, rather than onl y allowing exemestane.
Section 5.3: Exclusion Criteria #9 was updated to further clarify  drugs with overlappin g 
toxicities to include CDK 4/6 inhibitors and to better define the washout period.
Section 5.3: Exclusion Criteria #16 was updated to allow patient with clinically  and 
radiographically  unstable CNS tumor at the time of screening and not receiving steroids 
and/or enzy me inducing anti -epi[INVESTIGATOR_140895].
Section 5.3: Exclusion Criteria #25 was updated to exclude medication that cannot be 
discontinued within five half -lives.
Section 6.1: Updated to include cohort C treatment regimen. 
Table 6- 3: Added to explain dose de- escalation dosing levels.
Section 6.2.1: Updated to include dose de -escalation guidelines. 
Table 6- 4: Modified to explain dose escalation dose modifications.

[COMPANY_001] Confidential Page 20
Amended Protocol v03 ( clean ) CLEE011XUS29
Table 6- 5: Modified to explain dose de -escalation dose modifications.
Table 6-6: Updated to state: If toxicity  recurs at grade 3: temporary  dose interruption of 
ribociclib and everolimus until recovery  to grade ≤1 and reduce to the next lower dose 
level, or continue at same dose with growth -factor support at the discretion of the 
treating investigator .
Table 6-6: Modified to explain dose modifications if everolimus held more than 3 weeks.
Section 10.1.5: updated to state “A subset of Full Analy sis Set (FAS) excluding major 
protocol violations”.
Section 10.4.1: Updated to reflect new statistical analysis plan for the phase II portion 
of the trial.
Section 10.5.1: Updated to reflect new statistical analysis plan for the phase II portion 
of the trial.

[COMPANY_001] Confidential Page 21
Amended Protocol v03 ( clean ) CLEE011XUS29
Amendment 1 
Amendment 1 rationale
Study  CLEE011XUS29 (TRI NITI-1) was initiated i n June 2016. As of 4-Jan-17, a total of [ADDRESS_159911] been enrolled in the study . 
The current amendment is intended to update the existing information about ribociclib, clarify 
specific aspects of the original protocol and remove inclusion criteria nu mber 4 which required 
evaluation of total RB1. In addition the recommended phase II dose (RP2D) for this study  has 
been determined to be 300mg Ribociclib (daily ) + 2.5mg Everolimus (daily ) + 25mg 
Exemestane (daily ). 
A summary  of the key  changes proposed i n this amendment is listed below:
Ribociclib information was updated based on the data available in the current IB version 
(v10, release date: Oct -10-2016; safet y cut -off date: Jul-5-2016)
Detailed information from the pi[INVESTIGATOR_140896]011A2301 (MONALEESA -2) 
supporting the use of ribociclib + letrozole in aBC has been included to strengthen the 
study  rationale .
Remove inclusion criteria #4: Intact retinoblastoma protein (pRB). Confirmation of 
RB1status by  [CONTACT_140948] a CDK 4/[ADDRESS_159912] recent 
archival tissue should be tested for RB staining from metastatic site. This tissue sample 
should be tested locall y for RB1 status.
After c entral evaluation of total RB1of patients enrolled into the phase I , dose 
escalation portion on the trial, it was determined by  [CONTACT_5343], and the Steering 
Committee that the inclusion criteria could be removed.  
Amendment 01 also includes minor editorial changes a nd additional clarifications to address 
investigators’ questions as described in the list of changes below.  
Changes to the pro tocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions.
The changes being made to the protocol due to this amendment are incorpo rated in the following 
sections:
Throughout the document: Addition of language to refer to most recent version of the 
LEE011 Investigator’s  Brochure and minor text editorial changes
Throughout the document: Ty pographical and grammatical corrections

[COMPANY_001] Confidential Page 22
Amended Protocol v03 ( clean ) CLEE011XUS29
Throug hout the document: the term “randomization” was replaced with “start of/starting 
study  treatment” as this is an open label trial that is not randomized
Section 1.1.2: Updated to include data on clinical benefit of AIs in combination with 
ovarian function suppression (OFS) in premenopausal patients with breast cancer in 
neoadjuvant, adjuvant and advanced settings; Rationale for inclusion of male patients is 
further clarified.
Section [IP_ADDRESS] Updated based on new data from ongoing and completed trials with 
LEE011
Section 1.2.2: Added to provide CL EE011A2301 (MONALEESA -2) trial key  efficacy  
and safet y results of pre -planned interim anal ysis. 
Section 4.1: Updated to include the RP2D determined from the phase I dose escalation 
portion of the trial. ( 300mg riboci clib (daily ) + 2.5mg everolimus (daily ) + 25mg 
exemestane (dail y)
Section 5.2: I nclusion Criteria #4 was removed based on the finding from data generated 
in the phase I dose escalation portion of the trial
Section 5.2: I nclusion Criteria #[ADDRESS_159913] progressed on only  
one CDK 4/6 inhibitor
Section 5.2: I nclusion Criteria #12 was updated to define bone disease as “Evaluable 
disease”, for clarity
Section 5.2: I nclusion Criteria #13 w as updated to include 
alanine aminotransferase (ALT) 
limits
Section 5.3: Exclusion Criteria #8was updated to exclude patients who have progressed 
more than once on the same CDK 4/6 inhibitor
Section 5.3: Exclusion Criteria #2 5was updated to remove exclusion of the use of 
corticosteroids.
Table 6-1: Updated to remove the 1mg and 5mg doses of e verolimus as they  are not being 
used or provided. The size of the dexamethasone bottle (500mL ) was also added for 
clarity
Table 6- 2: Updated to provi de clarit y on what the dose levels of each cohort is
Section 6.2.1: Updated to state the RP2D to be used if unable to be determined in the 
phase I dose escalation
Section 6.2.4: Updated to state the RP2D for the phase II portion of this trial
Section 6.3: Updated for clarity  around dexamethasone use
Section 6.4: Updated language to clearl y state there are no dose reductions permitted for 
everolimus
Table 6- 4: Updated for clarity  and to state the RP2D for the phase II portion of this trial
Table 6- 11: Added consideration of using flovent for pneumonitis 
Section 8.4: Updated as there was/is no interim analy sis planed

[COMPANY_001] Confidential Page 23
Amended Protocol v03 ( clean ) CLEE011XUS29
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. 
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.

[COMPANY_001] Confidential Page 24
Amended Protocol v03 ( clean ) CLEE011XUS29
Synopsis
Title APhase I/II, single arm, open-label study  of Ribociclib in 
Combination with Everolimus + Exemestane in the Treatment of Men 
and Postmenopausal Womenwith HR+, HER2 Negative Locally 
Advanced or Metastatic Breast Cancer Following Progression on a 
CDK 4/6 Inhibitor
Sponsor and Clinical [COMPANY_001] -Region US
Phase Phase I run in followed by [CONTACT_140949]/Study T ype Drug/Interventional
Purpose To assess safety , tolerability and efficacy  of ribociclib+ everolimus + 
exemestane in patients that progressed on CDK4/6 inhibitor based 
therapy.
Number of Subjects Phase I: 9-24; Phase II :approximately 60 evaluable
Estimated time of Enrollment Phase 1: 4 months, Phase 2 :12 months 
Estimated Duration Estimated 30 months
Number of sites Approximately 30sites (total Phase I and II)
Rationale Hormone receptor -positive breast cancer is the most common form 
of breast cancer with endocrine therapy being the cornerstone of 
treatment. Unfortunately, endocrine resistance eventually develops 
resulting in the progression of disease and ultimately death forthese 
patients .Disruption of the phosphatidylinositol 3-kinase 
(PI3K)/mammalian target of rapam ycin (mTOR) pathway and cyclin 
D–CDK4/6 –INK4 –Rb pathway has been implicated in resistance to 
endocrine therapy and disease progression. Activation of this 
pathway can result in increased levels of CCND1 leading to 
upregulation of this pathway. Cyclin-dependent kinase (CDK) 4/[ADDRESS_159914] as it 
acts downstream of the PIK3CA/Protein Kinase B (AKT)/mTOR axis.
The addition of everolimus to exemestane significantly improves 
progression -free survival of patients with endocrine resistant HR+ 
HER2 -advanced breast cancer (Baselga J 2012 ) but eventually 
patients progress. Studies demonstrate that resistance to hormonal 
therapy, mTOR inhibition, and cytotoxic chemotherapy are at least in 
part mediated by [CONTACT_140950]4/[ADDRESS_159915] 
cancer, suggesting that there might be a role for CDK4/6 inhibition + 
mTOR inhibition in patients who have progressed on these therapi[INVESTIGATOR_014].
The effect of combining ribociclib with the mTORC1 -inhibitor 
everolimus (RAD001; Afinitor®) in the ER+, PIK3CA mutant MCF -7 
xenograft model was examined (RD-2013 -[ZIP_CODE]). While single 
agent treatments with ribociclib and everolimus resulted in modest 
tumor regressions of -9% and -21%, respectively, combination of 
ribociclib with everolimus increased tumor regressions to-49%. Data 
from in vivo studies showed that ribociclib, when combined with the 
mTOR inhibitor, everolimus (RAD001; Afinitor®),induced synergistic 
growth inhibitions in multiple tumor models, including cell lines 
derived from MCL, ER+ breast cancer, and M RT.

[COMPANY_001] Confidential Page 25
Amended Protocol v03 ( clean ) CLEE011XUS29
There is a role for continuing targeted therapi[INVESTIGATOR_140897], even beyond the point of disease progression. 
Everolimus appears to restore sensitivity to anti-estrogens by 
[CONTACT_140951]3K/Akt/mTOR pathway. 
Currently, there is no clinical data available that reports the efficacy 
of further treatments after prior CDK4/6 inhibitor failure, which 
represents an unmet medical need and requires further exploration. 
Potential reasons for progression on CDK4/6 inhibi tor include loss of 
the retinoblastoma protein (pRb) (the direct target of CDK4/6 
inhibitors), alterations in the estrogen receptor pathway as a 
consequence of endocrine therapy resistance, or activation of other 
signaling pathway s including the PI3K/AKT/m TOR pathway. The 
heterogeneity of the anticipated mechanism of resistance requires 
further exploration since some patients may still benefit from a 
sustained inhibition of the CDK4/[ADDRESS_159916] line therapy trials with 
CDK 4/6 inhibitors + aromatase inhibitors have suggested that some 
patients who discontinue therapy with the CDK 4/6 inhibitors develop 
an impressively rapid disease progression at initial imaging 
assessment to second line therapy. This lends the question of 
maintaining CDK 4/6 inhibition as a backbone therapy to keep the 
cell cycle arrested in G1 while adding mTOR inhibition to overcome 
resistance .
The CLEE011X2106 Phase -1b clinical trial tested a combination of 
exemestane + everolimus + ribociclib. The recommended dose for 
expansion was declared as exemestane 25 mgdaily, everolimus 2.5 
mg daily and ribociclib 300mg 3 weeks on/1 week off. This 
combination appeared to be safe and demonstrated clinical activity. 
Clinical activit y was seen in a heavily pre -treated population (median 
number of 4 prior therapi[INVESTIGATOR_014]) with 25.7% pts receiving prior 
PI3K/AKT/mTOR or CDK4/6 inhibitors for metastatic disease. The 
clinical benefit rate in these patients was 26% in 74 evaluable 
patients and disease control rate was noted to be 73%. Furthermore, 
there was a trend towards longer duration of treatment in the CCND1 
amplified group (n=10; median 166 days) than in the non-amplified 
group (n=22; median 60 days), something which was not appreciated 
with the treatment of everolimus + exemestane in BOLERO -2 (Bardia 
A 2015). PK analysis suggested that ribociclib increased dose -
dependent exposure of everolimus during the time that both 
everolimus + ribociclib were dosed concurrently (Bardia A 2014), 
howeve r, dose exposure of everolimus decreased during the week 
off of ribociclib therapy. By [CONTACT_140952] a lower and continuous 
dose when com bined with everolim us, both safety and efficacy  could 
potentially be improved by [CONTACT_140953] 4 and 6, while maximizing 
everolimus’ dose exposure. 
Thus, triplet combination of endocrine therapy with mTOR and 
CDK4/6 inhibition is tolerable, and shows prelim inary signs of clinical 
activity, including in patient s with prior exposure to PI3K/AKT/mTOR 

[COMPANY_001] Confidential Page 26
Amended Protocol v03 ( clean ) CLEE011XUS29
or CDK4/6 inhibitors, suggesting that triplet therapy could potentially 
overcome resistance to doublet therapy in a subset of patients. 
Therefore, this study  proposes to examine continuous dosing of 
ribociclib when administered concurrently with everolimus (Phase I) 
and to test whether the addition of everolimus + exem estane to 
ribociclib can reverse resistance to a CDK 4/6 inhibitor and ultimately 
improve the efficacy  of the approved combination regimen 
(everolimus + exemestane) in patients that progressed onCDK 4/6 
inhibitors (Phase II).
Phase I
Primary Objective(s) To determine theMaximum Tolerated Dose (MTD) and/or the 
Recommended Phase II dose (RP2D) for the triplet combination of 
ribociclib + everolimus + exemestane when administered 
continuously in subjects with HR+ HER2 -negative 
advanced /metastatic breast cancer
Secondary Objectives Characterize the safety and tolerability of the triplet combination of 
ribociclib + everolimus + exemestane when all drugs are 
administered continuously
Determine the PK profile ofthe combination of ribociclib + everolimus 
+ exemestane when administered continuously; evaluate the DDI 
potential (effect of ribociclib on the PK profile of everolimus)
Determine the overall response rate (ORR) by [CONTACT_393] 1.1 on 
treatment with combination of ribociclib + everolimus +exemestane 
when administered continuously
Phase II
Primary Objective(s) Determine the Clinical Benefit Rate (CBR) at 24 weeks among 
subjects receiving triple therapy with ribociclib +everolimus + 
exemestane for HR+, HER2 -negative, advanced/metastatic breast 
cancer following progression on CDK 4/6 inhibitor.
Secondary Objectives Secondary:
Progression Free Survival (PFS)
Overall Response Rate (ORR)
Duration o f overall response (DOR)
Overall Survival (OS)
Time to deterioration of ECOG performance status
Safety and tolerability
Determine the PK profile of ribociclib and everolimus when 
administered continuously.

[COMPANY_001] Confidential Page 27
Amended Protocol v03 ( clean ) CLEE011XUS29
 
Study design Phase I:
A Phase I dose escalation (cohort A and B) and dose de -escalation
(cohort C) will be initiated to ensure the safety and tolerability of
daily dosing of ribociclib + everolimus + exemestane in patients with
HR+,HER2 -negative advanced/metastatic breast cancer. Once the 
recommended Phase II dose is confirmed and safety and tolerabil ity 
are established, the trial will commence into a Phase II study. 
Phase II:
This portion of the trial will be an open label, Phase IIstudy to 
evaluate the antitumor activity  of the ribociclib + everolimus + 
exemestane combination in patients that have progressed on 
CDK4/6 inhibitor based therapy. 
Patients with advanced/metastatic HR+, HER2 -negative, breast
cancer will receive one of two RP2D determined by [CONTACT_7609] 1, both 
Group [ADDRESS_159917] progressed on a CDK 4/6 inhibitor. Prior CDK 4/6 inhibitor will 
be defined as disease progression while on, or within 30 days of 
discontinuing any CDK 4/6 inhibitor therapy (i.e. palbociclib, 
ribociclib, or abemaciclib).
Dose adjustment (reduction, interruption or dose re-escalation) 
according to safety findings will be allowed. Safety reviews by [CONTACT_140954] (IDMC) will be performed. 
Tumor assessments will be performed every [ADDRESS_159918] two cycles, then once per cycle from there 
on. The therapy on clinical trial will continue until disease progression 
(radiological), or intolerable adverse effects, or subject’s wish to 
withdraw consent. 
Follow up:
Subjects will be followed for safety until [ADDRESS_159919] dose of study treatment. 

[COMPANY_001] Confidential Page 28
Amended Protocol v03 ( clean ) CLEE011XUS29
Population For both Phase I and Phase II: Men and postmenopausal wom en 
with HR+, HER2 -negative, locally advanced or metastatic breast 
cancer whose disease is refractory  to at least one endocrine therapy. 
Refractory disease to endocrine therapy is defined as:
Recurrence while on, or within 12 months of end of 
adjuvant treatment with letroz ole, anastrozol e, tamoxifen, 
exemestane or fulvestrant
Progression while on, or within one month of end of 
letrozole, anastrozole, tamoxifen or fulvestrant treatment 
for locally advanced or metastatic breast cancer.
For Phase II only: Patients must have a documented recurrence or 
progression while on a CDK 4/6 inhibitor. Documented radiological
recurrence or progression on a CDK 4/6 inhibitor is defined as:
Remained on a CDK 4/6 inhibitor ≥ 4 months prior to 
disease progression, AND
Progressed while on or within 30 day s of discontinuing
treatment with a CDK 4/6 inhibitor, AND 
CDK 4/[ADDRESS_159920] treatment
regimen prior to starting study treatment.
*Note: Phase I does not require prior CDK 4/6 inhibitor exposure .
Key Inclusion criteria
(see protocol for detailed list)Patients eligible for inclusion in this study  have to meet all of the 
following criteria:
1.Adult men and women ( ≥18 years of age) with metastatic 
or locally advanced breast cancer not amenable to curative 
treatment by [CONTACT_140955].
2.Histological or cytological confirmation of hormone -
receptor positive (ER+ and/or PR+) breast cancer per local 
laborator y testing
3.Patient has HER2 -negative breast cancer (based on most 
recently analyzed biops y) defined as a negative in situ 
hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 
2+, a negative in situ hybridization (FISH, CISH, or SISH) 
test is required by [CONTACT_14978].
5.A representative tumor specimen must be available for 
molecular testing. Newly obtained t umor biopsy specimen is 
required if accessible prior to entr y on trial. If tissue is not 
accessible based on surgical evaluation, an archival tumor 
sample from metastatic site may  be submitted. 
6.Women must be postmenopausal. Postmenopausal status 
is define d either by: 
Amenorrhea for at least 12 months and both follicle -
stimulating hormone (FSH) and estradiol levels are in 
postmenopausal range (according to the local 
laborator y) OR
History of bilateral oophorectomy  (with or without 
hysterectom y) OR

[COMPANY_001] Confidential Page 29
Amended Protocol v03 ( clean ) CLEE011XUS29
History of partial hysterectomy  with FSH and /or
estradiol within post -menopausal range OR
Ovarian function suppressed with a GnRH agonists 
(negative HCG required) with estradiol levels in the 
postmenopausal range (according to the local 
laborator y)
7.Disease refract ory to either, AI, tamoxifen or fulvestrant 
defined as:
Recurrence while on, or within 12 months of end of 
adjuvant treatment with letrozole, anastrozole, 
exemestane, tamoxifen or fulvestrant OR
Progression while on, or within one month of 
discontinuing letrozole, anastrozole, tamoxifen or 
fulvestrant for the treatment of locally advanced or 
metastatic breast cancer.
*Note: There are no restrictions as to which endocrine therapy 
the patient sreceived as their last line of therapy just prior to 
study treat ment .
8.Patients who received up to [ADDRESS_159921] recovered to grade 1 or 
better from any adverse events (except alopecia and or 
neuropathy) related to previous therapy prior to starting 
study treatment .
* Note: If patient relapsed with documented evidence of 
progression on/or within 12 months from completion of 
adjuvant endocrine therapy, then this is considered one line of 
therapy
9.Patients previously treated on any CDK 4/6 inhibitor (i.e. 
ribociclib, abemaciclib OR palbociclib) must have:
Remained on treatment for ≥[ADDRESS_159922] cancer or metastatic disease prior to 
progression, AND
Progressed on, or within 30 days following the 
discontinuation of a CDK 4/6 inhibitor.
Phase II Only:
Patients must have progressed on only one CDK 4/6 
inhibitor. A CDK 4/[ADDRESS_159923] 
treatment prior to starting study treatment.
*Note: Phase Idoes not mandate prior CDK 4/6 inhibitor 
exposure .
**Note: For patients who received prior CDK4/[ADDRESS_159924] be unblinded in order to verify 
that the patient did receive a CDK4/6 inhibitor. 

[COMPANY_001] Confidential Page 30
Amended Protocol v03 ( clean ) CLEE011XUS29
10.ECOG Performance Status 0 – 1.
11.Radiological evidence of recurrence or progression on or 
after the last endocrine therapy prior to starting study 
treatment .
12.Patients must have:
Measurable disease: defined as at least one lesion 
that can be accurately measured in at least one 
dimension ≥20 mm with conventional imaging 
techniques or ≥[ADDRESS_159925] or MRI
OR
Evaluable disease: bone lesions -lytic or mixed (lytic + 
sclerotic) in the absence of measurable disease 
13.Patient has adequate bone marrow and organ function as 
defined by [CONTACT_140956] y values at 
screening: 
Absolute neutrophil count ≥1.5 × 109/L
Platelets ≥100 × 109/L 
Hemoglobin ≥ 9.0 g/dL 
Potassium within normal limits , total calcium 
(corrected for serum albumin), magnesium and 
sodium within normal limits as per local lab’s normal 
range or corrected to normal limits with supplements 
before first dose of study medicatio n 
INR ≤1.5 or ≤2.5 while on anti -coagulant
Serum creatinine <1.5 mg/dL or creatinine clearance 
≥50 mL/min 
Total bilirubin <ULN except for patients with Gilbert ’s 
syndrome who may only be included if the total 
bilirubin is ≤ 3.0 ×ULN or direct bilirubin ≤1.5 ×ULN.
Alanine aminotransferase (ALT) and a spartate 
transaminase (AST) <2.5 ×ULN, except for patients 
with liver metastasis, who are only included if the AST
and ALT are<5 ×ULN
14.Must be able to swallow ribociclib, everolimus and 
exemestane capsules/tablets
15.Patients with metastatic disease are allowed to receive 
≤28 days of endocrine therapy prior to starting study 
treatment 
Key Exclusion criteria
(see protocol for detailed list)Patients eligible for this study must notmeet any of the following 
criteria:
1.Patients with visceral crisis or any disease burden that 
makes the patient ineligible for this study per the 
investigator’s best judgment.
2.Patients who received more than one line of chemotherapy 
for advanced breast cancer.
3.HER2 overexpres sion by[CONTACT_14978] (IHC 3+ 
staining or in situ hybridization positive).

[COMPANY_001] Confidential Page 31
Amended Protocol v03 ( clean ) CLEE011XUS29
4.Patient has received prior treatment with anthracyclines at 
cumulative doses of 450 mg/m² or more for doxorubicin or 
900mg/m² or more for epi[INVESTIGATOR_14962].
5.Patient with a known hypersensitivity to any of the 
excipi[INVESTIGATOR_140898], mTOR inhibitors, e.g. sirolimus 
(rapam ycin), or exemestane.
6.Previous treatment with mTOR inhibitors
7.Previous treatment with exemestane for advanced disease 
(except patients who received ≤[ADDRESS_159926] cancer) 
8.Disease progression on more than one CDK 4/[ADDRESS_159927] progressed more than once on the same CDK 4/[ADDRESS_159928] 7 days
prior to study treatment (C1D1). Drugs with overlappi[INVESTIGATOR_140899] [ADDRESS_159929] resolved to CTCAE version 
4.03 Grade ≤1 prior to study treatment (including any CDK 
4/6 inhibitor).”
10.Patient has had major surgery within 14 days prior to 
starting study drug or has not recovered from major side 
effects due to surgery .
11.Patients with Child Pughscore B or C.
12.Active, bleeding diathesis, or on oral anti -vitamin K 
medication (except low dose warfarin, LMW H and 
acetylsalicylic acid or equivalent, as long as the INR is 
≤2.5 while on anti -coagulant). Fondaparinux is allowed.
13.Radiotherapy <[ADDRESS_159930] recovered from radiotherapy toxicities 
prior to starting study treatment , and recovered to grade 1 
or better from related side effects of such therapy (with the 
exception of alopecia). Radiotherapy is not allowed at 
target site following screening.
14.Another malignanc y within 3 years prior to starting study 
treatment , with the exception of adequately treated in- situ 
carcinoma of the cervix, uteri, basal or squamous cell skin 
carcinoma.
15.Patients with central n ervous sy stem (CNS) involvement 
unless they are at least 4 weeks out from prior therapy 
completion (including radiation and/or surger y) to starting 
the study treatment.
16.Patient has impairment of gastrointestinal (GI) function or 
GI disease that may  signifi cantly alter the absorption of the 
study drugs (e.g., ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption syndrome, or 
small bowel resection).
17.Patient has a known history of HIV infection (testing not 
mandatory) 

[COMPANY_001] Confidential Page 32
Amended Protocol v03 ( clean ) CLEE011XUS29
18.Patient has any oth er concurrent severe and/or 
uncontrolled medical condition that would, in the 
investigator’s judgment, cause unacceptable safety risks, 
contraindicate patient’s participation in the clinical study or 
comprom ise compliance with the protocol such as: 
chroni c pancreatitis 
active untreated or uncontrolled fungal, bacterial or 
viral infections, sepsis etc.
Uncontrolled diabetes as defined by [CONTACT_140957] >1.5 × ULN
Acute and chronic, active infectious disorders 
including viral and nonmalignant medical illnesses 
that are uncontrolled or whose control may  be 
jeopardized by [CONTACT_140958]
19.Fasting serum cholesterol >300 mg/dl or 7.75 mmol/L and 
fasting trigly cerides >2.5 × ULN. In case one or both of 
these thresholds are exceeded, the patient can only be 
included after initiation of statin therapy and when the 
above mentioned values have been achieved.
20.Significant sy mptomatic deterioration of lung function. If 
clinically indicated, pulmonary function tests including 
measures of pred icted lung volumes, DLco, O2 saturation 
at rest on room air should be considered to exclude 
restrictive pulmonary disease, pneumonitis or pulmonary 
infiltrates.
Clinically significant, uncontrolled heart disease 
and/or cardiac repolarization abnormality including 
any of the following :
History of angina pectoris, sy mptomatic pericarditis, 
coronary artery by[CONTACT_9292] (CABG) or m yocardial 
infarction within 6 months prior to study entr y
Documented cardiom yopathy
Left Ventricular Ejection Fraction (LVEF) < 50% as 
determined by [CONTACT_14982] (MUGA) 
scan or echocardiogram (ECHO) detected during 
screening
History of cardiac failure or significant/sy mptomatic 
bradycardia Long QT syndrome or family  histor y of 
idiopathic sudden death or congenital long Q T 
syndrome or any of the following:
Known risk to prolong the QT interval or induce 
Torsade’s de Pointes.
Uncorrected hypomagnesemia or hypokalemia
Systolic Blood Pressure (SBP) > 160mmHg or 
<90mmHg
Brady cardia (heart rate <[ADDRESS_159931]), by [CONTACT_140959].
On screening, inability to determine the QTcF interval 
on the ECG (i.e.: unreadable or not interpretable) or 

[COMPANY_001] Confidential Page 33
Amended Protocol v03 ( clean ) CLEE011XUS29
QTcF > 450msec for men and >470 msec for women 
(using Frederica’s correction). All as determined by 
[CONTACT_140960] (based on a mean of 3 ECGs).
21.Patient is currently receiving any of the following 
substances and cannot be discontinued 7 days prior to 
Cycle 1 Day 1:
That have a known risk to prolong the QT interval or 
induce Torsade’s de Pointes.
Known strong inducers or inhibitors of CYP3A4/5, 
including grapefruit, grapefruit hybrids, pummelos, 
star-fruit, and Seville oranges.
Medications that have a narrow therapeutic window 
and are predominantly metabolized through 
CYP3A4/5.
Herbal preparations/medications, (except for 
vitamins).
.
22.Not able to understand and to comply with study 
instructions and requirements .
23.Pregnant or nursing (lactating) women, where pregnancy  
is defined as the state of a female after conception and 
until the termination of gestation, confirmed by a positive 
hCG laboratory te st.
24.Sexually active males unless they use a condom during 
intercourse while taking drug and for 21 days after 
stoppi[INVESTIGATOR_140900] a child in this 
period. A condom is required to be used also by 
[CONTACT_140961].
Safety AssessmentsIncidence of Dose Limiting Toxicities (DLTs) in Cycle 1 
(Phase I only)
Adverse Events (AEs), serious AE (SAEs), changes in 
hematolog y and chemistry  values, vital signs, 
electrocardiograms (ECGs), dose interruptions, reductions 
and dose intensity 
Efficacy  Assessments CT/ MRI ever y [ADDRESS_159932]/guardian decision.
Brain CT or MRI as clinically indicated.
Whole bod y bone scan at screening and as clinical 
indicated
Bone x -ray, CT or MRI (if bon e lesion at screening) every [ADDRESS_159933] 12 m onths and then ever y 12 weeks 
thereafter until disease progression
Skin color photography (if skin lesions at screening) every 
[ADDRESS_159934] 12 months and then ever y 12 
weeks thereafter.

[COMPANY_001] Confidential Page 34
Amended Protocol v03 ( clean ) CLEE011XUS29
CT/MRI for any disease outside of the chest, abdomen, 
pelvis (if lesion identified at baseline) every [ADDRESS_159935] 12 months and then every 12 weeks thereafter.
Survival status
Other Assessments Pharmacokinetic: Ribociclib , everolimus and exemestane 
pharmacokinetic (PK) evaluations. PK parameters, including but not 
limited to AUC 0-6hrs, Cmax, Ctrough.
Investigational and reference 
therapyThe investigational or study drug refers to ribociclib. Investigational 
treatment/arm refers to the triple combination of ribociclib + 
everolimus + exemestane (R -E-E).
IDMC and SSC An Independent Data Monitoring Committee (IDMC) will be 
constituted. 
A Study Steering Committee (SSC) will also be constituted for 
overseeing the clinical trial
Dose, regimen Every 28 days will be considered one cycle. Everolimus, exem estane 
and ribociclib will be administered daily. 
Statistical methods Phase I:
The primary  purpose of the Phase I is to estimate the MTD(s) and/or 
identif y the RP2D of the combination treatment of ribociclib+ 
everolimus + exemestane when dosed continuously in adult men and 
postmenopausal women with HR+ HER 2-negative advanced breast 
cancer resistant to the non-steroidal aromatase inhibitors (letrozole 
or anastrozole), fulvestrant or tamoxifen. The corresponding primary 
endpoint is the incidence of DLTs in the first cycle.
Apatient isconsidered tohave metthe minimum exposure
requi rement ifhaving received at least 75% of the planned 
combination doses for allcompounds administered together (in the 
same day) for one cycle. The length of a c ycleis28days.
Phase II:
Open label, Phase II trial will evaluate the anti -tumor activity of 
exemestane, everolimus and ribociclib triplet. This part of the study 
will be continued after the MTD /RP2D is determined in the Phase I. 

[COMPANY_001] Confidential Page 35
Amended Protocol v03 ( clean ) CLEE011XUS29
A minimum of approximately 60evaluable patients (30per group
(group 1 , and group 2 ) are required for Phase II of this study to 
evaluate clinical benefit rate at [ADDRESS_159936] the null hypothesis H0: p ≤ 0.1 0, where p is the clinical benefit 
ratein 24 weeks.  If the true rate is p ≥ 30%, then with o ne-sided 
alpha level of 0.05% and a power of 80%, a minimum of 
approximately 30evaluable patients for each group are required for 
the study. Including dropout rate of 10%, to get at least 30 
evaluable patients, a total of approximately 33patients for eac h 
group (group 1 and group 2 )will be enrolled. 
If 8 or more patients show clinical benefit at 24 weeks then the null 
hypothesis will be rejected and significant clinical benefit will be 
demonstrated.  (See Section 10)
Details of the statistical analysis and data reporting will be provided 
in the RAP .
[ADDRESS_159937]
women inthe US in2015 ;excluding cancers oftheskin, breas t cance r is the most frequent ly 
diagnosed cancer inwomen. Anestimated 40,[ADDRESS_159938] cancer deaths (40,290 women) were
expected in 2015. Breast cancer rankssecond asacause of cancer death in women after
lung cancer (Cancer facts & figures 2015). Subty pes of BCareclassified by [CONTACT_140962] (ER), progesterone receptor (PgR), human epi[INVESTIGATOR_3506]
2(HER2) antigens aswell asb
y distinct geneexpression profiles (Perou et al 2000; Sotiriou 
and Pusztai 2009 ;Sotiriou and Pusztai 2009 ) andother features forprognostic andtreatm ent
purposes. Seventy percent ofinvasiv e breast cancers inwomen >45 ye ars of age , express
ERand/or PgR, but not HER2,and are termed hormone receptor positive (HR+, HER2- negativ e )
(Huang 2005 ).
1.1.[ADDRESS_159939] 
cancer
Expression oftheestrogen receptor (ER) and/or progesterone receptor (PgR) isone of the 
most important prognostic factors ininvasive breast cancer andisdetected inapproximatel y 
70% of cases. Estrogen deprivation therap yis thecore treatment modality inpatients with 
hormone receptor positive (HR+) advanced breast cancer. Endocrine thera py options for 
postmenopausal women with HR+ advanced breast cancer (local ly advanced, recurrent, or 
metastatic breast cancer) include selective estrogen receptor modulators (SERM ;tamoxifen), 
estrogen receptor antagonists (fulvestrant), selective nonsteroidal aromatase inhibitors (NSA I; 
anastrozole and letrozole) and steroidal aromatase inhibitors (exemestane). Tamoxifen is 

[COMPANY_001] Confidential Page 36
Amended Protocol v03 ( clean ) CLEE011XUS29
indicated for the treatment across the whole continuum of HR+ breast cancer in premenopausal 
women, ranging from risk reduction in women at high risk of developi[INVESTIGATOR_140901]. In postmenopausal women, aromatase inhibitors (AI) reduce
peripheral estrogen synthesis by [CONTACT_140963]-
ovarian tissues; s
ynthesis inthese tissues istheprimar y source ofestrogens inpostmenopausal
women. Aromatase inhibitors aregenerall y used asthefirst lineofthera py forwomen with
ER+ breast cance r (Beslija 2009, Cardoso 2011, NCCN Guidelines 2016 ). 
Despi[INVESTIGATOR_140902]+ advanced breast cancer, 
most eventuall ydevelop resistance to hormonal deprivation. One mechanism of endocrine 
resistance is aberrant signaling via phosphatid ylinosito l 3-kinase (PI3K)/Akt/mammalian target
ofrapam ycin(mTOR) (Burstein 2011, Johnston 2006, Schiff 2004). H yperactivation of 
PI3K/mTOR isobserved inendocrin e-resistant breast cancer cells, and treatment with mTOR 
inhibitors, including rapamyci
nanalogs, reverses this resistance (Miller 2010). Grow ing 
evidence alsosupport s
acloseinteractio n ofthemTO Rpathwa y with ERsignaling. S6kinas e-
1(S6K1), a substrate ofmTO RComplex 1(mTORC1), phosphor ylates theactivation domain
AF-1of theER,and stimulates ligand -independent activation of the recept or (Yamnik 2009; 
Yamnik 2010
;Yamnik 2010).
Everolimus isarapamycin derivative that inhibits mTORC1 through allosteric binding; it 
does notinhibit mTORC2 (Efey an 2010 ) . Intheclinic, everolimu s active incombination with 
exemestane inpatient s with ER+advanced breas t cance r resistan t to previou s hormona l 
deprivation thera py (BOLERO -2 study ; Baselga 2012 ;Baselga 2012 ).
Recentl y, the [LOCATION_002] Food and Drug Administration (FDA) approved palbociclib 
(Ibranc e®) incombination with letrozole for thetreatment of postmenopausal women with H R-
positive, HER2- negative advanced breast cancer as initial endocrin e-based thera py fortheir
metastati cdiseas e and fulvestrant in premenopausal, perimenopausal and postmenopausal 
women with AI refractory  HR+ HER2 -negative advanced breast cancer .Foradditional 
information, please refer to the Ibrance®Prescribing Information.
In premenopausal women who received a prior endocrine therapy  within 12 months, the 
preferred therapy  involves ovarian ablation or suppression + endocrine therap y -such as 
aromatase inhibitors (AIs) - as for post-menopausal patients. (NCCN Breast Cancer Guidelines, 
version 2.2016). 
Based on the clinical benefit shown in postmenopausal patients, AIs in combination with 
ovarian function suppression (OFS) have been investigated in premenopausal patients with 
breast cancer in neoadjuvant, adjuvant and advance d settings. Results from the randomized 
phase III trials SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and 
EXemestane Trial) showed that adjuvant treatment with exemestane+OFS as compared with 
tamoxifen+OFS, significantly  reduced recurre nce in premenopausal women with HR+ early 
breast cancer. Results from both trials (N=5,738) showed statisticall y significant differences in 
disease free survival (DFS) at 5 years (91.1% in exemestane + OFS vs 87.3% in tamoxifen + 
OFS) and rate of freedom f rom breast cancer at 5 years (92.8% in exemestane+OFS vs 88.8% 
in tamoxifen+OFS) (Pagani 2014 ).Studies exploring the combination of third generation AIs 

[COMPANY_001] Confidential Page 37
Amended Protocol v03 ( clean ) CLEE011XUS29
and goserelin in metastatic premenopausal BC patients are shown below in Table 1-1.
(Montagna 2013 )
Table [ADDRESS_159940] generation A Is in metastatic premenopausal BC 
patients
Study N AI+goserelin (G) ORR 
(CR+PR) (%)CB 
(CR+PR+SD) 
(%)TTP 
(months)First line 
endocrine 
therapy
Forward (2014) 16 Anastrozole+G 6.2 75 N/R No
Cheung (2010) 36
13Anastrozole+G
Exemestane+G*36
N/R67
3812
N/RYes
No
Carlson (2010) 35 Anastrozole+G 37 72 8.3 Yes
Park (2011) 35 Letrozole+G 46 77 9.5 Yes
[COMPANY_002] (2009) 52 Letrozole+G 21 71 10 Yes/No
Nishimura (2012) 33 Anastrozole+G [ADDRESS_159941] (2014) 37 Anastrozole+G 19 62 7.2 Yes/No
ORR=Objective response rate, CR=Complete response, PR=Partial response, CB=Clinical benefit, SD=Stable 
disease, PD=Progressive disease, TTP=Time to progression, N/R=Not reported
*In study by [CONTACT_14995], patients received treatment with exemestane after they received treatment with 
anastrozole.
Although data are limited (Montagna 2013), clinical benefit of the combination of AIs and OFS 
in premenopausal women with advanced ER+ breast cancer has been shown in small phase II 
studies with letrozole and anastrozole. In one study  (Cheung 2010 ), patients received 
exemestane, but only after they had received anastrozole, so the effect of single –agent 
exemestane has not been well characterized. Lastly , novel therapeutic approaches targeting 
promising pathway s should beexplored to further improve efficacy  in premenopausal women 
with advanced HR+ breast cancer.
Male breast cancer is rare, with less than 1% 
of all breast carcinomas occurring in men 
(Giordano 2005). The pathology  is similar to that of female breast cancer, and infiltrating ductal 
cancer is the most common tumor type. Male breast cancers have 
high rates of hormone -
receptor expression, with approximately  90% of male breast cancers expressing estrogen 
recept or, and 81% expressing progesterone receptor.
In general, the approach to the treatment of metastatic breast cancer is similar in male and 
female patients with breast cancer, with hormonal therap y being the often the first approach. 
Although, historically , surgical ablative therapi[INVESTIGATOR_140903], adrenalectom y, and 
hypophy sectomy  have been used effectivel y to control metastatic breast cancer in male patients, 
these surgical procedures are rarel y used toda y and have been supplanted b y additive hormonal 
therapi[INVESTIGATOR_014]. Tamoxifen has established effica cy in metastatic male breast cancer, with an 
approximate 50% response rate, and is considered an acceptable treatment option. Luteinizing 
hormone –releasing hormone agonists, with or without antiandrogens, have also been reported 
to be effective in male breast cancer. There have been case reports of responses to a wide variety 

[COMPANY_001] Confidential Page 38
Amended Protocol v03 ( clean ) CLEE011XUS29
of hormonal therapi[INVESTIGATOR_140904], androgens, steroids, aminoglutethamide, estrogens, 
and letrozole. 
Since the hormonal environment in male patients differs from that observed in female patients, 
the role of AIs in male patients may be different (Doyen, J 2010). In men, 80% of circulating 
estrogens are derived from peripheral aromatization of testicular and adrenal androgens , with 
direct production from the testes accounting for the remaining 20%. Studies in men patients had 
demonstrated that non
-steroidal AIs lead to a decrease in plasma E2 levels, but these levels can 
still be detectable in some patients, potentiall y becaus e of the baseline levels of peripheral 
androgens (with are subtracts for aromatization) and the testicular production of estrogens, 
which is not inhibited by [CONTACT_140964]. Additionall y, the use of NSAIs can be associated with 
feedback loop leading to increase of LH and FSH, which can lead of additional production of 
androgens, with increased availability  of subtracts for aromatization. All these elements 
converge to a suboptimal suppression of estrogen production in male patients submitted to 
treatment with monoth erapy AI, and create a rational for the combined use of these agents 
together with targeted therap y.
The use of aromatase inhibitors together with LHRH was studied as first-or second -line therapy 
for male patients with HR+ metastatic breast cancer (Giordano SH 2005); 19 patients were 
evaluated with promising results: 2 patients (10.5 %) had complete response, 7 patients (36.8 %) 
experienced a partial response, 7 patients (36.8 %) had stable disease last ing ≥6 months, and 3 
patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median 
progression
-free survival was 12.5 months (95 % CI 8.2–16.9), median overall survival was 
35.8 months (95 % CI 24.4–49.2), 1-and 2-year survival rates were 89.5 and 67 %, respectivel y. 
Safety  profile was expected and manageable, with no grade 3/[ADDRESS_159942] 
through thecyclin-dependent kinases 4 (CDK4 )and cyclin-dependent kinases 6 (CDK6 )
protein kinases topromote G1 progression (Musgrove 2011). CDK4 and CDK6, inturn,
h
yperphosphor ylateandactivate the retinoblastoma protein Rbto promote cell cycleentry and
cellproliferation. Consistent with their having an important role inhuman cancer, focal copy 
number abnormalities that result inincreased CDK activity are among themost commonly  
described mutations observed indiverse tumor types;these mutations include amplifications of 
thegenes thatencode cyclinD1or CDK4, and deletions affecting theCDKN2 locus, which 
encodes the p16INK4ainhibitor ofCDK activit y (Beroukhim 2010). I na mouse mode l ofHER2+
breast cancer, deletion ofeither theCCND1 orCDK4 gene prevented breast cancer formation 
(Yu 2006).
Data from TheCancer Genome Atlas highlight theimportance oftheCyclin/CDK/Rb pathway 
inluminal breast cancer (Beroukhim 2010). Abnormalities thatresult i nCDK activation are
highlyenriched intheluminal AandBmolecularly defined subgroups, ~85% of which were
ER+/HE R2−. Cy clinD1 amplifications wer e observed in29% and 58%of the luminal Aand
Bsubtypes,respectively, andCDK 4amplifications were observed in14% and 25% o fluminal

[COMPANY_001] Confidential Page 39
Amended Protocol v03 ( clean ) CLEE011XUS29
AandBsubtypes, respective ly. L uminal Asubtype tumors also haveloss of CDKN2 . The 
luminal subtypes also maintain expression of Rb (Beroukhim 2010 ), which would be essential 
for benefit from treatment with a CDK4/6 inhibitor.
Recent clinical datashowed thatinhibitors of CDK4/6 areactive inadvanced HR+ breast cancer.
Palbociclib isanoral, potent, selective inhibitor ofCDK4/6 that when used in combination with
thenon-steroidal aromatase inhibitor letrozole significantly  prolonged progression -free
surviva linpostmenopausal women with locally  recurrent oradvanced ER+, HER2− breast
cancer (Finn et 
al 2012, Finn et al 2015). Among patients with HR+, HER 2-negative metastatic
breast cance rwho had progression ofdisease during
prior endocrine thera py, palbociclib
combined with fulvestrant resulted insignificant longer progression- free survival than
fulvestrant alone (Turner et al 2015). These encouraging data warrant further clinical 
investigation ofCDK inhibitors inbreast 
and other cancers. Inanticipation of the imminent 
shift of treatment paradigms for HR+ HE R2-negative advanced breast cancer, additional stud y
in the post -CDK4/6 inhibitor settings would be valuable.
1.2 Intro
duction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of ribociclib (LEE011)
In the mammalian cell cycle, entry  into S phase is achieved by  [CONTACT_140965]4/6.Ribociclib is an orally 
bioavailable, highl y selective small molecule inhibitor ofCDK4/[ADDRESS_159943] s.Ribociclib may  therefore be an effective 
anti-cancer agent in a variety  of pRb-positive human neoplasms, especiall y in those that contain 
activated CDK4/[ADDRESS_159944] cancer patients; several other phase I or II clinical 
studies are being conducted and presented below.
[IP_ADDRESS] Pharmacology o
fribociclib (LEE011)
Ribociclib inhibits the CDK4/CCND1 and CDK6/cy clin-D3 enzyme complexes with
concentration resulting in 50% inhibition (IC50) values of 0.01 and 0.039 μMin biochemical
assay s, respectivel y. In Jeko-1 cells, the compound inhibits CDK4/6 -dependent pRb
phosphory lation with an average IC 50of 0.06 μM. Consistent with the observed inhib ition of
pRb phosphory lation, ribociclib also inhibited G1 to S phase cell cycle progression in Jeko-1
cells as judged by [CONTACT_140966] (BrdU) uptake (IC50of 0.1μM)and 
fluorescence activated cell sorting (FACS) analysis (half -maximal increase in cells in G1at 
0.11 μM).
The effect of ribociclib on pRb phosphory lation, BrdU uptake and cell cycle progression has
been assessed in more than [ADDRESS_159945] cancers. In pRb+ cell lines, ribociclib inhibits pRb phosphor ylation with a median 
IC50 value of 0.275 μM(range: 0.06 to 8.8μM). Similarly , ribociclib interferes with G1 to 

[COMPANY_001] Confidential Page 40
Amended Protocol v03 ( clean ) CLEE011XUS29
Sphase cell cycle progression in these cells as determine d by [CONTACT_140967] a median IC 50value of 0.[ADDRESS_159946] pRb.
[IP_ADDRESS].1 In vivo pharmacology
Ribociclib was well-tolerated in mice and rats with body  weight loss not exceeding 12.5% at
doses up to 250mgm
g/kg qd po or 150 mg/kg qd po, respectivel y, for up to 28 day s. However,
myelosuppression was observed and correlated with pRb phosphory lation inhibition. Treatment 
with ribociclib resulted in tumor regression in the Jeko-1 MCL  xenograft model atdoses greater 
than or equal to 75mg/kg, qd po. In vivo pharmacokinetics (PK)/pharmacody namics (PD) 
studies demonstrated dose-related inhibition of pRbphosphory lation in tumors, with continuous 
dosing over at least [ADDRESS_159947] s known to regulate D-cyclin levels, including inhibitors ofthe 
RAF/mitogen- activated protein kinase (MEK)/extracellular signal -regulated kinase (ERK), 
phosphoinositide 3- kinase (PIK3) and mTOR pathway s.
[IP_ADDRESS] Nonclinical pharmacokin etics (PK) and metabolism of LEE011 
(ribociclib)
The PK of ribociclib was investigated in mouse, rat, dog and monkey .Ribociclib showed high 
clearance (CL) in the mouse, rat, dog and monkey. The volume of distribution was large across 
species and the termi nal elimination half -life (T 1/2) was moderate in rodents and monkey (~2 to 
5 h) and longer in dog (18 h). Bioavailability  was low to moderate in rat (37%) andcynomolgus 
monkey (17%); moderate in mouse (65%) and dog (64%). Following oral administration, time 
to reach maximal plasma concentrations (Tmax)occurred between 2 to 4 h across species. Gender 
dependent toxicokinetics were observed inrats with higher exposure to ribociclib in males as 
compared to females and higher exposure to the metabolite, LEQ 803. Plasma protein binding 
was moderate in all species (unbound fraction (fu) in human: 30%).
In a  r at ADME (absorption, distribution, metabolism and excretion) study , extensive
distribution of [3H]L EE011 and its metabolites was observed. In pi[INVESTIGATOR_14922], radioactivity
was specificall y found in melanin -containing structures; the highest exposure to total
radiolabeled components was observed in ey e ciliary  body , eye choroid, meninges, tactile hair
and hair follicles. Radioactivity  was not detected in the brain. LEQ803 (N -demethy lation) was
a prominent metabolite found in mouse, rat, dog, monkey  and human hepatocy tes. This

[COMPANY_001] Confidential Page 41
Amended Protocol v03 ( clean ) CLEE011XUS29
metabolite retains some pharmacologic activity  and interacts with human Ether -a-go-goRelated 
Gene (hERG) channels in vitro.
Results from the ADME (male rats) study  showed that 3H-components were predominantly
excreted with bile (61.4% of dose). Minor urinary  excretion was observed (5.9% of dose after 
p.o.). The majority  of the administered dose (87.3%) was excreted within 24 h via urine, feces
(enteric secretion) and bile.
In vitro, ribociclib was a reversible inhibitor of cytochrome P450 (CYP) enzy mes CYP1A2,
CYP2E1 and CYP3A4 and a time-dependent inhibitor of CYP3A4. Ribociclib may inhibit
CYP3A4 under therapeutic conditions. No inductio n of CYP1A2, CYP2B6 or CYP3A4 was
observed. The in vitro inhibitory  potency  of ribociclib observed for the transporters organi c 
anion transporting polypeptide 1B1 (OATP1B1 ), breast cancer resistance protein (BCRP ), 
organic cation transporter 1 (OCT1), OCT2, multidrug and toxin extrusion protein 1 (MATE1 ), 
MATE2K and bile salt export pump (BSEP )may translate into clinically  relevant inhibition at 
therapeutic doses. Elimination of ribociclib is dominated by [CONTACT_14996]3A4 with a minor contribution by [CONTACT_14997] -containing monooxy genase 3 (FMO3). The 
elimination of ribociclib may be affected by [CONTACT_3252]-administered drugs that inhibit or induce 
CYP3A4. Although ribociclib is a substrate of the P -glycoprotein (P-gp) efflux transporter, this 
process is likely  not clinically  relevant due to the high passive permeability  of ribociclib.
[IP_ADDRESS] Safet ypharmacolo gy and toxicology ofribociclib (LEE011)
In vivo cardiac safet y studies demonstrated a signal for QT prolongation with the potential to
induce incidences of premature ventricular contractions (PVCs) at higher exposure levels.
The effects of ribociclib on the bone marrow (hypocellularity ), lymphoid system (lymphoid
depletion), intestinal mucosa (atrophy ), skin (atrophy ), bone (decreased bone formation) and
testes (atroph y) are considered to be related to the pharmacological inhibition of cellreplication 
in these tissues due to CDK4/[ADDRESS_159948] dose tested (20mg/kg/day ) and this effect could also be
related to the pharmacology  of ribociclib (arrest of estrous cy cle).
The liver, bile system and gall bladder (proliferative changes, cholestasis, sand -likegallbladder 
calculi and inspi[INVESTIGATOR_14919]) and the kidney  (concurrent degeneration and regeneration of 
tubular epi[INVESTIGATOR_1663]) were identified as additional target 
organs of toxicity  which are not 
likely  related to the primary  pharmacology  of ribociclib .
Inflammatory  changes in the lungs of dogs were considered secondary  to aspi[INVESTIGATOR_140905] -article in the respi[INVESTIGATOR_14921]. Correlating hematological and/or biochemistry  changes were seen for theeffects 
described in the bone marrow, l ymphoid s ystem and liver.
Generally  all changes demonstrated either reversibility  or a clear tendency  towards reversibility . 
Data from a rabbit embry ofetal development study , shows that ribociclib is teratogenic in the 
rabbit in the absence of maternal toxicity

[COMPANY_001] Confidential Page 42
Amended Protocol v03 ( clean ) CLEE011XUS29
Base d on itsmechanism ofaction and preclinical toxicology  studies, themajor potential 
toxicities forribociclib include myelosuppression, hepatic toxicit y,and prolongation of theQT 
interval. Theriskofthese toxicities may b
eamplifie d by [CONTACT_140968]3A4 or other combination treatments.
Please refer to (LEE011 Investigator’s Brochure )for additional details.
[IP_ADDRESS] Clinical experience with ribociclib (LEE011)
As of 5-July-2016, ribociclib is being investi gatedi n patients asa single agent in 3 phase I
studies ,in 1phase II study and incomb ination in 15 studies : 12 p hase Ib/I I studies and 3 
r
ando mizedphase III studies .Five studies were closed to enrol lment: (CLEE011A2201 ) , a 
randomized phase II study ; (CLEE011A2112C ) , a phase I dose finding study ; 
(CLEE011X2102
), a phase I study  in malignant rhabdoid tumors and neuroblastomas; and 
(CLEE011X2105) , a phase Ib/II study  in BRAF mutant melanoma; and (CLEE011X2201 ) , a 
phase II study  of relapsed refractory  unresectable teratoma. Ribociclib i s also being inv estigat ed
in2 clinical pharm acology s tudie s. Five clinical pharmacology  studies in healthy  patients have 
been completed .
Refer to latest edition of (LEE011 Investigator’s Brochure )for more details
.
[IP_ADDRESS].1 Clinical safety of ribociclib (LEE011) as single agent
As of 18-Sep-2015, [ADDRESS_159949]-in-
human (FIH) phase I study  (CLEE011X2101 ); [ADDRESS_159950] been treated in the initial dose 
escalation part for the 3 week on/1 week off regimen and 47 patients in the dose expansion part 
of the stud y; 19 patients were enrolled for the continuous dosing regimen with ribociclib and, 8 
patients were enrolled in the liquid formulation cohort.
Patients with advance d solid tumors or lymphomas were treated with increasing doses of 
ribociclib orally, once daily  (qd) for [ADDRESS_159951] (28-day cycle). Doses 
ranging from 50 mg to 1200 mg were evaluated on this schedule. Treatment 
has been 
discontinued in 127 (95%) patients; the primary reasons for treatment discontinuation were: 
disease progression (111 [83%] patients); adverse events (AEs) (9 [7%] patients); death (1.5%] 
patients); withdrawal of consent (4 [3%] patient); and loss to follow up (1 [1%] p atient).
The most frequentl y reported AEs ( ≥10%), regardless of grade, causality  and ribociclib dose 
Were(50mg -1200mg) : nausea (51.5%); fatigue (42.5%); diarrhea (36.6%); vomiting (35.8 %); 
neutropenia (35.1%);  anemia  (33.6%);  decreased  appetite  (23.1%);  constipation  (22.4%);  
leukopenia (21.6   %);   dyspnea   (20.1%);   asthenia   
(19.4%);  cough   (17.9%);   headache   
(17.9%); 
hypergly cemia and hy poalbuminemia (17.2% for each); AST increase, electrocardiogram 
QT prolongation (15.7% for each) ; abdominal pain (14.9%); lymphopenia (14.9%); blood 
creatinine increased, dizziness, pyrexia (14.2% foreach); neutrophil count decreased , 
peripheral edema (13.4 %); ALT increase (12.7%); Pain in extremity  (11.9%); hypocalcemia 
(11.2%) and blood alkaline phosphatase increase (10.4%).

[COMPANY_001] Confidential Page 43
Amended Protocol v03 ( clean ) CLEE011XUS29
For either continuous or intermittent dosing, the onset of neutropenia (most frequently  Grade 
2) occurs by [CONTACT_140969] y 15, reaching a nadir in the third or fourth week with recovery during the week 
of drug holiday for the three weeks on/one week off schedule . Some patients require additional 
time for recovery  (7 to 14 days). QT changes become evident in the first cycle by [CONTACT_2006] 8 and 
later (once steady  state is reached), are associated with the maximum drug levels between [ADDRESS_159952] been no deaths related to study  drug reported on study  (CLEE011X2101 ).The 
following serious adverse events shown in Table 1-2have been reported with a suspected causal 
relationship in study  
(CLEE011X2101 )as of 18-Sep-2015. For a complete list of AEs, all 
grades and Grade 3/4 that are suspected to be related to ribociclib refer to the (LEE011 
Investigator’s Brochure )
.
Table 1-[ADDRESS_159953] occurred with ribociclib ( single agent)
System Organ Class Preferred Term Preferred Term
Blood and lymphatic system disorders Anemia, Febrile neutropenia,
Neutropenia,Thrombocytopenia
Gastrointestinal disorders Diarrhea, Nausea , Pancreatitis
General disorders and administration site conditions Generalized edema
Infections and infestations Herpes simplex
Investigations Blood creatinine increased, Electrocardiogram QT 
prolonged
Events in italic font indicate those events which are newly included since the previous edition of the reference 
safety information.
[IP_ADDRESS].2 Clinical efficacy with ribociclib as si ngle agent
Preliminary  anti- tumor activity  of ribociclib from trial ( CLEE011X2101 )was assessed across 
all dose levels (50 mg –1200 mg). Out of 134 evaluable patients as of 18 -Sep- 2015, 4 partial 
responses were ob
served at the 600 mg dose level; one each in BRAF/NRAS wild ty pe with 
CCND1 amplified melanoma, and head and neck acinar carcinoma with CDKN2A loss (both 
on the 3 weeks on/1 week off regimen), and ER+/HER2- , PIK3CA mutant, CCND1 amplified 
breast cancer (on the continuous daily  dosing regimen). Stable disease (SD) was the best 
overall response in 47 (35%) patients. Enrollment in this study  is completed. Stable disease ≥4 
cycles and ≥6 cy cles was observed in 30 (22%) and 21 (16%) patients, respectivel y. Six 
patients with SD ≥4 cy cles received treatment for >1 y ear, of these 2 patients were on study  
for >2 years (Infante, JR ASCO [ADDRESS_159954] 2528 ).
R
eferto(LEE011 Investigator’s Brochure ) for more deta ils.
[IP_ADDRESS].3 Clinical Experienc e with Continuous Dosing of Ribociclib In Combination
CLEE011X2108 study  is anongoing Phase Ib/II study  of ribociclib in combination with 
fulvestrant and alpelisib or buparlisib in postmenopausal women with hormone receptor 

[COMPANY_001] Confidential Page 44
Amended Protocol v03 ( clean ) CLEE011XUS29
positive, HER2 negative, locally  recurrent or advanced metastatic breast cancer. Patients were 
enrolled to one of the following dose combinations: (1) ribociclib (600 mg) +fulvestrant 
(500 mg), n=13, (2) ribociclib (400 mg) [continuous] + fulvestrant (500 mg), n=9, (3)ribociclib 
(
200mg) + alpelisib ( 200 mg) + fulvestrant (500 mg), n=3, (4) ribociclib (400 mg) + alpelisib 
(150 mg) + fulvestrant (500 mg), n=6, (5) ribociclib (400 mg) + alpelisib (200 mg mg ) + 
fulvestrant (500 mg), n=9, (6) ribociclib (400 mg) + buparlisib (30 mg) + fulvestrant (500 mg), 
n=9, (7) ribociclib (400 mg) + buparlisib (40mg) + fulvestrant (500 mg), n=6, (8) ribociclib 
(600 mg) + buparlisib (30mg) + fulvestrant (500 mg), n=8. In the cohort with continuous 
ribociclib dosing at 400mg (n = 9), one DLT was reported, a Grade [ADDRESS_159955] 
frequentl y reported (≥10%) adverse events suspected to be related to study  drug in the 
continuous ribociclib dosing cohort were: nausea (55.6%), neutropenia (44.4%), fatigue 
(33.3%), diarrhea, ALT increase, stomatitis, headache (22.2%), AST increase, decreased 
appetite, rash, vomiting, and pruritus (11.1%), Grade 3/4 adverse events in this group were 
neutropenia (22.2%) an d AST increase (11.1%).
[IP_ADDRESS].4 Clinical pharmacokinetics of ribociclib (LEE011)
Asof18-Sep -2015 preliminary  PKdata were available from approximately 153patients from 
theFIHstudy CLEE011X2101 across thedose range of 50 to1200 mg. Following oral dosing, 
ribociclib was rapi[INVESTIGATOR_2478] y absorbed with median Tmaxranging from 1to4 h. Ribociclib plasma 
exposure exhibited slightly ove
r-proportional increases in exposure.
Stead y-state wasgenerally reached by [CONTACT_2006] 8andthemean effective T1/2based on accumulation
ratio (i.e., T1/2,acc) ranged from 12.0 to33.1 h.Theaccumulation ratio based on area under 
the curve ( AUC )obtained in a dosing interval (Racc) ranged from 1.[ADDRESS_159956] study  CLEE011A2111 in 24 healthy  subjects, asingle dose of ribociclib (600 
mg) was administered as drug-in-capsule (DiC) with a high-fat, high-
calorie meal and under 
fasted conditions. Compared to the fasted state, oral administration of a single 600 mg dose of 
ribociclib DiC with a high -fat, high-calorie meal decreased the rate of absorption of ribociclib 
resulting in a 23% decrease in Cmax (geometric mean ratio: 0.775; 90% confidence interval 
[CI]: 0.700, 0.858) and a median difference in Tmax of [ADDRESS_159957] 
on the extent of absorption of ribociclib as the overall exposure (AUCinf) was unaffected under 
fed conditions (geometric mean ratio: 0.994; 90% CI: 0.925, 1.070). A similar trend was 
observed for LEQ803, an active metabolite of ribociclib, with a decrease in Cmax (32% ), a 
delay  in median Tmax, and no substantial effect on overall exposure. Based on these data, 
ribociclib DiC can be taken without regard to meals.
In the human ADME study  CLEE011A2102 , a single oral dose of 600 mg [14C] LEE011 was 
administered to 6 health y male subjects. The majority of the administered dose was excreted in 
feces (69.1%), with a minor amount excreted in urine (22.6%). Absorption was estimated to be 
approximately  58.8%. Ribociclib accounted for approximately 23% of the total radioactivity i n 
plasma, based on AUCinf. Metabolites M1 (glucuronidation of M15), M4 (LEQ803, N-
demethy lation) and M13 (CCI284, N- hydroxylation) were the most abundant metabolites in 
plasma, representing an estimated 7.78%, 8.60% and 9.39% of total [14C]AUC0 -48h, and 17.9%, 
19.8% and 21.6% of ribociclib AUC0 -
48h, based on metabolite profiles.

[COMPANY_001] Confidential Page 45
Amended Protocol v03 ( clean ) CLEE011XUS29
A drug-drug interaction (DDI) study  with ritonavir (a strong CYP3A4 inhibitor) and rifampi[INVESTIGATOR_2513] 
(a strong CYP3A4 inducer) was conducted in 48 healthy  subjects (CLEE011A2101 ) . Compared 
to ribociclib alone, ritonavir (100 mg bid for 14days) increased ribociclib Cmax and AUCinf 
by 1.7-fold and 3.[ADDRESS_159958] 
for LEQ803 decreased by 96% and 98%, respectively . These results demonstrated 
that concurrent use of strong CYP3A4 inhibitors may markedl y increase ribociclib exposure 
and are prohibited.
Compared to ribociclib alone, rifampi[INVESTIGATOR_2513] (600 mg daily for 14 days) decreased ribociclib Cmax 
and AUCinf by  81% and 89%, respectivel y, following a single oral dose of 600 mg ribociclib. 
LEQ803 Cmax increased 1.7-fold and AUCinf decreased by 27%, respectively . These results 
demonstrated that concurrent use of strong CYP3A4 inducers may markedly  decrease ribociclib 
exposure and are prohibited.
A DDI cocktail stud y wit h midazolam (a sensitive CYP3A4 substrate) and caffeine (a sensitive 
CYP1A2 substrate) conducted in 25 healthy subjects (CLEE011A2106 )indicated that 
ribociclib (400 mg) is a moderate inhibitor of CYP3A4, but did not have a substantial effect on 
CYP1A2 substrates in humans . PK data indicated that compared to midazolam and caffeine 
alone, multiple doses of ribocic lib (400 mg qd for 8 days) increased midazolam Cmax and 
AUCinf by 2.1-fold and 3.8-fold, respectivel y. The effect of multiple doses of ribociclib on 
caffeine was minimal, with Cmax decreased by [CONTACT_3450]  10% and AUCinf increased 
slightly  by 20%. Based on these data, ribociclib (400 mg) is a moderate CYP3A4 inhibitor (≥ 
2-fold but < 5-fold increase in AUC). Concurrent use of sensitive CYP3A4 substrates with a 
narrow therapeutic index is prohibited.
Ribociclib (400 mg) did 
not have a substantial effect on CYP1A2 in humans; therefore 
concurrent use of CYP1A2 substrates is not expected to lead to clinicall y significant DDIs.
Refer to the 
(LEE011 Investigator’s Brochure ) for more details.
1.2.2 Summary  of result s from patients treated with the combination of 
ribociclib 600 mg and letrozole 2.5 mg daily from study CLEE011A 2301 
(MONA LEESA -2) 
MONALEESA -2 – (CLEE011A2301); a randomized, double blind, placebo controlled, 
multicenter global Phase III trial evaluate dthe safety  and efficacy  of ribociclib in combination 
with letrozole compared to letrozole alone in postmenopausal women with HR+/HER2- aBC 
who received no prior therapy for their advanced disease. See Table 1-3.
The study  met its primary  objective at the pre-planned interim analy sis; ribociclib in 
combination with letrozole demonstrated statistically  significant benefit over placebo in 
combination with letrozole in prolonging PFS based on Investigator assessment. Clinical 
benefit was evident relative to placebo plus letrozole with a 44.4% estimated risk reduction in 
the primary  PFS endpoint as per Investigator assessment (HR=0.556, 95% CI: 0.429, 0.720; 
p=3.29×10-
6).
Six hundred, sixty  eight patients were randomized; 334 patients each to the ribociclib plus 
letrozole arm and the placebo plus letrozole arm. The median study  follow -up was 15.3 months, 

[COMPANY_001] Confidential Page 46
Amended Protocol v03 ( clean ) CLEE011XUS29
as of the 29-Jan-2016 data cut-off date, and the proportion of patients continuing to receive 
treatment in the ribociclib plus letrozole arm was higher than in placebo plus letrozole arm (58.4% 
vs 46.1%, respectivel y). Disease progression was the primary  reason for treatment 
discontinuation and was more frequent in the placebo plus letrozole arm compared to the 
ribociclib plus letrozole arm (43.7% vs. 26%). Adverse events led to the discontinuation of 
study  treatment in 32 patients (4.8%): 25 patients (7.5%) in ribociclib plus letrozole arm and 7 
patients (2.1%) in placebo plus letrozole arm.
The median age of patients was 62 years (range: 23-91) and 44.2% were ≥ 65 years old. The 
majority  of the patients were Caucasian (82.2%). All patients had ECOG performance status of 
either [ADDRESS_159959] (34.0%) of the patients in this study  were de novo
metastatic breast cancer patients. Nearl y two-thirds (58.8%) of patients had visceral disease 
(19.8% with liver and 45.4% with lung involvement) and 22.0% had bone only metastases at 
study  entry . All except four patients had stage IV disease at the time of st udy entry (other four 
had stage III disease). One- third (34.0%) of the patients had ≥ 3 metastatic sites.
Table 1-3 Patient Demographic and baseline characteristics in study  
(CLEE011A 2301)
CharacteristicRibociclib + Letrozole
n=334Placebo + Letrozole
n=334
Median age, years (range) 62 (23 –91) 63 (29 –88)
Race, n (%)
Caucasian 269 (80.5) 280 (83.8)
Asian 28 (8.4) 23 (6.9)
Black 10 (3.0) 7 (2.1)
Other/unknown 27 (8.1) 24 (7.2)
ECOG performance status, n (%)
0 205 (61.4) 202 (60.5)
1 129 (38.6) 132 (39.5)
Metastatic sites, n (%)
Visceral disease (lung and/or liver metastases) 197 (59.0) 196 (58.7)
Bone -only disease 69 (20.7) 78 (23.4)
De novo metastatic disease, n (%) 114 (34.1) 113 (33.8)
Disease -free interval, n (%)
≤12 months 4 (1.2) 10 (3.0)
>12 months 216 (64.7) 210 (62.9)
Prior (neo)adjuvant therapy, n (%)
Chemotherapy and endocrine therapy 123 (36.8) 120 (36.0)
Endocrine therapy only 52 (15.6) 51 (15.3)
As of 29-Jan-2016 (cutoff date), the median duration of exposure to study  treatment was 13.0 
months in the ribociclib arm and 12.4 months in the placebo arm. The median duration of 
exposure to ribociclib/ placebo was 12.2 months in the ribociclib arm and 12.4 months in the 
placebo arm; 240 patients (71.9%) were exposed to ribociclib plus letrozole therap y for ≥ 9 

[COMPANY_001] Confidential Page 47
Amended Protocol v03 ( clean ) CLEE011XUS29
months. Median relative dose intensity  was 87.5% for ribociclib and 100% for placebo. 
Ribociclib dose interruptions occurred in 257 (76.9%) patients, and letrozole was interrupted in 
132 (39.5%) patients in the ribociclib arm. Placebo was interrupted in 134 (40.6 %) patients and 
letrozole was interrupted in 107 (32.4%) patients in the placebo arm. Dose reductions occurred 
in 53.9% and 7.0% of patients in the ribociclib and placebo arms, respectively , most commonl y 
for adverse events (169 [50.6%] vs. 14 [4.2%] patie nts; ribociclib vs. placebo arm). Dose 
reduction due to neutropenia occurred in 65% of patients who had a dose reduction due to AEs 
in the ribociclib arm.
The majority  of the patients experienced at least one AE in both treatment groups (98.5% vs. 
97%); th e most commonly ( ≥ 30%) reported AEs in ribociclib plus letrozole group irrespective 
of causalit y were: neutropenia (60.8%), nausea (51.5%), fatigue (36.5%), diarrhea (35%), and 
alopecia (33.2%) AEs where a higher proportion of ribociclib plus letrozole -treated patients 
reported events (and where there was a ≥ 10% difference to the placebo plus letrozole group) 
included neutropenia (+56.6%), nausea (+23%), decreased neutrophil count (+18%), alopecia 
(+17.7%), decreased white blood cell count (+17.4%), vomit ing (+13.8%), anemia (+13.8%), 
diarrhea (+12.9%), leukopenia (+12.9%), increased ALT (+11.7%), and increased AST 
(+11.4%). The incidence of SAEs was 21.3% and 11.8% in the ribociclib plus letrozole and 
placebo plus letrozole arms, respectivel y. Twent y-fivepatients (7.5%) from the ribociclib plus 
letrozole group experienced SAEs that were considered by [CONTACT_140970]. Febrile neutropenia was the onl y suspected SAE reported in >1% of patients (1.2%). 
Permanent discontinuati ons due to adverse events were reported in 7.5% of patients receiving 
ribociclib plus letrozole and in 2.1% of patients receiving placebo plus letrozole. The most 
common AEs leading to treatment discontinuation of both ribociclib and letrozole were ALT 
increased (2.7%), AST increased (2.4%) and vomiting (1.5%) ( Table 1 -
4).
Table 1
-4 Adverse events with suspected relationship to study  treatment in 
study  (CLEE011A 2301)
Adverse events with suspected 
relationship to study  treatment 
by [CONTACT_140971] (greater than 5%  in either 
arm) (Safety  set)Ribociclib + Letrozole
n=334Placebo + Letrozole
n=330
Preferred TermAll grades n 
(%)Grade 3 n 
(%)Grade 4 n 
(%)All grades n 
(%)Grade 3 n 
(%)Grade 4 n 
(%)
Total 319 (95.5) 199 (59.6) 43 (12.9) 249 (75.5) 27 (8.2) 1 (0.3)
Neutropenia 199 (59.6) 130 (38.9) 29 (8.7) 13 (3.9) 2 (0.6) 0
Nausea 144 (43.1) 6 (1.8) 0 54(16.4) 0 0
Alopecia 95 (28.4) 0 0 44 (13.3) 0 0
Fatigue 92 (27.5) 5 (1.5) 1 (0.3) 64 (19.4) 2 (0.6) 0
Diarrhoea 72 (21.6) 3 (0.9) 0 39 (11.8) 0 0
Neutrophil count decreased 63 (18.9) 44 (13.2) 3 (0.9) 3 (0.9) 1 (0.3) 0
Vomiting 62 (18.6) 6 (1.8) 0 22(6.7) 1 (0.3) 0

[COMPANY_001] Confidential Page 48
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse events with suspected 
relationship to study  treatment 
by [CONTACT_140971] (greater than 5%  in either 
arm) (Safety  set)Ribociclib + Letrozole
n=334Placebo + Letrozole
n=330
Preferred TermAll grades n 
(%)Grade 3 n 
(%)Grade 4 n 
(%)All grades n 
(%)Grade 3 n 
(%)Grade 4 n 
(%)
Total 319 (95.5) 199 (59.6) 43 (12.9) 249 (75.5) 27 (8.2) 1 (0.3)
White blood cell count
Decreased57 (17.1) 37 (11.1) 2 (0.6) 5 (1.5) 1 (0.3) 0
Hot flush 51 (15.3) 1 (0.3) 0 63 (19.1) 0 0
Arthralgia 48 (14.4) 1 (0.3) 0 52 (15.8) 1 (0.3) 0
Leukopenia 48 (14.4) 25 (7.5) 1 (0.3) 9 (2.7) 1 (0.3) 0
Anaemia 46 (13.8) 2 (0.6) 0 9 (2.7) 3 (0.9) 0
Rash 45 (13.5) 2 (0.6) 0 10 (3.0) 0 0
Alanine aminotransferase
Increased42 (12.6) 22 (6.6) 5 (1.5) 8 (2.4) 1 (0.3) 0
Constipation 40 (12.0) 0 0 20 (6.1) 0 0
Decreased appetite 39 (11.7) 3 (0.9) 0 18 (5.5) 0 0
Aspartate 
aminotransferase increased36 (10.8) 12 (3.6) 2 (0.6) 8 (2.4) 3 (0.9) 0
Stomatitis 33 (9.9) 1 (0.3) 0 15 (4.5) 0 0
Pruritus 30 (9.0) 1 (0.3) 0 3 (0.9) 0 0
Asthenia 27 (8.1) 1 (0.3) 0 23 (7.0) 1 (0.3) 0
Headache 27 (8.1) 1 (0.3) 0 24 (7.3) 0 0
Dyspepsia 23 (6.9) 0 0 12 (3.6) 0 0
Dry mouth 21 (6.3) 1 (0.3) 0 14 (4.2) 0 0
Dizziness 19 (5.7) 0 0 21 (6.4) 0 0
Thrombocytopenia 19 (5.7) 1 (0.3) 0 0 0 0
Lymphocyte count decreased 18 (5.4) 12 (3.6) 0 3 (0.9) 2 (0.6) 0
For additional information about the safet y profile of ribociclib (as monotherap y or in 
combination with letrozole), please refer to [ribociclib Investigator’s Brochure] (Section 6 
Reference Safet y Information).
Key efficacy results
Study  CLEE011A2301 met its primary  objective at the primary  analysis, with statistically  
significant clinical benefit in the treatment arm versus control arm. A 44.4% estimated risk 
reduction in ribociclib plus letrozole treated patients was evident in the primary  PFS endpoint 
as per investigator assessment (HR=0.556, 95% CI: 0.429, 0.720; one sided p value=3.29×10-
6). Updated analysis resulted in a PFS of 25.3 months in the treatment arm and 16 months in the 
control arm. Results were consistent across the subgroups of age, race, prior adjuvant or neo-
adjuvant chemotherap y or hormonal therapi[INVESTIGATOR_014], liver and/or lung involvement, and bone only 
metasta ticdisease (See Figure 1 -3).

[COMPANY_001] Confidential Page 49
Amended Protocol v03 ( clean ) CLEE011XUS29
Overall survival data were immature at the time of this interim analysis with 43 deaths being 
reported (23 patients [6.9%] and 20 patients [6.0%], respectivel y), from the ribociclib plus 
letrozole and placebo plus letrozole treatment arms.
There was an ORR of 52.7% vs. 37.1% and CBR of80.1% vs. 71.8% in patients with 
measurable disease. See Figure 1 -1.
Figure 1
-1 Kaplan -Meier plot of PFS based on Investigator assessment (Full 
Analysis Set)
1.2.3 Overview  of everolimus (RA D001/ A finitor®)
Everolimus (RAD001; Afinitor®)isa derivative ofrapam ycinand hasbeen inclinical 
development since [ADDRESS_159960] cancer in the 
US, EU and other countries.
The following isabriefsummary ofthemain characteristics
ofeverolimus. More detailed 
information can be obtained from the (everolimus Investigator’s Brochure ).
Everolimus isaselective mTOR inhibitor, specifical lytargeting themTO R-raptor 
(regulator y
-associated protein of mTOR, Raptor) signal transduction comple x 1(mTORC1). 
Everolimus potently  inhibit sproliferation ofendothelial cells (Yu 1999, Lane 2009) andhas 
antiangiogenic activi
tyin vivo (Guba 2002, Tsutsumi 2004, Mabuchi 2007, Lane 2009 ).

[COMPANY_001] Confidential Page 50
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Nonclinical experience 
Everolimus inhibitstheproliferation of a wide range ofhuman tumo rcelllines invitro at 
IC50s ranging from sub/low nMtoμM.
Theantitumor efficacy  ofeverolimus wascompared toother compounds inapanel ofsix breast 
cancer xenograft models established after direct transplantation of patients’ tumors onto nude
mice (Report RD-
2011-[ZIP_CODE]). This panel included an ER+ model, HBC x -3 (XTS-181), 
(Marangoni et al 2007 ).Everolimus given daily by [CONTACT_140972]21to35days at 20 mg/kg 
waswell tolerated with nosignificant mean body weight loss. In all breast cancer models tested,
tumor growt hwassignificant ly inhibited, andwas particular lyevident intheHBC x-3 (XTS-
181) model with nine partial regressions in ten mice tested (-13.5% mean tumor volume 
regression, p< 0.001).
Allsignificant adverse events observed intoxicology  studies with everolimus inmice, rats, 
monke ysand mini- pi[INVESTIGATOR_140906] a [ADDRESS_159961] notab
ly 
testes.
Base d on data generated using human liver microsomes andmicrosomes from cells expressing
single human cytochrome P450s enzymes, CYP3A4 was identified as themajor enzyme 
involved inthe microsomal biotransformation of everolimus. Everolimus inhibited 
competitively  themetabolism oftheCYP3A4 substrate c yclosporine with aKivalue of
2.3μMol/L(2204 ng/mL ) under in vitro conditions.
Further details can be found in the (everolimus Investigator’s Brochure )
.
[IP_ADDRESS] Clinical experience
[IP_ADDRESS].1 Everolimus pharmacokinetics
Everolimus israpi[INVESTIGATOR_140907]. The stead y-state 
AUC 0-τisdose- proportional over thedose range between 5to70mgwhengivenweek lyand 
5and10mgwhen given daily.Stead y-state was achieved within twoweeks with thedaily 
dosing regimen. Cmaxis dose- proportional betwee n 5and 10 mgfor both theweekl y anddaily 
regimens.
Inhealth ysubjects, high fatmeals reduce d systemic exposure of a 10 mgdose ofeverolimus 
(asmeasured by[CONTACT_12265]) by 22% andthepeak plasma concentration Cmaxby 54% . Li ghtfat 
meals reduced AUC by 32% andCmaxby 42%.Food had noapparent effect onthepost 
absorption phase concentration- time profile ( Study  RAD001C2120).
Theblood -
to-plasma ratio ofeverolimus, which i sconcentration- dependent over therange of 
5 to 5,000 ng/mL , is 17% to 73%. The amount of everolimus confined to the plasma is 
approximately  20%atbloodconcentrations observed incancer patients given everolimus

[COMPANY_001] Confidential Page 51
Amended Protocol v03 ( clean ) CLEE011XUS29
10mg/day [DMPK R303044 ].Plasma protein bindin gissimilar inhealthy patients andin 
subjects with moderate hepatic impairment (approximately 74%, (Study  RAD001A2303) ).
Themajor andnearl y exclusive enzymeresponsible forthemetabolism ofeverolimus inman 
was CYP3A4 (DMPK(US)1998/005; DMPK(CH) R99-2448), (Kuhn 2001). Other CYP 
isoenz ymeseither dono
tmetabolize everolimus or do soatvery lowrates. Everolimus isa 
moderate inhibitor of
P-glycoprotein- like mediated efflux systems, although the compound 
hasahighintrinsic permeability when P-glycoprotein isinhibited (Crowe 1998, Laplante 
2002, DMPK(CH) 1997/417 ).Following oraladministration, everolimus isthemain circulating
component inhuman blood
andcontributes themajority  oftheoverall pharmacologic activity
(Study  W107). Everolimus was also shown toincrease exposure of exemestane: I n (Study 
RAD001Y2301 ), average exemestane C minandC2hwere 45% and71% higher, respectively,
when
co-administered with everolimus.
No specific excretion studies have been undertaken in cancer patients; however, data available 
from the transplantation setting found the drug to be mainly
eliminated through the feces.
[IP_ADDRESS].2 Everolimus in combination with endocrine therapy in HR+ breast cancer
The combinat ionofeverolimus with hormonal thera py hasbeen assessed indifferent disease 
settings inHR+ breast cancer andshowed evidence of efficac y ofeverolimus inthispatient 
population (Bachelot et al 2012 ;Baselga et al 2012; Pi[INVESTIGATOR_140908] 2012 ).
Innewl y diagnosed patients with ER+ breast cancer, a neoadjuvant randomized 270-patient 
Phase I
Istudy compared thecombination ofeverolimus 10mgQDandletrozole 2.5mgQD 
toletrozole alone for16weeks oftherap y priortosurger y .The overall response rateinthe 
investigational everolimus +letrozole arm was highe rthan that with letrozole alone: 68%
vs.59% based onpalpation (p = 0.062) and 58% vs.47% based onultrasound (p=0.021) 
respective ly, meeting thepredetermined endpoint forefficac y.Additionall y,there wasa greater
antiproliferative response intheinvestigational arm, with a decreas e oftheKi67 proliferation
index to<1in57% ofpatients intheeverolimus arm compared to30% of patients in the 
placebo arm (p<0.01) (Baselga 2009). A randomized Phase III, double -blind, placebo -
controlled study ( BOLERO -2 Study ) demonstrated very  significant improvements in treatment 
of HR+ breast cancer that had recurred or progressed on letrozole or anastrozole. Response rate, 
progression- free survival (PFS), and clinical benefi t rate were all significantly  improved 
relative to exemestane monotherapy . The median PFS by  [CONTACT_140973] 7.8 months for
everolimus + exemestane versus 3.2 months for exemestane (HR = 0.45; 95% CI: 0.38- 0.54; 
p<.0001). Overall response rate (12.6 %vs 1.7%; p<.0001) and clinical benefit rate (51.3% vs 
26.4%; p<.0001) were superior in the everolimus + exemestane arm versus exemestane + 
placebo. Anal yses by [CONTACT_140974] a median progressi on-free survival of 11 
months with everolimus versus 4.1 months with placebo (HR = 0.38; 95% CI: 0.31 
–0.48; 
p<.0001) confirming the results of the primary  PFS analy sis (Pi[INVESTIGATOR_94899] 2012, Baselga 2012 ).

[COMPANY_001] Confidential Page 52
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Safety profile of everolimus
The following AEs areconsidered tobeclass- effects ofmTOR inhibitors: stomatitis/oral 
mucositis/ulcers, infections and infestations, rash and similar events, c
ytopenia, hemorrhages, 
non-infectious pneumonitis, h ypergl ycemia/ne w-onset diabetes mellitus, renal events, and 
thromboembolism. The more common metabolic side effects reported with mTOR inhibitors 
result from inhibitory effects onmTO R-regulated lipid and glucose pathwa ys,while infections
stem from theimmunosuppressive properties of these agents. Virtually a ll of the sideeffects
associated with mTOR inhibitors ca
n be managed effective ly with dose modification and/or 
supportive intervention.
The safe typrofile ofeverolimus observed in the Phase III BOLER O-2study isconsisten twith 
prior experience intheoncolog ysetting; events arepredominant lylowgrade(grade 1 or 2). 
An increased risk of non-infectious pneumonitis, infection, and stomatitis inthe everolimus 
plus exemestane armrelative tothecontrol arm[exemestane + placebo ]wasobserved, although 
each of these events can be effective ly managed in this setting.
Themost common adverse events (AEs) suspected toberelated totreatment, with an incidence
≥10%, reported inassociation with everolimus plus exemestane thera pywere consistent with
what waspreviously  reported: stomatitis, rash, fatigue, decreased appetite, diarrhea, dysg eusia,
nausea, pneumonitis, weight loss, anemia, epi[INVESTIGATOR_3940], hyperglycemia, thromboc ytopenia,and 
pruritus. The most common grade 3-4AEs suspected tobe related to treatment with an
incidence of
≥2% were: stomatitis, hyperglycemia ,anemia, pneumonitis, fatigue, elevated 
alanine and aspartate transaminase concentrations, elevated γ-gluta myltr ansferase
concentrations, dyspnea, neutropenia, andthromboc ytopenia (Pi[INVESTIGATOR_140908] 2012; Baselga et al 
2012). Nonew safety concerns have emerged compared toprevious experience with everolimus 
monothera py or combination thera py.
Further details related
toeverolimus safetycan be found inthe(everolimus I nvestigator’s 
Brochure )and package insert of the local supp lyof everolimus (if available) for more details.
1.2.[ADDRESS_159962] cancer. I tisindicated for 
adjuvant treatment ofpostmenopausal women with ER+ early breastcancer who have received
twotothree yearsoftamoxifen andare switched toexemestane forcompletion ofa total offive
consecutive yearsofadjuvant hormonal thera py. I t is also indicated forthe treatment of 
advanced breast cancer inpostmenopausal women whose disease has progressed following 
tamoxifen therapy (in the [LOCATION_003]) or following anti- estrogen therap y(in Europe).
Exemestane isinitiall y recognized by [CONTACT_140975] -dependent mechanism to an intermediate that binds 
irreversibl y totheenzyme, causing inactivation. Exemestane significantly lowers circulating 
estrogen concentrations (estradiol, estrone andestrone sulfate) buthasnodetectable effect on 

[COMPANY_001] Confidential Page 53
Amended Protocol v03 ( clean ) CLEE011XUS29
adrenal biosynthesi s of corticosteroids oraldosterone (Aromasin prescribing information 
[COMPANY_007] -Pharmacia 2005 )
.
The recommended daily dose of exemestane is25mgvia oral administration. Exemestane is 
rapi[INVESTIGATOR_140909]. Itsbioavailabilit y is limite d by [CONTACT_22705]- pass 
metabolism, butisincreased when taken with food. Exemestane iswidel ydistributed, and is 
extensively  bound toplasma proteins. The terminal half-lifeforexemestane is18-24 hours. 
The time needed toreach maximal E2suppression is7day
s (Demers 1993, Plourde 1995, 
Buzdar 2003). Exemestane ismetabolized by C YP3A4 andaldoketoreductases. Itdoes not 
inhibit any ofthemajor CYP isoenz ymes, including CYP 1A2, 2C9, 2D6, 2E1 and3A4. 
Although noformal drug-drug interaction studies have been conducted, significant effects on 
exemestane clearance by [CONTACT_140976][INVESTIGATOR_140910]
y (Aromasin prescribing 
information [COMPANY_007] -
Pharmacia 2011, Hutson 2005, Buzdar 2003 ).As noted in Section [IP_ADDRESS].1, 
everolimus increases exposure of exemestane.
Themost frequent ly reported adverse effects forexemestane aregastrointestinal disturbances, 
hotflushes, arthralgia, m
yalgia, sweating, fatigue, anddizziness. Other reported effects include 
headache, insomnia, somnolence, depression, skin rashes, alopecia, asthenia, and peripheral
and leg edema. Thromboc ytopenia and leukopenia have been reported occasional ly. 
Reductions in bone mineral densit y can occur with long -term use of exemestane. Atotal of
1058 patients were treated with exemestane
25mgonce daily intheclinical trials program.
Exemestane was general lywell tolerated, andadverse events were usual ly mild to moderate. 
Adverse even ts occurring in greater than 10% of patients include hot flushes (14%), nausea
(11.9%), insomnia, headache, increased sweating, joint and musculoskeletal pain, and fatigue
(USPI  [INVESTIGATOR_140911] 2008 ([LOCATION_006] asRMSfor EU MRP)) .Androgenic effects were 
reported in a limited number of patients (4.3%) (Buzdar 2003).
Refer to the prescribing information of the local supply of exemestane for more details.
1.2.5 Ribociclib in combination with everoli mus 
[IP_ADDRESS] Synerg ywitheverolimus and ribociclib (LEE011)
Theeffectofcombining ribociclib with the mTORC1 -inhibitor RAD001 (everolimus; Afinitor®) 
intheER+, PIK3CA -mutant MCF-7xenograft model was examined. As demonstrated in
Figure 1-2single agent treatments with ribociclib and RAD001 resulted in modest tumor
regressions of
-9%and-21%, respective ly. When ribociclib wascombined with RAD001 tumor 
regression increased to-49%. Moreover, single agent and combination treatments were well
tolerated asjudged b
y body weight loss (not shown). In addition, the tripl etcombination of 
ribociclib plus everolimus plus theendocrine therap y,fulvestrant, was evaluated in the ER+, 
PIK3C A-mutant KPL-1and PTEN -null XR751 xenograft models. The tripletcombination
demonstrated superior tumor regressio ncompare d to singl eagen tLEE011 orLEE01 1plus
fulvestrant (see Figure 1-3) or compared tosingle agent everolimus or everolimus combined
with fulvestrant. These data sugges tthatcombining inhibitors that target themTOR pathway
wit
hLEE01 1may be aneffective therapeutic strateg y inER+/P IK3C A-mutant tumors.

[COMPANY_001] Confidential Page 54
Amended Protocol v03 ( clean ) CLEE011XUS29
Figure 1-[ADDRESS_159963]-1 xenograft models
Mice treated with vehicle, LEE011 (LEE011;75 mg/kg qd x 28), fulvestrant (Fulv; 5 mgqwk x 4) and/or everolimus 
(RAD; 10 mg/kd qd x 28). 
[IP_ADDRESS].1 Drug interaction (ribociclib and everolimus)
Invitro experiments observe
dtime- dependent inhibition ofCYP3A4 by [CONTACT_140977]5μManda kinact value of 0.0245 min-1;a clinical DDIconfirmed these invitro results. 
Everolimus is a sensitive CYP3A4 substrate . Therefore, a PKDDI was possible with the 
combination
ofeverolimus andribociclib (LEE011 Investigator Brochure ).
As of March 2, 2015, [ADDRESS_159964] been treated with the combination of ribociclib + 
everolimus + exemestane in a Phase Ib study (CLEE011X2106). Everolimus (RAD001) was 

[COMPANY_001] Confidential Page 55
Amended Protocol v03 ( clean ) CLEE011XUS29
administered at 2.5 mg (qd) concurrently  with 200mg, 250 mgand300mgof ribociclib (qd, 3 
weeks on/1 week off) with orwithout food. Additionally  350mgof ribociclib was administered 
with 1mgof everolimus without food or 2.5mgeverolimus with food and 200 mgof ribociclib 
was administered with 5mgof everolimus with food. A fixed dose of 25mgof exemestane (qd) 
was administered in each combination (Bardia A et al 2015 ).
Preliminary  PK data for Cmaxand AUC 0-24hfor ribociclib andeverolimus were available on Day 
1 and after multiple doses on Day 15. Everolimus (2.5mgqd) exposure (AUC 0-24h) was 
increased in the presence of ribociclib (200-350 mg) to levels of 5 to 10 mg when compared to 
historical single agent data (Kovarik et al 2002 ;Kovarik et al 2005a ;Urva et al 2013 ; 
Everolimus Investigator’s Brochure ). In general, mean stead y state exposure for ribociclib and 
everolimus appeared to be lower in the presence of food at the same dose level; however ,
individual Cmaxand AUC 0-24hvalues with food were within the range ofvalues observed without 
food. Further evaluation of 2.5 mgof everolimus (RAD001) (qd) with 300 mgribociclib (qd, 3 
weeks on/1 week off) with food is ongoing in CL EE011X2106 dose expansion (Bardia A et al 
2015). See Table 1 - 5for full PK parameters.
Table 1-5 Pharmacokinetic Parameters of Ribociclib and Everolimus at Steady 
State (Cy cle 1, Day  15)
Analyte Dose (ribociclib + 
EVE + EXE, mgFasted/Fed N Cmax(ng/mL), 
Mean (SD) [n]AUC0-24h (h*ng/mL), 
mean (SD) [n]
Ribociclib 200 + 2.5 + 25 Fasted 6 473 (305) [6] 5200 (3540) [5]
200 + 2.5 + 25 Fed 3 315 (163) [3] 4330 (3920) [3]
250 + 2.5 + 25 Fasted 16 818 (549) [14] 9460 (6280) [11]
250 + 2.5 + 25 Fed 5 720 (301) [2] 10 000 (4960) [2]
300 + 2.5 + 25 Fasted 11 1250 (690) [8] 14 800 (9390) [8]
300 + 2.5 + 25 Fed 12 924 (505) [11] 13 500 (7680) [8]
350 + 1 + 25 Fasted 6 989 (362) [5] 11 900 (3390) [4]
350 + 2.5 + 25 Fed 5 896 (376) [5] 12 700 (5640) [5]
200 + 5 + 25 Fed 6 580 (216) [5] 6860 (2470) [5]
EVE 200 + 2.5 + 25 Fasted 6 20 (5) [5] 170 (47) [5]
200 + 2.5 + 25 Fed 3 8 (2) [3] 1120 (32) [3]
250 + 2.5 + 25 Fasted 16 33 (14) [13] 327 (161) [10]
250 + 2.5 + 25 Fed 5 24 (17) [2] 257 (182) [2]
300 + 2.5 + 25 Fasted 11 35 (18) [7] 365 (197) [7]
300 + 2.5 + 25 Fed 12 26 (9) [11] 305 (135) [9]
350 + 1 + 25 Fasted 6 13 (3) [4] 106 (30) [3]
350 + 2.5 + 25 Fed 5 26 (8) [5] 287 (103) [5]
200 + 5 + 25 Fed 6 40 (12) [5] 403 (124) [5]
Historical single -agent data (steady state)
EVE 5 mg134 32 (9) [4] 223 (74) [4]
10 mg137 60 (17) [7] 560 (283) [7]

[COMPANY_001] Confidential Page 56
Amended Protocol v03 ( clean ) CLEE011XUS29
Analyte Dose (ribociclib + 
EVE + EXE, mgFasted/Fed N Cmax(ng/mL), 
Mean (SD) [n]AUC0-24h (h*ng/mL), 
mean (SD) [n]
5 mg1423 54 (12) [23] 418 (87) [23]
AUC 0-24h, area under the curve from time zero to 24 h;    Cmaxmaximum plasm a concentration; EVE, 
everolimus; EXE, exemestane; SD, standard deviation
[IP_ADDRESS].2 Clinical safety of ribociclib when combined with everolimus and exemestane
In the ongoing Phase Ib/II clinical trial (CLEE011X2106), out of 70 patients treated with the 
triplet combination, ribociclib (200–350 mg3 weeks on, 1 week off ), everolimus (most at 
2.5mg), and exemestane (25 mg), the median number of prior regimens was 4, and 18 (25.7%) 
pts had received prior PI3K/AKT/mTOR or CDK4/6 inhibitors for metastatic disease. Grade 
3/4 treatment -related AEs (≥5% patients) were neutropenia (45.7%), leukope nia (8.6%), and 
thrombocytopenia (5.7%). Two (2.9%) patients discontinued due to AEs. Grade [ADDRESS_159965]/AL T 
AEs were appreciated i n 2 patients, febrile neutropenia and h ypophosphatemia (1 patient), oral 
mucositis (1 patient), rash and thrombocy topenia (1 patient ), and thrombocy topenia with 
bleeding (1 patient ). MTD and RDE were declared atribociclib 300mg 3weeks on, 1 week off, 
everolimus 2.5mg daily  and exemestane 25mg daily . This combination dose appeared to be 
tolerable and safe. (Bardia A et al 2015 ).See Table 1 -6for full AE listing
Table 1-6 LEE011X2106: A dverse Events (A ll-grade greater than or equal to 15% 
in All Patients Receiving Triplet Therapy ) Suspected to Be Related to 
Treatments
Adverse 
EventGrade R 200 mg + 
E 2.5 mgR 250 mg + 
E 2.5 mgR 300 mg + 
E 2.5 mgR 350 
mg + E 
1 mgR 350 
mg+ E 
2.5 mgR200 
mg + E 
5 mgAll Patients 
With Triplet 
Therapy
Fasted /
Fed NFast
ed 
n=6Fed 
n=3Fast
ed 
n=18Fed 
n=6Fast
ed 
n=11Fed 
n=12Fasted 
n=6Fed 
n=9Fed 
n=6N/A 
N=77
Total All 6 
(100)3 
(100)17 
(94)5 
(83)11 
(100)12 
(100)6 (100) 9 (100) 6 (100) 75 (97)
G3/4 2 
(33)0 11 
(61)1 
(17)10 
(91)10 
(83)2 (33) 8 (89) 4 (67) 48 (62)
Stomatitis All 4(67) 3 
(100)8 
(44)5 
(83)7 
(64)6 
(50)2 (33) 5 (56) 2 (33) 42 (55)
G3/4 0 0 0 0 0 1 (8) 0 0 0 1 (1)
Anemia All 3 
(50)1 
(33)9 
(50)2 
(33)7 
(64)6 
(50)2 (33) 3 (33) 3 (50) 36 (47)
G3/4 0 0 2 
(11)1 
(17)1 (9) 0 0 0 1 (17) 5 (7)
Neutropeni
aAll 4 
(67)0 5 
(28)1 
(17)6 
(55)6 
(50)3 (50) 8 (89) 3 (50) 36 (47)
G3/4 2 
(33)0 2 
(11)1 
(17)6 
(55)4 
(33)0 7 (78) 2 (33) 24 (31)

[COMPANY_001] Confidential Page 57
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse 
EventGrade R 200 mg + 
E 2.5 mgR 250 mg + 
E 2.5 mgR 300 mg + 
E 2.5 mgR 350 
mg + E 
1 mgR 350 
mg+ E 
2.5 mgR200 
mg + E 
5 mgAll Patients 
With Triplet 
Therapy
Neutrophil 
count 
decreasedAll 0 1 
(33)10 
(56)1 
(17)5 
(46)5 
(42)1 (17) 2 (22) 2 (33) 27 (35)
G3/4 0 0 6 
(33)0 3 
(27)4 
(33)0 0 1 (17) 14 (18)
White 
blood cell 
count 
decreasedAll 1 
(17)2 
(67)5 
(28)1 
(17)7 
(64)3 
(25)4 (67) 1 (11) 1 (17) 25 (33)
G3/4 0 0 2 
(11)0 3 
(27)2 
(17)1 (17) 1 (11) 0 9 (12)
Thrombocy
topeniaAll 1 
(17)0 6 
(33)1 
(17)5 
(46)6 
(50)1 (17) 4 (44) 1 (17) 25 (33)
G3/4 0 0 0 1 
(17)2 
(18)1 (8) 0 1 (11) 0 5 (7)
AST 
increaseAll 2 
(33)1 
(33)5 
(28)0 4 
(36)4 
(33)1 (17) 2 (22) 2 (33) 21 (27)
G3/4 0 0 0 0 2 
(18)0 0 1 (11) 0 3 (4)
ALT 
increaseAll 3 
(50)0 2 
(11)1 
(17)6 
(55)5 
(42)0 1 (11) 3 (50) 21 (27)
G3/4 0 0 0 0 2 
(18)1 (8) 0 0 1 (17) 4 (5)
Nausea All 1 
(17)1 
(33)6 
(33)1 
(17)3 
(27)3 
(25)1 (17) 2 (22) 1 (17) 19 (25)
G3/4 0 0 0 0 0 0 0 0 0 0
Rash All 1 
(17)1 
(33)2 
(11)1 
(17)5 
(46)2 
(17)0 2 (22) 2 (33) 16 (21)
G3/4 0 0 0 0 1 (9) 0 0 0 0 1 (1)
Platelet 
count 
decreaseAll 2 
(33)0 3 
(17)1 
(17)3 
(27)2 
(17)0 2 (22) 2 (33) 15 (20)
G3/4 1 
(17)0 0 0 0 0 0 0 0 1 (1)
Diarrhea All 1 
(17)1 
(33)4 
(22)0 2 
(18)2 
(17)0 1 (11) 3 (50) 14 (18)
G3/4 0 0 0 0 0 0 0 0 0 0
Lymphope
niaAll 3 
(50)1 
(33)4 
(22)0 1 (9) 2 
(17)2 (33) 0 1 (17) 14 (18)
G3/4 1 
(17)0 3 
(17)0 0 1 (8) 0 0 0 5 (7)
Fatigue All 0 1
(33)3 
(17)1 
(17)2 
(18)2 
(17)2 (33) 1 (11) 1 (17) 13 (17)
G3/4 0 0 0 0 0 0 0 0 0 0
Lymphocyt
e count 
decreasedAll 0 0 5 
(28)1 
(17)4 
(36)1 (8) 1 (17) 0 1 (17) 13 (17)
G3/4 0 0 3 
(17)0 0 0 0 0 0 3 (4)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; E, everolimus; G, Grade; R, ribociclib.

[COMPANY_001] Confidential Page 58
Amended Protocol v03 ( clean ) CLEE011XUS29
At the time of the completion of cohort A, and cohort B in the phase I portion of TRI NTI-1 
(LEE011XUS29) an interim analy sis was done on 16 evaluable patients (8 patients in cohort 
A [250mg qd Ribociclib + 2.5mg qd Everolimus + 25mg qd Exemestane], and 8 patient in 
cohort B [300mg qd Ribociclib + 2.5mg qd Everolim us + 25mg qd Exemestane]). The most 
common all -grade AEs (>20% in either cohort) were neutropenia (Cohort A, 4 patients 
[50.0%]; Cohort B, 4 patients [50.0%]), fatigue (Cohort A, 3 patients [37.5%]; Cohort B, 0 
patients), thrombocy topenia (Cohort A, 2 pati ents[25.0%]; Cohort B, 2 patients [25.0%]), and 
mucositis (Cohort A, 0 patients ; Cohort B, 2 patients [25.0%]). The most common Grade 3/4 
AE (>20% in either cohort) was neutropenia (Cohort A, 3 patients [37.5%]; Cohort B,
3 patients [37.5%]) . 2 patients (12.5%) experienced Grade 3/4 febrile neutropenia, 1 in each 
cohort . There were no cases of QT interval prolongation, abnormal liver function tests, or 
pneumonitis in either cohort. ( Hurvitz S et al 2017) . See Table 1 -7for full AE listing .
Table 1-7 LEE011XUS29: A dverse Events ( cohort A and B ) Suspected to Be 
Related to Treatments
Patients, n (%)
Ribociclib 250 mg
+ EVE 2.5 mg
+ EXE 25 mg
(n=8)Ribociclib 300 mg
+ EVE 2.5 mg
+ EXE 25 mg
(n=8)All patients
(n=16)
Adverse event, n (%) All grade Grade 3/4 All grade Grade 3/4 All grade Grade 3/4
Total 7 (87.5) 6 (75.0) 7(87.5) 6 (75.0) 14 (87.5) 12 (75.0)
Neutropeniaa4 (50.0) 3 (37.5) 4 (50.0) 3 (37.5) 8 (50.0) 6 (37.5)
Thrombocytopeniab2 (25.0) 0 2 (25.0) 1 (12.5) 4 (25.0) 1 (6.3)
Fatigue 3 (37.5) 0 0 0 3 (18.8) 0
Anemia 1 (12.5) 1 (12.5) 1 (12.5) 1 (12.5) 2 (12.5) 2 (12.5)
Febrile neutropenia 1 (12.5) 1 (12.5) 1 (12.5) 1 (12.5) 2 (12.5) 2 (12.5)
Mucositis 0 0 2 (25.0) 0 2 (12.5) 0
Urticaria 1 (12.5) 1 (12.5) 1 (12.5) 0 2 (12.5) 1 (6.3)
AKI 1 (12.5) 1 (12.5) 0 0 1 (6.3) 1 (6.3)
Diarrhea 0 0 1 (12.5) 0 1 (6.3) 0
Dry mouth 0 0 1 (12.5) 0 1 (6.3) 0
Dyspepsia 0 0 1 (12.5) 0 1 (6.3) 0
GGT increased 0 0 1 (12.5) 0 1 (6.3) 0
Hyperglycemia 0 0 1 (12.5) 1 (12.5) 1 (6.3) 1 (6.3)
Leukopenia 0 0 1 (12.5) 1 (12.5) 1 (6.3) 1 (6.3)
Lymphopenia 0 0 1 (12.5) 0 1 (6.3) 0
Muscle spasm 0 0 1 (12.5) 0 1 (6.3) 0
Nausea 0 0 1 (12.5) 0 1 (6.3) 0
Pruritus 1 (12.5) 0 0 0 1 (6.3) 0
Vomiting 0 0 1 (12.5) 0 1 (6.3) 0
Weight decreased 1 (12.5) 0 0 0 1 (6.3) 0
AKI, acute kidney injury; EVE, everolimus; EXE, exemestane; GGT, gamma -glutamyltransferase. a Includes neutropenia, 
neutrophil count decreased, and white blood cell count decreased. bIncludes thrombocytopenia and platelet count 
decreased. 

[COMPANY_001] Confidential Page 59
Amended Protocol v03 ( clean ) CLEE011XUS29
[ADDRESS_159966] cancer. Resistance
tohorm onal-deprivation therap yistheleading cause ofdeath forwomen with this diagnosis .
Disruption of the PI3K/mTOR pathway  and cyclin D-CDK4/6– INK4–Rb pathway  has been 
implicated in resistance to endocrine therapy  and disease progression. Activating mutations in 
the mTOR, AKT, PIK3CA genes are oncogenic driver s in a variet y of cancer ty pes, including
ER+ breast cancer. The addition of everolimus to exemestane significantly  improves 
progression
-free survival of women with disease resistant to hormonal deprivation (Baselga J 
2012 )
;however, this too ultimately  results in disease progressi on.Studies demonstrate that 
resistance to hormonal therapy , mTOR inhibition, and cytotoxic chemotherap y are at least in 
part mediated by [CONTACT_140950]4/[ADDRESS_159967] cancer, suggesting that 
there might be a role for CDK4/6 inhibition + mTOR inhibition in patients who have progressed 
on these therapi[INVESTIGATOR_014]. Cyclin-dependent kinase (CDK) 4/[ADDRESS_159968]  as they actdownstream of the PIK3C A/Protein Kinase B 
(AKT)/mTOR axis. The effect of combining ribociclib with the mTORC1- inhibitor everolimus
(RAD001; Afinitor® ) in the ER+, PIK3CA mutant MCF -7 xenograft model was examined 
(RD-2013- [ZIP_CODE]). While single agent treatments with ribociclib, and everolimus resulte d in 
modest tumor regressions 
of -9% and -21%, respectivel y, combination of ribociclib with 
everolimus increased tumor regressions to -49%. Data from invivo studies showed that 
ribociclib, when combined with the mTOR inhibitor, everolimus (RAD001; Afinitor®),induced 
synergistic growth inhibitions in multiple tumor models, including cell lines derived from MCL , 
ER+ breast cancer, and MRT ( LEE011 Investigator’s Brochure ).
There is a role for continuing targeted therapi[INVESTIGATOR_140912], even beyond the 
point of disease progression. Inhibition of CDK 4/6 has been associated with autophagy -
senescence transition (AST) in stromal fibroblasts, which leads to mitochondrial dysfunction 
and catabolism, a process that releases high-energy mitochondrial fuels into the stroma where 
they drive anabolic tumor growth and cancer metastasis (Capparelli C, 2012 ). When fibroblasts 
with induced senescence were co-cultured with the MDA -MB- [ADDRESS_159969] cancer cell line, a 
near 2-fold increase in tumor growth was noted compared to control (Capparelli C ,2012 ).
Release of CDK inhibition in a primed microenvironment could have the potential to cause 
rapid tumor 
progression, although this is still not well understood. Additional preclinical 
experiments have also suggested that inhibition of cy clinD1 or CDK 4/[ADDRESS_159970] and pancreatic cancer cell lines, predominately throu gh activation of TGF -, which 
induces Akt-TOR signaling (Tobin NP, 2011 )As such, treatment with the mTOR inhibitor 
everolimus may overcome a potential pathway of drug resistance to CDK 4/6/Cy clin D 
inhibition.
Everolimus appears to restore sensitivity to anti -estrogens b y inhibiting resistance mediated b y 
the PI3K/AKT /mTOR pathway . Currentl y,there isnoclinical data available reporting the
efficac y o
ffurther treatments after prior CDK4/6 inhibitor failure, which represents an unmet
medical need andrequires further exploration. Potential reasons for progression onCDK4/6

[COMPANY_001] Confidential Page 60
Amended Protocol v03 ( clean ) CLEE011XUS29
inhibitor include loss of theretinoblastoma protein (pRb) (the direct target ofCDK4/6
inhibitors), alterations intheestroge nreceptor pathway  asa consequence ofendocrine thera py 
resistance, oractivation ofother signaling pathways including thePI3K/AKT/mTOR pathwa y.
Anecdotal observations of a small subset of patients treated on 1st line therapy trials with CDK 
4/6 inhibitors + aromatase inhibitors have suggested that some patients who discontinue therap y 
with the CDK 4/6 inhibitors develop rapid disease progression at initial imaging assessment to 
second line therapy . This lends the question of maintaining CDK 4/6 i nhibition as a backbone 
therap y to keep the cell cycle arrested in G1 while adding mTORinhibition to overcome 
secondary resistance.
The heterogenei ty oftheanticipated mechanism of resistance requires further exploration in 
identify ing the subset of patients that may stillbenefit from asustained inhibition ofthe
CDK4/6 pathwa y.Therefor e,theanalysisofnewly acquired tumor biops y at progression after
CDK4/6 inhibitor based therap ywill be a preferred waytoidentify  potential mechanisms of 
resistance in such patients.
The LEE011X2106 Phase-1b clinical trial tested a combination of exemestane + everolimus + 
ribociclib. This combination appeared to be safe and demonstrated clinical activity at the RDE 
of ribociclib 300mg(3weeks on/1 week off), everolimus 2.5 mg daily , and exemestane 25mg
daily . PK anal ysisindicated that ribociclib (200 mg-350 mg) increased exposure of everolimus
(2.5mg) due to CYP3A4 inhibition by [CONTACT_140978]. At stead y-state, everolimus exposure was 
largel y within the exposures achieved with multiple doses of 5 and 10mgof single agent 
everolimus. (Bardia A 2015 ).Clinical activity  was seen in a heavily  pre-treated population with 
median number of prior regimens being 4, and 25.7% pts had rece
ived prior PI3K/AKT/mTOR 
or CDK4/6 inhibitors for metastatic disease. The clinical benefit rate (confirmed CR + PR + SD 
≥24 weeks + NCRNPD ≥24 weeks) was 26% in 74 evaluable patients (n=19; 95% CI: 16–37%)
anda disease control rate (CR + PR + SD + NCRNPD) of 73% (n=56; 95% CI: 61–82%). 
Further more, there was a trend towards longer duration of treatment in the CCND1 amplified 
group (n=10; median 166 days) than in the non -amplified group (n=22; median 60 days), 
something which was not seen in BOLERO -2 (Bardia A2015 ). Thus, triplet combination of 
endocrine therapy  with mTOR and CDK4/6 inhibition is feasible , permits lower dosing of 
everolimus with acceptable dose exposure levels , and shows encouraging signs of clinical 
activity , including in patients with prior exposure to PI 3K/AKT/mTOR or CDK4/[ADDRESS_159971] whether the addition of everolimus + exemestane to 
ribociclib can reverse resistance to a CDK 4/6 inhibitor and ultimately  improve the efficacy  of 
the approved combination regimen (everoli mus + exemestane) in patients that progressed on
CDK 4/6 inhibitor s.
2.1.1 Rationale for Continuous D osing -Phase I -Dose Escalation
The RDE for the Phase I CLEE011X2106 dose 
escalation study , was declared at ribociclib 
(300 mg 3weeks on/ 1 week off), everolimus 2.5mg daily , and exemestane 25mg daily .Based 
on the PK data from CLEE011X2106 study , when ribociclib (300 mg) and everolimus (2.5mg) 

[COMPANY_001] Confidential Page 61
Amended Protocol v03 ( clean ) CLEE011XUS29
were dosed concurrentl y, steady  state exposure of ribociclib was generall y within the range of 
exposures observed for single agent ribociclib at similar doses (Bardia A 2015 ). However, 
riboc iclib increased the exposure of everolimus by [CONTACT_3450] 2 and 4 fold (5 and 10mg 
respectivel y) when ribociclib was dosed 21/28 days at200mgand 300mg respectivel y(see
Section 
[IP_ADDRESS].1). D uring the week of rest for ribociclib (days 22-28), levels of everolimus 
decrease dbelow the single agent recommended dose levels of everolimus. 
Continuous dosing of ribociclib has been evaluated in both X2108 (400 mg ribociclib daily + 
fulvestrant) and X2101 300mg and400mg single agent ribociclib. Both studies demonstrate 
acceptable tolerability . In X2108, when compared to 600 mg 3 week s on/1 week, daily  dosing 
of ribociclib at 400 mg resulted in a decrease in neutropenia, ALT elevation , QTc prolongation
and fatigue (Section 1.2.1 ). 
The design ofthePhase I,open label, dose finding part ofthestudy was chosen inorder to 
establish theMTD(s)/RP2D ofcontinuous dosing of ribociclib at 250mgstarting dose in
combination with a fixed, dose of everolimus (2.5mg) based on the CLEE011X2106 Phase I 
study  and standard dose ofexemestan e (25mg) inmen and postmenopausal women with HR+
HER2negative advanced breast cancer. Based on the decrease dlevels of everolimus during the 
rest week of ribociclib and the improved safet y data demonstrated with the continuous dosing 
of ribociclib in both the CLEE 011X2101 study  and CLEEX2108 study , it is believed that dosing 
ribociclib continuously  with daily  everolimus and exemestane may lead to improved safet y and  
efficacy . Because the exposure of ribociclib does not change when administered concurrently 
with everolimus, we believe that 250mgof ribociclib will be safe to administer with 2.5 mgof 
everolimus daily .
The decisi ons on new dose combinations aremade by [CONTACT_140979] a sy nthesis oftherecommendations made by [CONTACT_140980] (IDMC), patient tolerability and safety,PKand efficac y
information available atthetime ofthe decision. The discussion and decisions will be 
documented inthedose escalation meeting minutes.
Thedose escalation part ofthisstudy willalso assess thePK of everolimus andribociclib in 
HR+ HER2- negative advanced breast cancer patients receiving thetriple tcombination 
(ribociclib +everolimus +exemestane) with continuous dosing and will compare the
findings with historical data for the approved combination ofeverolimus +exemestane as well 
as the data from the ongoing CLEE011X2106 study .This comparison willbedone inorder to
determine the optimal dosing ofthe triple t combination when all drugs are dosed continuously .
Each cy cle was determined to be 28 day s. Inthe initial cohort(s) ofsubjects, ifthera py iswell
tolerated after two cycles and have no evidence of grade 3 or 4 clinically significant AEs,
subjects mayundergo intra-patient dose escalation(s) to ensure thatthey receive a therap eutic
dose ofeverolimus and ribociclib. SeeSection 6.2 fordetails onstarting dose and escalation 
guidelines.

[COMPANY_001] Confidential Page 62
Amended Protocol v03 ( clean ) CLEE011XUS29
2.1.2 Rational for stomatitis prevention mouthwash
[IP_ADDRESS] Overview  of stomatitis and current treatment
Stomatitis, the inflammation of mucous membranes lining the mouth and throat, has been 
observed inapproximately  44-86% of everolimus -treated patients ( Afinitor®prescribing 
information [COMPANY_001] 2013). In the BOLERO - 2 trial, patients who received everolimus 
+exemestane had a 67% overall reported incidence of stomatitis (Afinitor®prescribing 
information [COMPANY_001] 2013 ) including 33% incidence grade ≥
2 (Data on file). The median time 
to first onset of stomatitis (Gr ≥2) in the BOLERO -2 trial was 15.5 d ays (Perez et al2013) and 
the incidence of new stomatitis (Gr
≥2) plateaued at 6 weeks (Rugo etal2013 ). Reports from 
clinicians indicate that in routine practice, everolimus treated advanced breast cancer patients 
who develop stomatitis tend to develop it within the first month of therapy . Clinicians also 
report that once resolved the stomatitis typi[INVESTIGATOR_140913]’t recur or recurs at lower grade, 
even in patients who have been maintained or re -escalated to full -dose everolimus .
Specific strategies to prevent and/or ameliorate the severity  of everolimus
-associated stomatitis 
are still ongoing. One recent study  evaluated the clinical presentation and management of 
stomatitis in [ADDRESS_159972] orated. Clinical improvement was noted in over 85% of topi[INVESTIGATOR_11977] -treated 
patients ( de Oliveira et al 2011 ). Another recent study prospectively evaluated the presentation 
and management of oral stomatitis in advanced breast cancer patients being treated with 
everolimus combined with exemestane. Seven out of 15 women (46.6%) developed stomatitis 
grade ≥2. All (100%) ulcers were treated with topi[INVESTIGATOR_140914] 
a media n of 2 weeks.
Four patients (57.1%) required a temporary  interruption of their everolimus, and two 
patients 
(28.6%) required an everolimus dose reduction ( Nicolatou -Galitis et al 2013 ). 
Anecdotal report s from clinicians indicate that prophy lactic use of a steroid- based oral 
mouthwash may help to prevent stomatitis in patients treated with everolimus. [LOCATION_007]
Oncology –Baylor Ch arles A. Sammons Cancer Center in Dallas, [LOCATION_007] reported overwhelming 
success in preventing Gr≥2 stomatitis since they began prescribing a prophy lactic mouthwash 
(hydrocortisone, tetracy cline, nystatin, and diphenhy dramine) to their advanced breast cancer 
patients on everolimus (Dive rs et al 2013 ). A Phase II single arm stomatitis prevention trial 
(SWISH) with Dexamethasone mouthwash administered QID for 56 day s is currently  ongoing 
and interim results will be reported at American Society  of Clinical Oncology (ASCO )in June 
2016.
2.2 Risk
s and benefits
Therisktosubjects inthistrial maybeminimized by [CONTACT_140981] y criteria ,
study procedures andclose clinical monitorin g.

[COMPANY_001] Confidential Page 63
Amended Protocol v03 ( clean ) CLEE011XUS29
2.2.[ADDRESS_159973]- menopausal women (seeSection 1.1.2). They  will
receive triplet
(ribociclib + everolimus + exemestane) combination toevaluate their effect on
delayingtheemergence ofresistance toendocrine therapy  and CDK 4/6 inhibitors. Based 
onpreclinical and clinical data (Section 1.2.5), treatment with ribociclib incombination
everolimus +
exemestane isexpected tobe well tolerated and i tishypothesized that itwill result 
indelayed disease progression by [CONTACT_140982] -resistant and CDK [ADDRESS_159974] beenobserved 
with ribociclib (Section 1.2.1 ),everolimus (Section1.2.3), andexemestane (Section1.2.4) with
thefollowing assessments (Section 7 ):periodic laborator y
,renal andliver function, urinal ysis
andECG. Risk willbefurther minimized by [CONTACT_140983]/exclusion selection criteria
(Section 5), avoidance of prohibited medication (Section 6.5.2 ),close safet ymonitoring
(Section 8) and dose adjustment guidelines (Section 6.4 and current everolimus and 
exemestane prescribing information ).PKsampling will be conducted inpatients toassess
plasma concentration ofthestudy drug tofurther evaluate thedrug -druginteraction when 
ribociclib is dosed continuously . An independent data monitoring committee (IDMC) will be 
constituted and will monitor safety , efficacy  and available PK data as comprising of 
investigators and [COMPANY_001] personnel participating in the trial to ensure t ransparent management 
of the trial according to the protocol. A[COMPANY_001] Safety Management Team (SMT) periodical ly 
reviews andevaluates allemergin gdataacros stheribociclib progra mforpotential safety signal 
assessment in a timely  manner.
3 Study  objectives and endpoints
3.1 Objectives and related endpoints -Phase I
Table 3-1 O bjectives and related endpoints -Phase I
Objective Endpoint
PHASE I
Primary To determine the maximum 
tolerated dose (MTD) and/or 
recommended Phase II dose 
(RP2D) for the combination of 
ribociclib + everolimus 
+exemestane when dosed 
continuouslyIncidence of Dose Limiting 
Toxicities (DLTs) in Cycle 1 (28 
day c ycle)
Secondary To determine the safety and 
tolerability based on NCI Incidence and severity of
adverse event s(AE) and serious 

[COMPANY_001] Confidential Page 64
Amended Protocol v03 ( clean ) CLEE011XUS29
Objective Endpoint
Common Terminology for 
Adverse Events Version 4 when 
treated with ribociclib + 
everolimus + exemestane
continuously in subjects with 
HR+ HER2 -negative advanced 
breast cancer .adverse events (SAE), clinical 
laborator y values, vit al signs 
and electrocardiogram ( ECGs ), 
dose interruptions, reductions 
and dose intensity .
To determine the 
pharmacokinetic ( PK)profile of 
everolimus and ribociclib when
dosed continuously in the triple t
combination .PK parameters including, but 
not limited to, AUC 0-4h, Ctrough, 
Cmax, accumulation ratio (Racc).
To assess the preliminary anti -
tumor activity of the triplet 
combination of ribociclib + 
everolimus + exemestane when 
combination is given 
continuously.Overall response rate ( ORR ), 
Disease Control Rate ( DCR ),
Clinical benefit rate ( CBR )
based on central assessment
perRECIST v1.1, CBR is 
defined as CR, PR, SDor Non -
CR, Non -PD (NCRNPD) lasting 
24 weeks or longer.
3.2 Objectives and related endpoints -phase II 
Table 3-2 Objectives and related endpoints -phase II 
Objective Endpoint
PHASE II
Primary Determine the Clinical Benefit 
Rate (CBR) at [ADDRESS_159975] patients receiving triple 
therapy with ribociclib +
everolimus + exemestane , for 
advanced/metastatic HR +, 
HER2 -negative breast cancer 
following progression on CDK 
4/6 inhibitor.Clinical Benefit R ate (CBR) 
defined as the proportion of 
patients with a complete (CR) or 
partial response (PR), or with 
stable disease (SD) at [ADDRESS_159976] 1.1 or Non -CR 
Non-PD (NCRNPD) at week 24 .
Secondary To determine centrally assessed 
progression Free Surv ival (PFS) 
in HR+ HER2 -negative 
advanced breast cancer .Progression -free survival (PFS), 
defined as the time from date of 
treatment to the date of first 
documented progression or 
death due to any cause. If a 

[COMPANY_001] Confidential Page 65
Amended Protocol v03 ( clean ) CLEE011XUS29
Objective Endpoint
subject has not had an event, 
PFS will be censo red at the date 
of last adequate tumor 
assessment. Disease 
progression for primary  efficacy 
endpoint derivation will be 
based on the central 
radiologist’s tumor assessment.
To determine overall response 
rate (ORR)Overall response rate (ORR) 
defined as the proportion of 
patients whose best overall 
response is either complete 
response (CR) or partial 
response (PR) according to 
RECIST 1.1.
To determine Overall Survival 
(OS)
To determine Duration of 
Overall Response (DOR)
To evaluate time to deterioration 
or ECOG performance statusThis is defined as the time from 
treatment initiation with study 
treatment until death as a result 
of any cause.
Duration of Overall Response 
defined as the time between the 
initial response to the treatment 
with the combination of 
ribociclib+everolimus+ 
exemestane, and subsequent 
disease progression or 
recurrence.
Time to definitive deterioration 
of ECOG performance status 
from baseline .
To determine safety and 
tolerabilityAdverse Events (AEs), serious 
AE (SAEs), changes in 
hematolog y and chemistry  
values, vital signs, dose 
interruptions, reductions and 
dose intensity .
To determine the PK profile of 
ribociclib and everolimus in the 
triplet combination PK parameters including, but 
not limited to, AUC 0-4h, Ctrough, 
Cmax, accumulation ratio (Racc) 

[COMPANY_001] Confidential Page 66
Amended Protocol v03 ( clean ) CLEE011XUS29
4 Study  design
4.1 Description of study  design
This isamulti- center, open -label, Phase I/IIstudy consisting oftwo phases :Phase I andPhase 
II. The Phase Iwill be conducte d in men andpostmenopausa l women with HR+ ,HER2 -
negativ e advanced breast cancer that is endocrine resistant, anda Phase IIpart inmen and 
postmenopausal women with HR+ ,HER2 negative advanced breast cancer thatisresistant to
at least one endocrine therap y and who have progressed on a CDK 4/6 inhibitor. 
Phase I: Thedose escalation partofthestudy isdesigned toestimate theMTD and/or RP2D
forthe combination of ribociclib when dosed continuously with everolimus and exemestane .It 
will consist of 3cohorts (A and B,and C). Each cohort will enroll 3-[ADDRESS_159977] 6 patients at the RP2D level. Between 9-24 patients are expected to be treated 
in the phase I part of this study . 
Once an optimal safety  dose is determined based on tolerability, 
AEs, serious AE (SAEs), changes in hematology  and chemistry  values, vital signs, dose 
interruptions, reductions and dose intensity , this study  will commence to a phase II design.
The study  will initiate with a 2 cohort dose escalation design. Cohort A: rib ociclib ( 250mg
daily ), everolimus ( 2.5 mg daily) and exemestane ( 25mgdaily ). If no DLTs are appreciated
after 1 cy cle, patients will then be enrolled in Cohort B: ribociclib ( 300mgdaily ), everolimus 
(2.5 mg daily ) and exemestane (25 mgdaily). The opt imal dose will then be selected and 
expanded in Group 1 ofthe Phase II part of the study .
An additional cohort, Cohort C , will be explored as a dose de -escalation cohort. A starting 
dose of: R ibociclib ( 200mgdaily), everolimus ( 5 mg daily) and exemestane ( 25mgdaily )
will we explored
.If DLT’s are appreciated, a lower dose of: R ibociclib ( 200mgdaily), 
everolimus ( 2.5 mg daily) and exemestane (25 mgdaily )will b e explored. For further details 
about DLT criteria reference section 6.2.1 . 

[COMPANY_001] Confidential Page 67
Amended Protocol v03 ( clean ) CLEE011XUS29
Phase II: This is a multi -center open label stud y to evaluate the antitumor activity  of the 
ribociclib (LEE011) + everolimus + exemestane combination in patients with 
advanced/metastatic HR +, HER [ADDRESS_159978] progressed on CDK4/6 
inhibitor based therap y. This part of the study  will be continued after the MTD/RP2D is 
determined in the Phase I. 
A minimum of approximately  60 evaluable patients ( 30 per group (Group 1 and G roup 2)) are 
required for Phase II of this study  to evaluate clinical benefit rate at 24 weeks. 
In each phase II group (1 and 2), if [ADDRESS_159979] rate significant clinical benefit.
RP2D : 
Following completion of the phase I, dose escalation portion of this trial, it was determined that 
the RP2D to be explored in group 1 of phase II is as follows:
300mg ribociclib (daily) + 2.5mg everolimus (daily) + 25mg exemestane (daily)
RP2D for group 2 of phase II was determined after completion of cohort C, of phase I, as follows:
         200mg ribociclib (daily) + 5 mg everolimus ( daily) + 25mg exemestane (daily) During 
Phase II, all patients must have progress edon any CDK 4/6 inhibitor. Prior CDK 4/6 inhibitor 
will be defined as disease progression while on, or within one month of discontinuing any CDK 
4/6 inhibitor ( i.e. palbociclib, ribociclib, or abemaciclib).

[COMPANY_001] Confidential Page 68
Amended Protocol v03 ( clean ) CLEE011XUS29
Figure 4-1 Study  design
4.1.1 Screening phase ( Phase I and II)
Men and postmenopausal women with HR+, HER2 -negative advanced breast cancer will b e
screened foreligibility within a 21 dayscreening window prior to starting study  treatment of 
ribociclib +everolimus + exemesta ne .During thistime, the inclusion and exclusion criteria
will beassessed and allscreening assessments, laboratory  tests, and procedures will be
performed. .
Results of allscreening/baseline eligibility  criteria must bereviewed by [CONTACT_140984]/her designee prior topatient enrollment intothestudy inorder toassure thatallinclusion
andexclusion criteria have been satisfied.
Allstudy patients must bethoroughl y informed about allaspects ofthestudy,including the 
study agents, visit schedule, required evaluations, andallregulatory requirements for informed 
consent. The signed infor med consent must be obtained to participate in this study  prior tothe
performance of
any study-related activities. If thepatient isunable toread, an impartial 
witness must be present during theentire informed consent discussion. Eligibility  willbe
determined according totheinclusion/exclusion criteria asdescribed inSection 5.2.A list of
procedures tob
eperformed atthetime ofscreening issummarized inTable 7-1. Patients 
must meet all eligibility criteria to be considered for enrollment in the stud
y.

[COMPANY_001] Confidential Page 69
Amended Protocol v03 ( clean ) CLEE011XUS29
4.1.2 Treatment phase
Patient eligibility  willbechecke donce allscreening procedures arecompleted. Aneligibility 
review andconfirmation will beembedded intheInteractive Respons eTechnology  (IRT) 
system. Please refer toand compl ywith detailed guidelines intheIRT manual.
Subjects may continue study treatment until disease progression, occurrence ofunacceptable 
toxicit y,withdrawal ofconsent by [CONTACT_15619], patient islosttofollow-up, or thesponsor 
terminates the study.
Dose adjustment (reduction, interruption or dose re-escalation) according to safety  findings will 
be allowed. Regular safety reviews b y an IDMC will be performed. 
Tumor assessments will be performed every 8 weeks (+/ -1 week) starting from the first date of 
study  treatment, and as clinically indicated, until the first 12 months of treatment are complete, 
or disease progression. Following 12 months if no disease progression, tumor assessments will 
occur ever y 12 weeks (+/ -2 weeks), and as clinically  indica ted until disease progression. Scans 
could be obtained earlier if there is concern of disease progression. If additional tumor 
assessments are performed prior to starting further anticancer therap y, the corresponding tumor 
assessments should also be sent f or central review. Additional evaluation should be performed 
to confirm response at least [ADDRESS_159980] two cy cles, then once a cy cle from there on. 
The therapy  on clinical trial will continue until disease progression (radiological), or intolerable 
adverse effects, or patient wishes to withdraw consent.
4.1.[ADDRESS_159981]. If treatment discontinuation for 
any reason, other than progression, tumor assessments will continue every 8 weeks +/-1week 
for at least [ADDRESS_159982] dose of study treatment .
The study  evaluation completion (SEC) eCRF page records the end of study  for every  individual 
subject . 
4.1.[ADDRESS_159983] dose 
of the study  treatment .
4.2 Timing of interim analy ses 
Not applicable.

[COMPANY_001] Confidential Page 70
Amended Protocol v03 ( clean ) CLEE011XUS29
4.3 Definition of end of study
Theendofthestudy foragiven patient isdefined aswhen thepatient permanent ly discontinues
study treatment with ribociclib +everolimus +exemestane (Phase 1 and 2) andallthe end of 
trial procedures are completed.
End of study  (Last Patient L ast Visit [L PLV]) will be upon completion of the follow up period 
for the last patient treated in the study . This will be after all patients ha ve 
been on study  for at 
least [ADDRESS_159984] patient enrolled.
4.4 Early study  termination
The study  can be terminated by  [CONTACT_140985]. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
[COMPANY_001] will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contact[CONTACT_49428], when the subject should stop taking drug, when the subject should come for afinal visit) 
and treated as a prematurely  withdrawn subject. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the 
protection of the subject’s interests. The investigator orsponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
5 Population
5.1 Patient population
Men and postmenopausal women with hormonal receptor positive (HR+) , HER2 -negative, 
locally  advanced or metastatic breast cancer whose disease is refractory  to at least one endocrine 
therap yand have a documented recurrence or progression on their last therapy  for breast cancer.
Refractory  disease to endocrine therapy  is defined as (Phase I and Phase II) :
Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole, 
anastroz ole, tamoxifen, exemestane or Fulvestrant
Progression while on, or within one month of end of letrozole, anastrozole, tamoxifen or 
fulvestrant treatment for loca lly advanced or metastatic breast cancer.
Phase II will require that patients with HR+, HER2 -negative advanced/metastatic breast cancer 
have documented progression on a CDK 4/6 inhibitor. 
Documented progression on a CDK 4/6 inhibitor is defined as:
Treatm ent duration while on a CDK 4/[ADDRESS_159985] been for >4 months prior to 
progression, AND
Progressed while on or within 30 day s of discontinuing CDK 4/6 inhibitor for locally  
advanced or metastatic disease , AND
CDK 4/[ADDRESS_159986] treatment prior to starting stud y treatment.

[COMPANY_001] Confidential Page 71
Amended Protocol v03 ( clean ) CLEE011XUS29
Of note, Phase I does not require prior CDK 4/[ADDRESS_159987] 
therap y prior to starting study  treatment. No more than 1 line of chemotherapy  with a maximum 
of 3lines of therap y (including endocrine therapy  and chemotherap y) is allowed in the advanced 
setting.
Incancer patients with hepatitis B, whether carriers or in chronic state, use of antivirals during 
antic ancer therap y hasbeen shown toreduce therisk of hepatitis Bvirus (HBV) reactivation 
and associate d HBV morbidity andmortality (Loomba et al. 2008 ).
5.1.1 Screening for Hepatitis B
Prior toenrollment, thefollowing three categories ofpatients should betested forhepatitis B 
viral load and serologic markers, that is HBV- DNA, HBsAg, HBs Ab, and HBc Ab:
1.All patients who currently live in (or have lived in) Asia, Africa, Central and South 
America, Eastern Europe, Spain, Portugal, and/or Greece.
2.Patients with any of the following risk factors:
known or suspected past hepatitis B infection
blood transfusion( s) prior to 1990
current or prior IV drug users
current or prior dia lysis
household contact [CONTACT_084] B infected patient(s)
current or prior high -risk sexual activit y
body pi[INVESTIGATOR_025]
mother known to have hepatitis B
history suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper 
quadrant pain.
3.Additional patients at the discretion of the investigator .
The management guidelines forpatients indose escalation, inSection 6.4areprovided 
according totheresults ofthe
baseline assessment ofviral load andserolog ical markers for 
hepatitis B.
5.1.2 Screening for Hepatitis C
Patients with anyofthefollowing riskfactors forhepatitis Cshould betested using quantitative 
RNA-PCR:
known or suspected past hepatitis C infection (including patients with past interferon
‘curative’ treatment)
blood transfusions prior to 1990
current or prior IV drug users
current or prior dia lysis

[COMPANY_001] Confidential Page 72
Amended Protocol v03 ( clean ) CLEE011XUS29
household contact [CONTACT_085] C infected patient(s)
current or prior high -risk sexual activit y
body pi[INVESTIGATOR_140915], additional patients may also be tested for hepatitis C.
5.[ADDRESS_159988] to meet all of the following criteria:
1.Adult men and women ( ≥18 years of age) with metastatic or locall y advanced breast 
cancer not amenable to curative treatment by  [CONTACT_140986] y.
*Note: sexua llyactive males should useacondom during intercourse while taking study 
treatment and for 21days after stoppi[INVESTIGATOR_140900] a child in this 
period. A condom is required to be used also by [CONTACT_64079] a male partner in order to prevent delivery of the drug via seminal fluid.
2.Histologic al or cy tological confirmation of hormone -receptor positive (ER+ and/or PR+) 
breast cancer by [CONTACT_140987] .
3. Patient has HER2-negative breast cancer (based on most recentl y anal yzed biopsy ) 
defined as a negative in s itu hy bridization test or an I HC status of 0, 1+ or 2+. If IHC is 
2+, a negative in situ hy bridization (FI SH, CISH, or SI SH) test is required by  [CONTACT_15010].
5.A representative tumo r specimen must be available for molecular testing. N ewly obtai ned 
tumor biopsy  specimen is required if accessible prior to entry  on trial. If tissue is not 
accessible based on surgical evaluation, an archival tumor sample from metastatic site 
may be submitted. 
6.Women must be p
ostmenopausal . Postmenopausal status is defined either by: 
Amenorrhea for at least 12 months and both follicle -stimulating hormone (FSH) 
and/orestradiol levels are in postmenopausal range (according to the local laboratory ) 
OR
History  of bilateral oophorectom y(with or without hy sterectom y)OR
History  of partial hy sterectomy  with FSH and /orestradiol within post -menopausal 
range OR
Ovarian function suppressed with a GnRH agonists (neg ative HCG required) with 
estradiol levels in the postmenopausal range (according to the local laborat ory)
7. Dis ease refractory to either, AI, tamoxifen or fulvestrant defined as:

[COMPANY_001] Confidential Page 73
Amended Protocol v03 ( clean ) CLEE011XUS29
Recurrence while on, or within 12 months of end of adjuvant treatment with letrozole, 
anastrozole, exemestane, tamoxifen or fulvestrant OR
Progression while on, or within one month of discontinuing letrozole, anastrozole, 
tamoxifen or fulvestrant for the treatment of locally advanced or metastatic breast 
cancer.
*Note: There are no restrictions as to which endocrine therapy patient sreceived as their last 
line of therapy just prior to randomization.
8.Patients who received up [ADDRESS_159989] recovered to grade 1 or better from any adverse 
events (except alopecia and /or neuropath y) related to previous therap y prior to starting 
study treatment .
Note: If patient relapsed with documented evidence of progression on/or within 12 months 
from completion of adjuvant endocrine therapy, then this is considered one line of therapy .
9.Patients previously  treated on a nyCDK 4/6 inhibitor ( i.e. ribociclib, abemaciclib OR 
palbociclib) must have:
Remained on treatment for >[ADDRESS_159990] cancer or metastatic 
disease prior to progression, AND
Progressed on, or within 30 day s following the discontinuation of a CDK 4/6 
inhibitor .
Phase II Only:
Patients must have progressed on only one CDK 4/6 inhibitor. A CDK 4/[ADDRESS_159991] treatment regimen prior to starting study  treatment.
*Note: Phase I does not require prior CDK 4/6 inhibitor exposure
*Note: For patients who re ceived prior C DK4/[ADDRESS_159992] be unblinded in order to verify that the patient did receive a CDK4/6 inhibitor. 
10.ECOG Performance Status 0 
– 1.
11.Radiological evidence of recurrence or progression on or after the last therapy  prior to 
starting stud y treatment .
12. Patients must have:
Measurable disease (based on RECI ST 1.1) : defined as at least one lesion that can be 
accuratel y measured in at least one dimension ≥20 mm with conventional imaging 
techni ques or ≥[ADDRESS_159993] or MRI ,
OR
Evaluable disease: b one lesions -lytic or mixed (lytic + sclerotic) in the absence of 
measurable disease 
13.Patient has adequate bone marrow and organ function as defined b y the following LOCAL 
laboratory  values at screening: 

[COMPANY_001] Confidential Page 74
Amended Protocol v03 ( clean ) CLEE011XUS29
Absolute neutrophil count ≥1.5 × 109/L.
Platelets ≥100 × 109/L.
Hemoglobin ≥9.0 g/dL .
Potassium, total calcium (corrected for serum albu min), magnesium andsodium
within normal limits for the institution or corrected to within normal limits with 
supplements before first dose of study  medication .
INR ≤1.5 or ≤ 2.5 while on anti -coagulant .
Estimated glomerular filtration rate (eGFR) ≥ 30 mL /min/1.73m2 according to the 
Modification of Diet in Renal Disease (MDRD) formula
Serum creatinine <1.5 mg/dL or creatinine clearance ≥ 50 mL /min.
Total bilirubin <ULN except for patients with Gilbert ’s syndrome who may  only  be 
included if the total bilirubin is 
≤3.0 × ULN or direct bilirubin ≤1.5 × ULN.
Alanine aminotransferase (ALT) and a spartate transaminase (AST) <
2.5 ×ULN, 
except for patients with liver metastasis, who are only  included if the AST is <5 ×
ULN .
14.
Must be able to swallow ribociclib, everolimus and exemestane capsules/tablets.
15.Patients with metastatic disease are allowed to receive <[ADDRESS_159994] not meet anyof the following criteria:
1.Patient with visceral crisis or an y disease burden that makes the patient ineligible for this 
study per the investigator’s best judgment.
2.Patients who received more than one lin e of chemotherap y for advanced breast cancer.
*Note: A chemotherapy line in advanced disease is an anticancer regimen(s) that contains at 
least 1 cytotoxic chemotherapy agent and given for greater 21 days or longer. If a cytotoxic 
chemotherapy regimen was discontinued for a reason other than disease progression and 
lasted 21 days or less, then this regimen does not count as a "prior line of chemotherapy"
3.HER2 overexpressi onby[CONTACT_14978] (IHC 3+ staining or in situ hybridization 
positive).
4.Patient has received prior treatment with anthracy clines at cumulative doses of 450mg/m² 
or more for doxorubicin or 900 mg/m² or more for epi[INVESTIGATOR_14962].
5.Patient with a known hy persensitivity  to an y of the excipi[INVESTIGATOR_140898], mTOR 
inhibitors, e.g. sirolimus (rapam ycin), exemestane.
6.Previous treatment with mTOR inhibitors .
7.Previous treatment with exemestane for metastatic disease (except patients who received ≤
28days of exemestane for advance dbreast cancer and did not progress).

[COMPANY_001] Confidential Page 75
Amended Protocol v03 ( clean ) CLEE011XUS29
8.Disease progression on m ore than one CDK 4/[ADDRESS_159995] progressed more than 
once on the same CDK 4/[ADDRESS_159996] 7 day s to study  treatment (C1D1). Drugs with ove rlappi[INVESTIGATOR_140916] [ADDRESS_159997] resolved to CTCAE version 4.03 
Grade ≤1 prior to study  treatment (including any  CDK 4/6 inhibit or).”.
10.
Patient has not recovered from all toxicities related to prior anticancer therapi[INVESTIGATOR_140917] 
≤1(based on NCI CTCAE version 4.03) . Exception to this criterion: patients with any  
grade of alopecia and or neuropath y are allowed to enter the stud y.
11. Pat ient has had major surgery  within 14 day s prior to starting study  drug or has not 
recovered from major side effects.
12.Patients with Child P ugh score B or C.
13.Active, bleeding diathesis, or on oral anti -vitamin K medication (except low dose 
warfarin, Low mole cular weight heparin ( LMWH )and acety lsalicy lic acid or equivalent, 
as long as the INR is ≤2.5 while on anti - coagulant). Fondaparinux is allowed.
14.Radiotherap y <[ADDRESS_159998] recovered 
from radiotherap y toxicities prior to starting stud y treatment , and recovered to grade 1 or 
better from related side effects of such therapy  (with the exception of alopecia). 
Radiotherap y is not allowed at target site followi ng screening.
15.Another malignancy  within 3 years prior to starting study  treatment , with the exception of 
adequately treated in- situ carcinoma of the cervix, uteri, basal or squamous cell skin 
carcinoma .
16.Patients with central nervous sy stem (CNS) involvemen t unless they  are at least 4 weeks 
from prior therap
y completion (including radiation and/or surgery) to starting the stud y 
treatment.
17.Patient has impairment of gastrointestinal (GI) function or GI disease that may  
significantl y alter the absorption of th e study  drugs (e.g., ulcerative diseases, uncontrolled 
nausea, vomiting, diarrhea, malabsorption sy ndrome, or small bowel resection).
18.Patient has a known history  of HIV infection (testing not mandatory ).
19.Patient has any  other concurrent severe and/or uncontrolled medical condition that would, 
in the investigator’s judgment, cause unacceptable safet y risks, contraindicate patient’s 
participation in the clinical study  or compromise compliance with the protocol such as: 
chronic pancreatitis.
active untreated or uncontrolled fungal, bacterial o r viral infections, sepsis etc.
Uncontrolled diabetes as defined b yfasting serum glucose >1.5 × ULN .
Acute and chronic, active infectious disorders including viral and nonmalignant 
medical illnesses that are uncontrolled or whose control may bejeopardized by[CONTACT_140988] .

[COMPANY_001] Confidential Page 76
Amended Protocol v03 ( clean ) CLEE011XUS29
20.Fasting serum cholesterol >300 mg/dl or 7.75 mmol/L and fasting trig lycerides > 2.5 × 
ULN. In case one or both of these thresholds are exceeded, the patient can only be 
included after initiation of statin therap y and when the above mentioned values have been 
achieved.
21.Significant s ymptomatic deterioration of lung function. If clinicall y indicated, pulmonary  
function tests including measures of predicted lung volu mes, DLco, O2 saturation at rest 
on room air should be considered to exclude restrictive pulmonary  disease, pneumonitis or 
pulmonary  infiltrates.
22.Active skin, mucosa, ocular or GI disorders of Grade >1.
23.Bilateral diffuse 
lymphangitic carcinomatosis.
24.Clinic ally significant, uncontrolled heart disease and/or cardiac repolarization abnormality  
including an y of the following :
History  of angina pectoris, sy mptomatic pericarditis, coronary  artery  by[CONTACT_9292] 
(CABG) or myocardial infarction within 6months prior to study  entry .
Documented cardiom yopathy .
Left Ventricular Ejection Fraction (LVEF) <50% as determined by  [CONTACT_140989] (MUGA) scan or echocardiogram (ECHO) detected during screening .
History  of cardiac failure ,significant/s ymptomatic brady cardia , Long QT sy ndrome , 
family  history  of idiopathic sudden death or congenital long QT s yndrome or an y of 
the following:
Known risk to prolong the QT interval or induce Torsade’s de Pointes.
Uncorrected h ypomagnesemia or h ypokalemia .
Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg .
Brad ycardia (heart rate < [ADDRESS_159999]), b y ECG or pulse.
On screening, inability  to determine the QTcF interval on the ECG ( i.e.
: 
unreadable or not interpretable) or QTcF >450 msec for men and >470 msec for 
women (using Frederica’s correction). All as determined by  [CONTACT_140960] 
(based on a mean of 3 ECGs).
25.Patient is currently  receiving any  of the following substances and cannot be discontinued 5 
half-lives prior to C ycle 1 Day 1:
That have a known risk to prolong the QT interval or induce Torsade’s de Pointes.
Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit 
hybrids, pummelos, star -fruit, and Seville oranges.
Medications that have a narrow therapeutic window and are predominantly 
metaboli zed through CYP3A4/5.
26.Not able to understand and to comply  with study  instructions and requirements.
27.Pregnant or nursing (lactating) women, where pregnancy  is defined as the state of a female 
after conception and until the termination of gestation, confirmed by  a positive hCG 
laboratory  test.

[COMPANY_001] Confidential Page 77
Amended Protocol v03 ( clean ) CLEE011XUS29
28.Sexually  active males unless they  use a condom during intercourse while taking drug and 
for 21 day s after stoppi[INVESTIGATOR_140900] a child in this period. A 
condom is required to be used also by  [CONTACT_140990].
6 Treat ment
6.1 Stud y treatment
For this study, the terms “investigational drug” or “study  drug” refer to ribociclib (LEE011). 
“Investigational treatment” , or “study  treatment/group” refers to the triplet combination of 
ribociclib, everolimus and exemestane. “Study treatment” refers to all drug comb inations given 
during the course of the trial. All dosages prescribed and dispensed to the patient and all dose 
changes during the stud y must be recorded on the Dosag e Administration Record eCRF.
The investigator or responsible site personnel should instru ct the patient to take the stud y dru gs 
as per protocol (promote compliance). Drug accountability  must be performed on a regular basis. 
Patients will be instructed to return unused stud y drugs to the site at the end of each cy cle. The 
site personnel will ensure that the appropriate dose of each study  drug is administered at each 
visit and will provide the patient with the correct amount of drugs for subsequent dosing.
In phase I dose escalation (c ohort A and B )the subjects will receive everolimus 2.5 mg orally, 
once daily , and exemestane 25mgorally, once daily and anincreasing/decreasing doses of 
ribociclib to establish MTD and/or RP2D for Phase II Group 1.
In phase I
 dose de -escalation (cohort C )the subjects will receive ribociclib 200mg orally, on ce 
daily , and exemestane 25mgorally , once daily and anincreasing/decreasing doses of 
everolimus to establish MTD and/or RP2D for Phase II Group 2.
6.1.1 Dosing regimen
Table 6
-1 Dose and treatment schedule forthe follo wing combination : ribociclib 
+ everolimus +exemestane ( Phase II )
Study 
treatmentsForm and route of administration Dose Frequency/regimen
Ribociclib Capsules /tablets -50mg, 200 mg
For oral useRP2D Group 1 or
RP2D Group 2Days 1 –28 of each 
cycle
Continuous –no rest 
days
Everolimus Tablet -2.5mg
For oral useRP2D Group 1 or 
PR2D Group 2Days 1 –28 of each cycle
Continuous –no rest 
days
Exemestane Tablet -25mg 25mg Days 1 –28 of each cycle

[COMPANY_001] Confidential Page 78
Amended Protocol v03 ( clean ) CLEE011XUS29
For oral use Continuous –no rest 
days
Dexamethasone mouthwash (500mL bottle) : TID swish and spit (NPO X1 h) for 2 cy cles (56 day s)
The study  drugs will be administered as a flat-fixed dose, and not by [CONTACT_140991]. Everolimus and exemestane will be taken orally, once a day ever y day.Ribociclib 
will be administered based on RP2D.
6.2 Dose escalation and de -escalation guidelines: Phase I Safety  
Run-in
The starting doses fortheribociclib +everolimus +exemestane (R-E- E)combination inthe 
dose escalation (cohort A and B) is250mgQDforribociclib, 2.5mgQDforeverolimus, and
exemestane attheapproved dose of 25 mgQD. The doses ofeverolimus and exemestane 
forallpatient sinthis portion will be fixed at 2
.5mgand 25mgrespectively . 
The starting doses fortheribociclib +everolimus +exemestane (R-E- E)combination inthe 
dose de-escalation (Cohort C)is200mgQDforribociclib, 5mgQDforeverolimus, and
exemestane at theapproved dose of 25 mgQD. Thedoses ofribociclib and exemestane for
allpatient sinthis portion will be fixed at 2
00mgand 25 mg respectively . 
The starting doses ofribociclib and everolimus are based upon a review ofthesafety,
tolerability, andPKobserved in th eclinical studies outlined inSection 1.2. Because ofthe
potential drug interaction between ribociclib andeverolimus thatmay inhibit themetabolism
o
feverolimus andincrease drugexposure by [CONTACT_140992] y 3-5-fold, thedose ofeverolimus
will bereduce dto2.5mg or 5mg (based on CLEE011X2106 RDE) from thestandard dose
recommended in the treatment of breast cancer of 10mgQD ( Section 1.2.2). The starting dose
ofribociclib issupported by a recommendation from the CLEE011X2106 study (Section 1.2.4) , 
CLEE011X2101 stud y and CL
EEX2108 stud y (Section [IP_ADDRESS]).
Table 6-2 Dose levels for ribociclib, everolimus and exemestane in Phase I dose 
escalation (cohort A  and B)
Dose Level Ribociclib Everolimus Exemestane
+1 Cohort B 300mgPO daily 2.5 mg PO daily 25mgPO daily
1 Cohort A (Start) 250mgPO daily 2.5 mg PO daily 25mgPO daily
Table 6-3 Dose levels for ribociclib, everolimus and exemestane in Phase I dose 
de-escalation (cohort C)
Dose Level Ribociclib Everolimus Exemestane
0 (start) 200mg PO daily 5 mg PO daily 25mg PO daily
-1 200mgPO daily 2.5 mg PO daily 25mgPO daily

[COMPANY_001] Confidential Page 79
Amended Protocol v03 ( clean ) CLEE011XUS29
6.2.1 Criteria for dose escalation and determination of MTD(s)/RP2D
[IP_ADDRESS] MTD definition
The MTD isdefined as the highest combination drug dosage not causing medicall y 
unacceptable DLTs in more than 33% of thetreated patients inthe first c ycleoftreatment.
AEs andlaborator y abnormalities considered tobeDLTs aredefined in Table 6 -4.Only one
RP2Dwill betested inthePhase II.
In the dose escalation atotal of 6 
patients will be treated at dose-level 1(cohort A). Patients
must complete a minimum of one cy cleoftreatment with theminimum safety evaluation and
drug exposure orhave hada DLT within thefirstcycleoftreatment tobe considered evaluab le
fordose escalatio n decisions . 
If ≤33% of patients experience a DLT in cohort A (dose level 1) , the dose will be 
escalated 
tothe next level cohort B(dose level +1) where 3 patients will be enrolled .
If ≤33% patients experience DLTs in cohort B , an additional 3 patients will be treated at 
the same dose level. 
If ≤33% patients experience a DLT in both cohorts, then the optimal treatment dose based 
on tolerability  and safet yprofile after two cycles will move into Phase II.
If >33% patients experience DLTs in both cohorts , the dose will be de -escalated to the 
next level down .
Dose escalation and R2PD decisions will be/were made jointly by[CONTACT_140993], Steering Committee ,and[COMPANY_001] study personnel.
In the dose de -escalation ( cohort C ), the starting dose ofribociclib andeverolimus are based
upon a review ofthesafety, tolerability, andPKobserved in theclinical studies outlined in
Section 1.2. Because ofthepotential drug interaction between ribociclib andeverolimus that
may inhibit the metabolism ofeverolimus andincrease drugexposure by[CONTACT_140992] y 2-
fold, if ribociclib is dosed at 200mg (based on CLEE011X2106) from thestandard dose
recommended in the treatment of breast cancer of 10mg QD ( Section 1.2.2 ). The starting
dose ofribociclib issupported by a recommendation from the CL EE011X2106 study (Section 
1.2.4)
The MTD is defined as the highest combination drug dosage not causing medica lly 
unacceptable DLTs in more than 33% of the treated patients in t
he first cycle of treatment. AEs 
and laboratory  abnormalities considered to be DLTs are defined in Table 6-4. Only  one RP2D 
will be test ed in the Phase II.
Three patients will be treated at dose
-level 0 (cohort C ). Patients must complete a minimum
of one cycleoftreatment with theminimum safety evaluation anddrug exposure orhave had

[COMPANY_001] Confidential Page 80
Amended Protocol v03 ( clean ) CLEE011XUS29
a DLT within thefirstcycleoftreatment tobe considered evaluab lefordose escalatio n 
decisions. 
If ≤33% of patie nts experience a DLT in cohort C (dose level 0 ), then an additional 3 
patients will be added. 
If ≤33% of patie nts experience a DLT then an expansion phase will be initiated
pending approval from DMC.
If >33% patients experience a DLT in Dose level 0, the dose will be de -escalated to 
the next level down (-1) .  A total of 6 patients with ≤ 33% of patie nts experience a 
DLT will be needed in order for dose to be considered for expansion
6.2.2 Definitions of dose limiting toxicities (DLTs)
A dose- limiting toxicit y (DLT)isdefined as an adverse event orabnormal laboratory  value 
assessed ashaving areasonab lypossible relationship tothestudy medication(s) and is 
unrelated todisease, disease progression, inter-current illness, orconcomitant medications 
that occurs within thefirst 28days of treatment (cycle1)with ribociclib + everolimus + 
exemestane andmeets any ofthecriteria included inTable 6
-4.National Cancer Institute 
Common Terminology Criteria forAdverse event s(NCI CTCAE) version 4.03 will beused 
for all grading.
Whenever apatient experiences toxicit y thatfulfills thecriteria fora
DLT, treatment with the 
study drugcombination will beinterrupted andthetoxicit y will be followed upasdescribed 
inSection 6.2.3. For thepurposes of dose escalation and determination ofthe MTD(s), DLTs 
thatoccu rduring c
ycle1will benecessaril y considered, including those inwhich the event 
started inCycle 1and the confirmation of the DLT occurs ina subsequent cycle. The 
investigator must notify theSponsor immediatel y ofany unexpected CTCAE grade ≥3 adverse
events or laborator y abnormalities . Prior to enrollin g patient s into a highe r dose level, CTCAE 
grade ≥[ADDRESS_160000] completed ≥75% of ribociclib + everolimus + exemestane in cycle 1 (≥21 
days out of 28 days) to be considered for DLT evaluation. Patients not evaluable for DLT could 
be replaced after discussing with the steering committee. 
Appropriate eligibility  criteria and specific DLT definitions, aswell asspecific dose 
modification and stoppi[INVESTIGATOR_140918]. Recommended guidelines for 
proph ylactic orsupportive treatment forexpected toxicities, including management ofstudy 
drug induced adverse events are provided in Table [ADDRESS_160001] eCRF.
Table 6-4 Criteria for defining Dose Limiting Toxicities 
TOXICITY DLT CRITERIA
CTCAE grade 3 thrombocytopenia with bleeding

[COMPANY_001] Confidential Page 81
Amended Protocol v03 ( clean ) CLEE011XUS29
Hematology Febrile neu tropenia (decre asein neu trophils as sociated with fever ≥38.5°C, ANC
<1.0 x109/L)
CTCAE grade 4 neutropenia lasting more than 7 consecutive day s
CTCAE grade 4 thrombocytopenia
Gastr o-intestinal CTCAE grade ≥3 vomiting ≥48 hrs.despi[INVESTIGATOR_140919] i-emetic therapy
CTCAE grade ≥3 diarrhea ≥48 hrs.despi[INVESTIGATOR_140919] i-diarrhea treatment
Hepat o-biliar y CTCAE grade ≥3 total bilirubin
CTCAE gr ade≥[ADDRESS_160002] withtotal bilirubin >2.[ADDRESS_160003] without evidence of 
cholestasis***
OR
For subjects with abnormal baseline AST or ALT or total bilirubin value:
[AST or ALT>2x baseline AND > 3.[ADDRESS_160004]] OR [AST or ALT > 8.[ADDRESS_160005]], 
whichever is lower, combined with [total bilirubin > 2 x baseline AND > 2.[ADDRESS_160006]]
≥ CTCAE grade 3 ALT for more than 4 consecutive days
Cardiac Cardiactoxicity≥CTCAEgrade3
Clinical si gnsof cardi acdisease,such as unstable anginaor myocardial infarction,
orTroponin ≥CT CAE grade3
ECG QT Interval QTcF interval ≥[ADDRESS_160007] two separate ECGs
Renal CTCAE grade ≥3 serum creatinine
Stom atitis CTCAE grade ≥4 stomatitis
Hyperglycemia CTCAE grade ≥4 hypergly cemia
Events not CTCAE grade ≥3, except for the exclusions noted below
Exceptions to DLT 
criteria<7days of CTCAE grade 3 fatigue
<48 hours of CTCAE grade 3 edema
Grade 3 laborator yabnormalities that are responsive to oral supplementation or 
deem ed by [CONTACT_140994]
*** “Cholestasis” defined as ALP elevation [>2.[ADDRESS_160008] and R value < 2] in subjects without bone 
metastasis, or elevation of ALP liver fraction in subjects with bone metastasis)
Note: (The R value is calculated by [CONTACT_6612], using multiples of the ULN for both 
values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to cholestatic (R ≤ 2), 
hepatocellular ( R ≥ 5), or mixed (R >2 and < 5) liver injury)
CTCAE versi on4.03willbeused for all grading.
Optimal ther apyforvomiti ng or diarrhea will be bas edon instituti onal g uidelines,withconsiderati onof
the prohibited medications listed in this proto col.
6.2.[ADDRESS_160009] once every 7days(or more frequent ly
ifrequired by[CONTACT_15931], orif clinically indicated) for30days, andsubsequent ly

[COMPANY_001] Confidential Page 82
Amended Protocol v03 ( clean ) CLEE011XUS29
atapproximately  30dayintervals, until resolution or stabilization ofthe event, whichever 
comes first.
Appropriate clinical experts should be consulted as deemed necessar y .
6.2.4 Doses for Phase II
Thedose used in Phase II,group 1 recommended by [CONTACT_140995] (Phase 
I), was determined to be 
300mg ribociclib (daily) + 2.5mg everolimus (daily ) + 25mg exemestane 
(daily ).
The dose used for phase II ,group 2 recommended by [CONTACT_140996]  
(Phase I), was determined to be 200mg ribociclib (daily ) + 5mg everolimus (daily ) + 25mg 
exemestane (dail y).
[IP_ADDRESS] Ribociclib, everolimus and exemestane administration
Detailed instructions regarding administration of ribociclib capsules /tablets will be supplied to 
Investigator sites in a separate document fr om this protocol.
Complete guidelines for management and administration of exemestane can be found in 
(Section 6.4) and the package insert.
Ribociclib, everolimus and exemestane should be taken as follows:
Patients should be instructed to take the stud y drug combination of one or more 
capsules /tablets of ribociclib with one tablet of everolimus and one tablet of exemestane 
with a large glass of water (~250 mL ) dail y approximately  the same time every  day.
Pat
ients should be instructed to swallow the ribociclib capsules/tablets and everolimus and 
exemestane tablets whole and not to chew, crush or open them.
Patients should take all three drugs after eating a light low fat meal
On day s when PKcollection /ECG is scheduled at the clinic, patients will take ribociclib ,
everolimus and exemestane in the clinic under the supervision of the investigator or 
designee. On all other day s patients will take the ribociclib, everolimus and exemestane 
combination at home.
If vo miting occurs during the course of treatment, no r e-dosing of the patient is allowed 
before the next scheduled dose. The occurrence and frequency ofanyvomiting and/or 
diarrhea (or increase stool frequenc y) during a treatment c ycle must be noted in the 
adverse events section of the eCRF. 
Any
doses that are missed (not taken within 6 hours of the intended time) should be 
skipped and should not be replaced or made up on a subsequent da y.
Patients must avoid consumption of grapefru it, Seville orange s,grapefruit hybrids, 
pomelos, star fruit or products containing the juice of each during the entire study and 
preferab ly [ADDRESS_160010] dose of stu dy medications, due to potential CYP3A4 
interaction with the study medications. Orange juice is allowed.

[COMPANY_001] Confidential Page 83
Amended Protocol v03 ( clean ) CLEE011XUS29
Herbal or dietary  supplements known as strong inhibitors or inducers of CYP3A4/5 or 
those with a known risk of QT prolongation are not permitted. Multivitamins are 
permitted. If the potential for interactions are unknown, then the herbal / dietary
supplements should be avoided.
[IP_ADDRESS] Additional dosing guidelines for scheduled visit days
On days with PK, ECG sampling, chemistry  and/or lipid profile sampling as outlined in Table 7-
1, the following additional guidelines should be followed:
On a day  when PK blood collection is scheduled at the clinic, patients must take study  
treatment in the clinic under the supervision of the I
nvestigator or designee. On all other 
days patients may  take th e study  treatment at home.
The patient must be fasting for at least 8 hours prior to cycle visits that include fasting 
glucose and lipid profile samples. Coffee, tea and water without milk and sugar (or 
artificial sweeteners ) are allowed. 
If a pre -dose E CG measurement should be collected, then the ECG measurement should 
occur before dosing of the study  treatment.
When both PK and ECG are required, please complete the ECG prior to PK draw.
Post-dose ECGs a nd PKs should be collected after dosing of the stud y treatment. ECG 
will be performed according to Section [IP_ADDRESS] and Table 7-5.
Pre-dose samples should be drawn prior to dosing. The sampling time of the PK samples 
and the dosing time must be precisely  recorded in the eCRF.
Post-dose PK samples should be collected after dosing of the stud y treatment. PK sample 
collection will be performed according to Table 7 -6.
6.3 Overview of Dexamethasone oral solution
Dexamethasone steroid
-based oral solution comprised of 0.5 milligrams per 5mL  of alcohol 
free dexamethasone. The oral solution contains citric acid, disodium edentate , flavoring, 
glycerin, meth ylparaben, propy lene gl ycol, propylparaben, sorbitol and water. 
[IP_ADDRESS] Dexamethasone administration
All patients will be given 0.5mg/5 mL dexamethasone steroid mouthwash . The patient will 
initiate the dexamethasone steroid mouthwash on the same day that they  initiate the study  
treatment (C1D1). The alcohol -free, 0.5mg/5mL dexamethasone steroid mouthwash should be 
administered based on the following instructions:
10mL of mouthwash swish and spit 3 times daily  (TID). The mouthwash is to be held in 
mouth and swished around mouth to come in contact [CONTACT_140997] a minimum of two minutes, and then spit out. 
Patient should remain NPO (no food, no drinks, nothing in mouth) for at least an hour 
after administering mouthwash, with the exception of Ny statin (or another topi[INVESTIGATOR_126654]).

[COMPANY_001] Confidential Page 84
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Dexamethasone treatment regimen
Cycle 1 Day  1 (C1D1) is the day  the patient initiates the mouthwash regimen and study  drugs. 
A treatment cycle consists of 28 days. Patients should use mouthwash regimen for two 
consecutive treatment cycles (56 day s).
All patients will be instructed to perform routine “good oral care” each day during the trial. 
Good oral care will consist of: brushing teeth at least twice daily with soft bristled toothbrush 
continue current daily  flossing routine (if patients were not already  flossing daily , they  should
not be instructed to start flossing as this could cause oral trauma), and continue routine dental 
care/maintenance with their dentist, if they  have one. 
Salt water mouth rinse and the stero id mouthwash should be administered based on the 
following instructions:
The Salt water mouth rinse will only  be administered once the onset of Grade 1 stomatitis 
has been noted.
If the salt water (0.9%) mouth rinse is needed, it will be administered as 10mL  swish and spit 
TID and must be done prior to the dexamethasone mouthwash. The patient should administer 
the salt water (0.9%) mouth rinse (swish and spit) and wait for 10-15 minutes before 
administering the dexamethasone mouthwash.
The alcohol -free, 0.5mg /5mL  dexamethasone steroid mouthwash should be administered based 
on the following instructions:
10mL of mouthwash swish and spit TI D. The mouthwash is to be held in mouth and 
swished around mouth to come in contact [CONTACT_140998] a 
minimum of two minutes, and then spit out.
Patient should remain NPO (no food, no drinks, nothing in mouth) for at least an hour
after administering mouthwash, with the exception of Ny statin (or another topi[INVESTIGATOR_126654]).
6.4 Dose modification
6.4.1 Dose cohort modification
For patients who do not tolerate the protocol -specified dosing schedule, ribociclib adjustments 
are recommended in order to allow the patient to continue the study  treatment. 
Dose reductions are not permitted for everolimus, exemestane or GnRH agonists (if 
patient is currently taking). Any changes to the dose or interruption of dosing must be 
recorded on the Dosage Administration Record eCRF. Patients who require a study  treatment 
hold of more than 28 days will be discontinued from the study unless discussed and approved 
by [CONTACT_456] (Section 7.1.2 )
. Once dose-reduced the dose may be re-escalated once discussed 
and approved by [CONTACT_456]. All patients will be followed for AEs and for SAEs for [ADDRESS_160011] dose of study  drug.

[COMPANY_001] Confidential Page 85
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Ribociclib (LEE011)
Management of severe or intolerable adverse reactions requires dose reduction, temporary 
interruption, and/or discontinuation of ribociclib therap y. Each patient is allowed a maximum 
of two dose reductions for ribociclib. After this, the patient will be discontinued from the study 
treatment. For each patient, once a dose level reduction for ribociclib has occurred, the dose 
level may be re -escalated during subsequent treatment cy cles once di scussed and approved by 
[CONTACT_456] . If a dose reduction is required, ribociclib should be reduced one dose level. Dose
levels for ribociclib are provided in Table 6-5.
A dose-dependent DDI was observed between ribociclib and everolimus based on clinical PK 
analyses in a separate dose escalation trial, where everolimus exposure increased 2 -to 4-fold in 
the presence of ribociclib. If a dose adjustment of both ribociclib and everolimus are required, 
a dose reduction in ribociclib is considered as a method to reduce exposure to both drugs since 
everolimus exposure is increased with increased ribociclib doses through a DDI. After 
permanent discontinuation of either ribociclib, everolimus or exemestane, patien
ts should be 
discontinued from study  treatment The dose modification guidelines for study  treatment are 
found in Table 6-5 and Table 6 -6.
Table 6
-5 Phase I dose escalation (cohort A  and B) and Phase II group 1: Dose 
modification guidelines for Ribociclib + everolimus + exemestane 
Ribociclib Everolimus Exemestane
Dose Dose Dose
Starting dose Phase I: refer to 
cohort A, or B.
Phase II cohort 1 : 
300m g (daily)2.5mgdaily 25mg
First dose reduction Reduced by 50mg 2.5mgdaily
Second dose reduction Change current dose
to 21day s out of 282.5mgdaily
Table 6-6 Phase I dose de -escalation (cohort C) and Phase II cohort 2 : Dose 
modification guidelines for Ribociclib + everolimus + exemestane
Ribociclib Everolimus Exemestan e
Dose Dose Dose
Starting dose 200m g daily If starting at dose 
level 0: 5mg daily25mg

[COMPANY_001] Confidential Page 86
Amended Protocol v03 ( clean ) CLEE011XUS29
If starting at dose 
level -1: 2.5mg 
daily
First dose reduction 200m g daily If starting at dose 
level 0: 2.5mg 
daily
If starting at dose 
level -1: 2.5mg 
every other day
Second dose reduction 200m g daily If starting at dose 
level 0: 2.5mg 
every other day
If starting at dose 
level -1: 
discontinue from 
trial
Managem ent of everolimus specific adverse reactions may require temporary  dose reduction 
and/or interruption of everolimus therap y longer than 3 weeks. Recommendations for dose 
interruption of everolimus longer than 3 weeks in the management of everolimus specific 
adverse reactions are summarized inTable 6-7. Clinical judgment of the treating physician 
should guide the management plan of each patient based on individual benefit/risk assessment 
([LOCATION_003] Afinitor®PI 2012). 
Table 6
-7 Dose modification guidelines for ribociclib (if everolimus is held 
longer than 3 weeks for pneumonitis )
Ribociclib Exemestane
Dose Dose
Starting dose 400mgdaily 25mg
First dose reduction 200mg daily
Second dose reduction 200m g 3 weeks on, 1 week 
off
[IP_ADDRESS] Exemestane
No specific dose modifications are recommended for exemestane. Toxicities attributed to
exemestane should be managed in a manner consistent with the investigator’s usual clinical 
practice. Per (exemestane package insert ).

[COMPANY_001] Confidential Page 87
Amended Protocol v03 ( clean ) CLEE011XUS29
6.4.[ADDRESS_160012] few overlappi[INVESTIGATOR_140920]. Special attention will be paid tobloodcounts (cytopenias), mucositis, liver 
function test abnormalities andQTc prolongation. Clinical data from the[CLEE011X2101]
study do not show marked accumulation inribociclib with time, suggesting that itdoes not
substantially inhibit itsown metabolism orclearance. Based ontheknown properties of
exemestane andribociclib ,a clinically significant drug-drug interaction thatwould increase the
toxicities ofeither drug is not a nticipated.
Everolimus andribociclib areinvitro inhibitors andsubstrates ofCYP3A4, andthelatter
is also a time- dependent CYP3A4 inactivator. The available preclinical and clinical data 
therefore suggest thepossibilit y of a drug interaction, specifical lyone that mayincrease 
exposure toeverolimus. Based onsimulation using Simc ypsoftware (Simc ypVersion 12, 
release 1), the proje cted increase in the AUC leac0-6h of everolimus was 3.5-fold following the 
starting daily dos e of [ADDRESS_160013] onribociclib metabolism waspredicted when c o-administered with 
everolimus. Appropriate eligibilit y criteria, dose modification guidelines and stoppi[INVESTIGATOR_63956].
6.4.3 Dose modifications for ribociclib+everolimus+exemestane 
combination
[IP_ADDRESS] Dose modifications and management recommendations for 
hematologic adverse r eactions
Table 6-8 D ose modifications and management recommendations for 
hematologic adverse reactions
(see Table 6 -5and Table 6 -6for dose reduction guide)
Toxicity Grade Dose A djustment and 
Management 
Recommendations
Thrombocy topenia Thrombocy topenia
Grade 1( ≥75 x 109/L) No dose adjustment required.
Grade 2 ( ≥50x 109/L –<75 x 
109/L)Dose interruption of ribociclib 
and everolimus until recovery to 
grade  1.
Re-initiate study treatment at 
the same dose.
Grade 3 ( ≥25 x 109/L -<50 x 
109/L)Dose interruption of ribociclib 
and everolimus until recovery to 
grade  1.

[COMPANY_001] Confidential Page 88
Amended Protocol v03 ( clean ) CLEE011XUS29
Toxicity Grade Dose A djustment and 
Management 
Recommendations
Re-initiate study treatment at 
the same dose level.
If toxicity recurs at grade 3: 
temporary  dose interruption of 
ribociclib and everolimus until 
recover y to grade 1 and 
reduce to the next lower dose 
level. Maintain everolimus at 
same dose
Grade 4(<25 x 109/L) Dose interruption of ribociclib 
and everolimus until recovery to 
grade  1.
Re-initiate study treatment at 
the next lower dose level. If 
toxicity recurs at grade 4: 
discontinue study  treatment
Neutropenia Absolute neutrophil count (ANC)
Grade 1 (≥1.5 x 109/L) No dose adjustment required.
Grade 2 (≥ 1.0 -<1.5 x 109/L) No dose adjustment required.
Grade 3 (≥ 0.5 -<1.0 x 109/L) Dose interruption of ribociclib 
and everolimus until recovery to 
≥1.0 x 109/L.
Re-initiate study treatment at 
the sam e dose level.
If toxicity recurs at grade 3: 
temporary  dose interruption of 
ribociclib and everolimus until 
recover y to grade ≤1 and 
reduce to the next lower dose 
level, or continue at same dose 
with growth -factor support at the 
discretion of the treating 
investigator .
Grade 4 (< 0.5 x 109/L) Dose interruption of ribociclib 
and everolimus until recovery to 
≥1.0 x 109/L.
Re-initiate ribociclib at the next 
lower dose level (first dose 
reduction level) . Maintain 
everolimus at same dose
If toxicity recurs at grade 4: 
temporary  dose interruption of 
ribociclib and everolimus until 
recover y to ≥1.0 x 109/L and 
reduce at the next lower dose 

[COMPANY_001] Confidential Page 89
Amended Protocol v03 ( clean ) CLEE011XUS29
Toxicity Grade Dose A djustment and 
Management 
Recommendations
level. Maintain everolimus at 
same dose 
Febrile Neutropenia Grade 3: ANC<1.0 x 109/L with 
[a single temperature of >38.3 
degrees C (101 degrees F) or a 
sustained temperature of >=38 
degrees C (100.4 degrees F)
for more than one hour]
.Dose interruption of both 
ribociclib and everolimus until 
improvement of ANC ≥ 1.0 x 
109/L and no fever. Restart at 
the n ext lower dose level.
If febrile neutropenia recurs, 
discontinue study  treatment .
Colony Stimulating Factors 
should be considered in patients 
with fever and profound 
neutropenia (<1.0 x 109/L)
Grade 4 Life-threatening
consequences; urgent 
intervention indicatedDiscontinue study treatment
Anem ia (Hemoglobin) Grade 1: ≥10.0 –LLN g/dL No dose adjustment required
Grade 2: ≥8.0 –<10.0 g/dL No dose adjustment required.
Grade 3: <8.0 g/dL Dose interruption of ribociclib 
and everolimus recovery to 
grade 1.
Re-initiate study treatment at 
the same dose.
Grade 4: Life -threatening
consequences;
urgent intervention
indicatedDiscontinue study treatment
PRBC transfusion to be 
considered per NCCN 
guidelines
[IP_ADDRESS] Ribociclib/everolimus dose modification and management for QTcF 
prolongation
Table 6-9 Ribociclib/everolimus dose modification and management for QTcF 
prolongation
(see Table 6 -5and Table 6 -6for dose reduction guide)
Adverse drug reaction Severity Dose adjustment and 
management 
recommendations
QTcF prolongation For All Grades Check the quality of the ECG 
and the QT value and repeat if 
needed.

[COMPANY_001] Confidential Page 90
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse drug reaction Severity Dose adjustment and 
management 
recommendations
Perform analy sis of serum 
electrolytes (K +, Ca++,
Phos phorus , Mg++). If outside 
of normal range, hold ribociclib 
and everolimus, correct with 
supplements or appropriate 
therapy as soon as possible, 
and repeat electrolytes until 
documented as normal.
Review concomitant medication 
usage for the potential to inhibit 
CYP3A4 and/or to prolong the 
QT interval.
Check compliance with correct 
dose and administration of study 
treatment
Consider collecting a time 
matched PK sample; record 
date and time of last study drug 
intake.
Grade 1
QTc 450 -480 msPerform steps 1 -4 as directed in 
“For All Grades.” No dose 
adjustment required.
Grade 2
QTc 481 -500 msHold ribociclib and everolimus.
Perform steps 1 -4 as directed in 
“For All Grades.”  
Repeat ECG as clinically 
indicated until the QTcF returns 
to <481 ms. Restart ribociclib 
withdose reduced
by 1 dose level.
If QTcF ≥ 481 m s recurs, 
ribociclib should be reduced 
again by 1 dose level.
Repeat ECGs 7 days and 14 
days after doseresumption of 
study treatment (then as 
clinically indicated ) for any 
patients who had therapy 
interrupted due to QTcF ≥481 
ms.
Grade 3
QTc ≥[ADDRESS_160014] two 
separate ECGsHold ribociclib and everolimus . 
Perform steps 1 -4 as directed in 
“For All Grades.”  
Transmit ECG immediately and 
confirm prolongation/

[COMPANY_001] Confidential Page 91
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse drug reaction Severity Dose adjustment and 
management 
recommendations
abnormalities with central 
assessment. Perform arepeat 
ECG within one hour of the first 
QTcF of ≥501 m s.
IfQTcF remains ≥[ADDRESS_160015] (or 
qualified specialist) and repeat 
cardiac monitoring as indicated 
until the QTcF returns to <481 
ms.
If QTcF returns to <481 ms, 
study treatment will be reduced
by 1 dose level; 
If QTcF remains ≥ 481 ms after 
performing steps 1 -4 as directed 
in “For All Grades,” discontinue 
ribociclib.
Repeat ECGs 7 days and 14 
days after dose resumption 
(then as clinically indicated) for 
any patients who had therapy 
interrupted due to QTcF 
≥501ms
If QTcF of ≥501 ms recurs, 
discontinue study treatment. 
Perform frequent ECGs until the 
QTcF is <500 msec. Address 
electrolyte, calcium and 
magnesium abnormalities. 
Grade 4
QT/QTc ≥501 or > 60 ms change 
from baseline and
Torsade’s de pointes or 
polymorphic ventricular 
tachycardia, or signs/sy mptoms
of serious arrh ythmiaDiscontinue study  treatment . 
Perform steps 1 -4 as directed in 
“For All Grades.”  
Transmit ECG immediately and 
confirm prolongation/
abnormalities with central 
assessment. Obtain local 
cardiologist (or qualified 
specialist) consultation and 
repeat c ardiac monitoring as 
indicated until the QTcF returns 
to <481 ms.

[COMPANY_001] Confidential Page 92
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Ribociclib/everolimus dose modification and management for 
cardiac dy sfunction
Table 6-10 Ribociclib/everolimus dose modification and management for cardiac 
dysfunction
(see Table 6 -5and Table 6 -6for dose reduction guide)
Adverse drug rea ction Severity Dose adjustment and 
management 
recommendations
Cardiac -Left Ventricular 
Systolic DysfunctionAsymptomatic,
resting ejection fraction 40 -50%;
or 10- 20% drop from baselineMaintain dose level, and 
continue ribociclib and 
everolimus with caution.
Repeat LVEF within 4 weeks or 
as clinically appropriate.
Symptomatic,
responsive to intervention, 
ejection fraction 20 -39%
or >20% drop from baselineHold ribociclib and everolimus 
until resolved, then reduce study 
treatment by [CONTACT_30560];
LVEF measurement to be 
repeated, if not resolved within 
28 days permanently 
discontinue ribociclib and 
everolimus if applicable.
[IP_ADDRESS] Ribociclib/everolimus dose modification and management for 
hepatotoxicity ’s
Table 6-11 Ribociclib/everolimus dose modification and management for 
hepatotoxicit y
(see Table 6 -5and Table 6 -6for dose reduction guide)
HEPA TOTOXICITY (BILIRUBIN, SGPT/A LT, SGOT/AST)
TOTA L BILIRUBIN without A LT/A ST increase above baseline value
Grade 1 (> ULN –1.[ADDRESS_160016]) 
(confirmed 48 to 72hrs later)If confirmed, maintain dose level with LFTs monitored bi-weekly until 
normalizes.
Grade 2 (>1.5 –3.[ADDRESS_160017]) Dose interruption of ribociclib and everolimus
If resolved to ≤grade 1 in ≤21 days, then maintain dose level
If resolved to ≤grade 1 in >21 days or toxicity recurs, lower 1 dose 
level,.Repeat liver enzy mes and bilirubin tests twice weekly  for 2 
weeks after dose resumption
If toxicity recurs after t wo dose reductions, discontinue study 
treatment

[COMPANY_001] Confidential Page 93
Amended Protocol v03 ( clean ) CLEE011XUS29
HEPA TOTOXICITY (A ST or A LT)
AST or A LT without bilirubin elevation >[ADDRESS_160018]
Same grade as baseline or 
increase from
baseline grade 0 to grade 1No dose adjustment required with LFTs monitored per protocol if 
same grade as baseline or bi -weekly in case of increase from 
baseline grade 0 to 1
Increase from baseline grade 0 
or 1 to
grade 2 ( >3.0 –5.[ADDRESS_160019])Dose interruption of ribociclib and everolimus until recovery to 
≤baseline
If resolved to ≤baseline in ≤21 days, then maintain dose level
If resolved to ≤baseline in >21 days or toxicity recurs, then reduce 1 
dose level. Repeat liver enzy me and bilirubin tests twice weekly for 
2 weeks after dose resumption
If toxicity recurs after two dose reductions or recovery to ≤baseline 
grade is >28 day s, discontinue study treatment
Increase from baseline grade 0 
or 1 to
grade 3 ( >5.0 –20.[ADDRESS_160020])Dose in terruption of ribociclib and everolimus until resolved to 
≤baseline grade, then lower 1 dose level of study treatment. 
Repeat liver enzy me and bilirubin tests twice weekly for 2 weeks 
after dose resumption
If recovery to ≤baseline grade is >28 days, discontinue study 
treatment
If toxicity recurs after two dose reductions or recovery to
baseline is > 28 days , discontinue study treatment
Increase from baseline grade 2 
to grade 3
(>5.0 –20.[ADDRESS_160021])Dose interruption of ribociclib and everolimus until resolved to 
baseline, then lower 1 dose level of study treatment
Repeat liver enzy me and bilirubin tests twice weekly for 2 weeks 
after dose resumption
If toxicity recurs after two dose reductions or recovery to ≤baseline 
grade is >28 day s, discontin ue study  treatment
Grade 4 (>10.[ADDRESS_160022]) Discontinue study  treatmentGrade 3 (>3.0 –10.[ADDRESS_160023]) Dose interruption of ribociclib and everolimus
If resolved to ≤ Grade 1 in ≤21days, lower 1 dose level.
Repeat liver enzy mes and bilirubin tests twice weekly for 2 weeks 
after dose resumption
If resolved to ≤grade 1 in >21 days or toxicity recurs, discontinue 
study treatment
Grade 4 (>10.[ADDRESS_160024]) Discontinue ribociclib
Confounding  factors  and/or  alternative  causes  for  increase  of total  bilirubin  should  be excluded  
before dose interruption/reduction. They include but are not limited to: evidence of obstruction, such as 
elevated ALP and GGT typi[INVESTIGATOR_14931], hyperbilirubinemia due to the 
indirect component only (i.e. direct bilirubin component ≤[ADDRESS_160025]) due to hemolysis or Gilbert ’s
Syndrome, pharmacologic treatment, viral hepatitis, alcoholic or autoimmune hepatitis, other 
hepatotoxic drugs. For patients with Gilbert ’sSyndrome, these dose modifications apply to changes in 
direct bilirubin only. Bilirubin will be fractionated if elevated.

[COMPANY_001] Confidential Page 94
Amended Protocol v03 ( clean ) CLEE011XUS29
AST or A LT and concurrent Bilirubin
For patients with normal ALT 
and AST and total
bilirubin at baseline: AST or 
ALT > [ADDRESS_160026] combined
with total bilirubin > [ADDRESS_160027] or 
ALT or total bilirubin at baseline: 
baseline : [AST or ALT >2 x 
baseline AND >3.0x ULN] OR 
[AST or ALT 8.[ADDRESS_160028]] -
whichever is lower -combined 
with [total bilirubin 2 x
baseline AND >2.[ADDRESS_160029]]Discontin ue study  treatment
Confounding factors and/or alternative causes for increased transaminases should be excluded before 
dose interruption/reduction. They include but are not limited to: concomitant medications, herbal 
preparations or dietar y supplements, i nfection, hepato -biliary disorder or obstruction, new or 
progressive liver metastasis, and alcohol intake.
[IP_ADDRESS].1 Additional follow -up for hepatic toxicities
Hepatic toxicity  monitoring includes assessment of the following liver function tests (LFTs ): 
albumin, ALT, AST, total bilirubin, direct and indirect bilirubin alkaline phosphatase 
(fractionated if alkaline phosphatase is grade 2 or hi gher), creatinine kinase, prothrombin time 
(PT)/(PTT), international normalized ratio (INR)and Gamma -glutam yl transpeptidase (GGT ). 
For patients with Gilbert ’sSyndrome: total and direct bilirubin must be monitored, intensified 
monitoring applies to changes in direct bilirubin only. Close observation is recommended in
case of AST, ALT, and/or bilirubin increase requiring dose interruption, which involves:
Repeating liver enzy me and serum bilirubin tests approx. two times weekly . Frequency  of re -
testing can decrease to once a week or less if abnormalities stabilize or return to normal values.
Obtaining a more detailed history  of current sy mptoms.
Obtaining a more detailed history  of prior and/or concurrent diseases including history  of 
any pre-existing liver conditions or risk factors.
Obtaining a history  of concomitant drug use (including non -prescription medication s, 
herbal and dietary  supplements), alcohol use, recreational drug use, and special diets.
Ruling out acute viral hepatitis ty pes A, B, C, D, and E; hepatotropic virus infections 
cytomegalovirus (CMV), Epstein- Barr virus (EBV), or herpes simplex virus (HSV ); 
autoimmune or alcoholic hepatitis; NASH; hy poxic/ischemic hepatopathy ; and biliary  
tract disease.
Obtaining a history  of exposure to environmental chemical agents.
Obtaining additional tests to evaluate liver function, as appropriate (e.g., INR, direct 
bilirubin).
Considering gastroenterology  or hepatology  consultations.

[COMPANY_001] Confidential Page 95
Amended Protocol v03 ( clean ) CLEE011XUS29
Assessing cardiovascular dy sfunction or impaired liver oxy genation, including 
hypotension or right heart failure as possible etiologies for liver dy sfunction.
Obtaining a PK sample, as c lose as possible to last dose of study  drug.
Liver biopsy  as clinicall y indicated to assess pathological change and degree of potential 
liver injury .
Increase in transaminases combined with total bilirubin (TBIL) increase may be indicative of 
drug-induced liver injury (DILI), and should be considered as clinically  important events. The 
threshold for potential DILI may depend on the patient’s baseline AST/ALT and TBIL value; 
patients meeting an y of the following criteria will require further follow -up as out lined below:
For patients with normal AL T AND AST AND TBIL value at baseline: AST or AL T >3.[ADDRESS_160030] combined with TBIL >2.0 x UL N.
For patients with elevated AST or ALT or TBIL value at baseline: [AST or AL T >2 x 
baseline AND >3.[ADDRESS_160031]] OR [AST or AL T >8.[ADDRESS_160032]], whichever is lower, 
combined with [TBIL >2 x baseline AND > 2.[ADDRESS_160033]] .
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as: Alkaline phosphatase (ALP)elevation >2.[ADDRESS_160034] with R value <2 in patients without bone 
metastasis, or elevation of AL P liver fraction in patients with bone metastasis.
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both values [R value = ALT/ULN)/(ALP/ULN)]. It denotes therelative pattern of ALT 
and/or ALP elevation is due to cholesteric or hepatocellular liver injury or mixed type injury .
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat LFT testing as s oon as possible, preferabl y within 48 hours from the 
awareness of the abnormal results. The evaluation should include laboratory  tests, detailed 
history , physical assessment and the possibility of liver metastasis or new liver lesions, 
obstructions/compressions, etc.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medicall y 
significant”, thus met the definition of SAE ( Section 8.2 ), and reported as SAE using the term 
“potential drug-induced liver injury ”. All events should be followed up with the outcome clearl y 
documented.
6.4.4 Dose modification and management for everolimus specific toxicities
Table 6-12 Everolimus specific toxicities management and recommendations
(Refer to dose modification Table 6-5 and Table 6 -6)
A
dverse drug reaction Severity Dose adjustment and 
management 
recommendations
Stomatitis Grade 1 No dose adjustment required.

[COMPANY_001] Confidential Page 96
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse drug reaction Severity Dose adjustment and 
management 
recommendations
Minimal sy mptoms, normal diet Manage with no n-alcoholic 
steroid mouthwash and salt 
water (0.9%) mouth wash four 
times a day.
Grade 2
Symptomatic but can eat and 
swallow modified dietInterrupt everolimus and 
ribociclib until recovery to grade
1.
Re-initiate study treatment at 
the same dose.
If stomatitis recu rs, interrupt 
ribociclib and everolimus until 
recover y to grade 1.Re-initiate 
study treatment at a one dose 
lower. 
Manage with topi[INVESTIGATOR_129515] (e.g. 
benzocaine,butyl minobenzoate, 
tetracaine hydrochloride, 
menthol or phenol) with or 
without topi[INVESTIGATOR_11930] 
(i.e. triamcinolone oral paste) .
Grade 3
Symptomatic and unable to 
adequately aliment or hydrate 
orallyInterrupt everolimus and 
ribociclib until recovery to grade
≤1.Re-initiate study treatment at 
a reduced dos e; 
If reoccurs, interrupt ribociclib 
and everolimus until recovery to 
grade ≤ 1.Re-initiate study 
treatment at second dose level.
Manage with topi[INVESTIGATOR_129515] (i.e. 
benzocaine, butyl 
aminobenzoate, tetracaine 
hydrochloride, ment hol or 
phenol ) with or without topi[INVESTIGATOR_030] (i.e. 
triamcinolone oral paste) .
Grade 4
Symptoms associated with life-
threatening consequencesHold ribociclib and everolimus 
and provide appropriate medical 
therapy. If recovered to ≤grade 
1 within 3 weeks, Re- initiate 
study treatment at a reduced 
dose. If >3 weeks, then 
discontinue study  treatment . 
Serum creatinineGrade 1No dose adjustment required. 
Initiate appropriate monitoring.

[COMPANY_001] Confidential Page 97
Amended Protocol v03 ( clean ) CLEE011XUS29
Adverse drug reaction Severity Dose adjustment and 
management 
recommendations
Grade 2Hold ribociclib and everolimus 
until res olved to grade ≤1, then
re-initiate study treatment at the 
same dose level.
If toxicity recurs at Grade 2, 
interrupt ribociclib and 
everolimus until recover y to
grade ≤1, re- initiate and study 
treatment by [CONTACT_30560]. 
Grade 3Hold ribociclib and everolimus 
until resolved to grade ≤1, then 
reduce study treatment by 1 
dose leve l.If toxicity recurs after 
two dose reductions, 
discontinue study  treatment
Grade 4Discontinue study treatment and 
manage appropriately.
Metabolic events (e.g. 
hyperglycemia, dy slipi[INVESTIGATOR_035])Grade 1No dose adjustment required.
Initiate appropriate medical 
therapy and closely monitor. 
Consider metformin for 
hyperglycemia
Grade 2No dose adjustment required.
Manage with appropriate 
medical therapy and monitor. 
For hyperglycemia, consider 
metform inand follow up with 
endocrinologist
Grade 3Hold ribociclib and everolimus 
until resolved to grade ≤1, then 
reduce study treatment by 1 
dose leve l;.
Manage with appropriate 
medical therapy and monitor.
Grade 4Hold ribociclib and everolimus 
until reso lved to grade ≤1 then 
discontinue study  treatment
[IP_ADDRESS] Pneumonitis
Table 6-13 Management of Pneumonitis
(refer to Table 6 -5and Table 6 -6for dose reduction guide)

[COMPANY_001] Confidential Page 98
Amended Protocol v03 ( clean ) CLEE011XUS29
Worst Grade
PneumonitisRequired 
InvestigationsManagement of
PneumonitisDose A djustment
Grade [ADDRESS_160035] ever y
8-12 weeks until return 
to within normal limits.No specific therapy is 
required
Consider flovent until 
resolutionAdminister 100% of 
study treatment
dose.
Grade [ADDRESS_160036] scan with lung
windows.
Consider pulmonary 
function
testing includes: 
spi[INVESTIGATOR_038] ,
DLCO, and room air O [ADDRESS_160037] ever y
8-12 weeks until return 
to within normal limits.
Consider a 
bronchoscopy with 
biopsy and / or BALSymptomatic only.
Consider flovent and 
corticosteroids if
symptoms are
troublesome.Reduce study 
treatment by [CONTACT_140999] y to 
≤Grade 1. 
Ribociclib and 
everolimus may also be 
interrupted if sy mptoms 
are troublesome.
If failure to recover to 
≤Grade 1 within 3 
weeks , subj ects can 
resume ribociclib at full 
treatment dose (Table 
6-5and Table 6 -6)
until 
recover y to Grade 
≤1. Once recovered, to 
Grade ≤
1, reinitiate 
study treatment and 
reduce study treatment 
(ribociclib+everolimus+
exemestane) by [CONTACT_23615]. 
Grade 3
Symptomatic,
interfering with
ADL; O2
indicatedCT scan with lung 
windows
and pulmonary function 
testing includes: 
spi[INVESTIGATOR_038] , DLCO, and 
room air O 2saturation 
at rest.
Repeat at least ever y 6 
weeks until return to 
within normal limits. 
Bronchoscopy with
biopsy and / or BAL is
recommended.Consider 
corticosteroids if
infective origin is ruled
out. 
Taper as
medically indicated.Hold study treatment 
until recover y to Grade 
≤1.Mayrestart study 
treatm ent within 3
weeks ata reduced
dose (by[CONTACT_141000]) if 
evide nceofclinical
benefit.
Grade 4
Life threatening;
ventilator y
supportCT scan with lung 
windows
and required 
pulm onaryConsider
corticos teroids if
infective origin is ruled
out. Taper asDiscontinue study  
treatment

[COMPANY_001] Confidential Page 99
Amended Protocol v03 ( clean ) CLEE011XUS29
Worst Grade
PneumonitisRequired 
InvestigationsManagement of
PneumonitisDose A djustment
indicated function testing, if 
possible,
includes: spi[INVESTIGATOR_038] , 
DLCO, and room air 
O2 saturation at rest.
Repeat at least ever y 6 
weeks until return to 
within normal limits. 
Bronchoscopy with 
biopsy and / or BAL is 
recommended if 
possible.medically indicated.
6.4.[ADDRESS_160038] Result Result Result Result Result
HBV-DNA + + or - - - -
HBsAg + or - + - - -
HBs Ab + or - + or - +
and no prior HBV 
vaccination+ or - -
or +with 
prior HBV 
vaccination
HBc Ab + or - + or - + or - + -
Recommendation Prophylaxis treatment should be started 
1-[ADDRESS_160039] dose of study 
drug
Monitor HBV -DNA approximately every 
6 weeksNo prophylaxis Monitor HBV -
DNA approximately ever y 4 
weeks at the end of treatment 
and until EOT + [ADDRESS_160040] 4weeks after lastdose ofstudy 
drug. Forhepatitis B reactivation, definition and management guidelines seeTable 6-15
Guidelines for management of hepatitis B.
Table 6
-15 Guidelines for management of hepatitis B
Reactivation is Defined 
as:Treatment
Increase of 1 log in HBV -
DNA relative to baseline 
HBV-DNA value OR new Start appropriate antiviral therapy
AND
Interrupt ribociclib and everolimus administration until resolution:

[COMPANY_001] Confidential Page 100
Amended Protocol v03 ( clean ) CLEE011XUS29
appearance of measurable 
HBV-DNA
AND
ALT elevation x [ADDRESS_160041]≤grade 1 ALT (or baseline ALT, if >grade 1) and
≤baseline HBV -DNA levels
If resolution occurs within ≤21daysstudy  treatment should be r e-
started at one dose lower, if applicable. If the patient is already 
receiving the lowest dose of study drug according to the protocol, the 
patient should restart at the same dose after resolution. Both antiviral 
therapi[INVESTIGATOR_140921] [ADDRESS_160042] dose of study 
drug.
Ifresoluti on occurs >21days Patients should discontinue study  
treatment but continue both antiviral therapi[INVESTIGATOR_140922] [ADDRESS_160043] dose of study treatment
6.4.6 Guidance for all other adverse reactions
Consider performing an analysis of serum potassium, calcium, phosphorus, and magnesium for 
all adverse reactions, if indicated. If electrol yte values are outside of the normal range, interrupt 
ribociclib/everolimus administration, correct electroly tes with supplements or appropriate 
therap y as soon as possible, and repeat electrol yte testing until documented normalization of 
the electrol ytes.
Table 6-16 Ribociclib/everolimus dose adjustment and management 
recommendation for all other adverse reactions
(see Table 6 -5and Table 6 -6for dose reduction guide)
Grade/Severity Dose adjustment and management recommendations
Grade 1 No dose adjustment -maximize AE m anagement
Grade 2 Dose interruption of ribociclib/everolimus until recover y to 
Grade ≤1
Initiate appropriate medical therapy and monitor
Re-initiate study  treatment at the same dose
If the same toxicity recurs at Grade 2, interrupt 
ribociclib/everolimus until recover y to Grade ≤1. Re -initiate 
study treatment at the next lower dose level .
Grade 3 Hold both everolimus and ribociclib until it resolves to ≤Grade 
1.
Initiate appropriate medical management and monitor
Re-initiate study  treatment at the next lower dose level 
If toxicity recurs at grade 3, discontinue study  treatment
Grade 4 Discontinue study  treatment
Additional recommendations (see supplementary management brochure for further 
recommendations) :
Nausea :Ensure adequate hydration or fluid repletion. Consider performing an analy sis of serum 
potassium, calcium, phosphorus and magnesium, if indicated . If electrolyte values are below LLN, 
interrupt ribociclib, correct electrolytes with supplements as soon as possibl e, and repeat electrolyte 
testing until documented normalization. 

[COMPANY_001] Confidential Page 101
Amended Protocol v03 ( clean ) CLEE011XUS29
Diarrhea : At the first sign of loose stools ( Grade 1), initiate loperamide. Patient should remain well 
hydrated. Fluids and electrolytes should be replaced as needed . Consider performing a n analysis of 
serum potassium, calcium, phosphorus and magnesium, if indicated .If electrolyte values are below 
LLN, interrupt ribociclib, correct electrolytes with supplements as soon as possible, and repeat 
electrolyte testing until documented normalizat ion. 
6.5 Concomitant medications
6.5.1 Permitted concomitant therapy  for all treatment groups
Medications required totreat AEs, manage cancer symptoms, concurrent diseases and 
supportive care agents, such aspacked redbloodcells (PRBCs), pain medications, anti-
emetics, short courses ofsteroids, chronic useofa low dose steroid forphysiologic replacement, 
topi[INVESTIGATOR_140923]-diarrheal are allowed . The use of any other potential 
new concomitant medications may be discussed between the investigator and the sponsor on a 
case by  [CONTACT_413].
The patient must betold tonotif y theinvestigational siteabout any new medications he/she 
takes after thestart ofthestudy drugcombination. Allmedications (other than study drugs) 
and significant non-dr ug therapi[INVESTIGATOR_014] (including vitamins, herbal medicines, ph ysical thera p yand 
blood transfusions) administered within [ADDRESS_160044] be 
listed on the Concomitant medications/Significant non- drug therapi[INVESTIGATOR_14932].
Patients taking concomitant medication chronically should bemaintained onthesame dose 
anddose schedule throughout thestudyperiod, asmedical ly feasible.
Refe r tothe (LEE011 Investigator’s Brochure ), (everolimus Investigator’s Brochure ), 
(aromasin package insert )and(Appendix 1 for concomitant medications).
[IP_ADDRESS] Hematopoietic growth factors
The use of Transfusions orHematopoietic growt hfactor support (e.g. erythropoietins, G -CSF
andG
M-CSF) should be according toASCO guidelines .
[IP_ADDRESS] Bisphosphonates and denosumab
Bisphosphonates and denosumab are generally allowed with the following comments:
Bisphosphonat e/denosumab thera py for the treatment of osteoporosis is permitted.
Bisphosphonat e/denosumab thera py for the prevention of skeletal related events for 
patients with existing bone metastases is permitted.
If bisphosphonate therapy is to be started after the first dose of study drug, prior 
consultation and approval by [CONTACT_141001] y 
documented.

[COMPANY_001] Confidential Page 102
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Palliative radiotherapy
Palliative radiation ispermitted while on study  after discussion with sponsor . Itshould not
be delivered to a target lesion and it should not encompass more than 25% of irradiated bone 
marrow.
Ifpalliative radiotherapy isinitiated afterthestart ofstudy treatment, thereason foritsuse 
must be clear ly documented and progression as per REC IST 1.[ADDRESS_160045] be ruled out.
No dose modification of study treatment is needed during palliative radiothera py.
[IP_ADDRESS] Use of antiemetic medications
Ribociclib has low to minimal emetogenic potential according to a the definition of 
antineoplastic agent emetogenicit y (Grunberg et al 2010). Antiemetic therapy  can be used 
according to clinical guidelines for antineoplastic medications with low to minimal emetogenic 
potential for treatment and/or prevention of nausea and vomiting as a result of study  treatme nt 
(NCCN Clinical Practice Guidelines in Oncology . Antiemesis, 2017; Roila F et al 2016).
Potential drug interaction between ribociclib and antiemetic medications should alway s betaken into 
consideration. Example of a prohibited antiemetic medication is ondansetron that incombination 
with ribociclib may precipi[INVESTIGATOR_14933]. Refer to Appendix [ADDRESS_160046] of medications that are prohibited 
or allowed to be used with ribociclib.
6.5.2 Prohibited concomitant therapy  during combined ribociclib + 
everolimus + exemestane
The following medications are prohibited during study  treatment in the study  (see Table 14-[ADDRESS_160047] the medic al monitor with any  questions):
Strong and moderate inhibitors or inducers of CYP3A4/5
.
Substrates of CYP3A4/5 with a narrow therapeutic index .
Medications with a known risk for QT prolongation.
Other investigational and anti- neoplastic therapie s , including chemotherap y, 
immunotherap y,target therap y, biological response modifiers, or endocrine therap yother 
than exemestane .
Hormone replacement thera py, topi[INVESTIGATOR_4575] (including a nyintra-vaginal 
preparations), megestrol acetate and sele ctive est rogen-receptor modulators (e.g. 
raloxifene).
Prolonged systemic corticosteroid treatment (≥2 weeks) , except for topi[INVESTIGATOR_14929] 
(e.g. rash), inhaled spray s (e.g. obstructive airwa ys diseases), dexamethasone mouthwash 
(provided b y [COMPANY_001]), ey e drops or local injections (e.g. intraarticular) should not be 
given. A short duration of sy stemic corticosteroids is allowed (e.g. chronic obstructive 
pulmonary disease, LFT abnormality )
.
Herbal preparations/medications (except for vitamins) or dietary  supplemen ts that are 
strong inhibitors or inducers of CYP3A4/5 or those with a known risk of QT prolongation ,

[COMPANY_001] Confidential Page 103
Amended Protocol v03 ( clean ) CLEE011XUS29
including, but not limited to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, black cohosh and ginseng. 
Patients should stop using these preparations at least [ADDRESS_160048] dose of study
treatment.
6.5.3 Permitted concomitant therapy  requiring caution and/or action w hile 
on study
Permitted medications tobeused with caution combined ribociclib +everolimus + exemestane 
treatment inthis stu dy (Appendix 1, Table 14-2) arelisted below. These medications should 
be
excluded from patient useifpossible. Ifthey must begiven based ontheinvestigator’s 
judgment, then usewith caution and consider aribociclib interruption iftheconcomitant 
medication is only needed for a short tim e:
Moderate inhibitors or inducers of C YP3 A4/5.
Sensitive substrat eso f CYP3A4 /[ADDRESS_160049] na rrow ther apeu tic index.
Str
ong inhibitors of BSEP.
Med
ications that carry a possible risk for QT prolon gat ion.
Sensitive substrates of the renal transporters, MATE1 and OCT2.
Sensitive substrates of BCRP (has a potential to increase exposure to substrates of these 
transporters, although no animal or clinical data are available to support these statements)
[IP_ADDRESS]   Corticosteroids
Chronic dosing of corticosteroids such as dexamethasone and prednisone is known to lead to
induction of CYP3A enzymes, thereb y potentially  increasing the risk of reducing ribociclib drug 
exposure to subtherapeutic levels. Sy stemic corticosteroid treatment should not be given during the 
study , except for:
Topi[INVESTIGATOR_14929] (e.g., rash), inhaled spray s (e.g., obstructive airway s diseases), eyedrops 
or local injections (e.g., intra -articular);
A short duration (< 5 days) of systemic corticosteroids ≤ to the anti -inflammatory potency
of 4 mg dexamethasone (e.g. for chronic obstruc tive pulmonary  disease, or as an antiemetic)
6.5.4 Drugs with QTc prolongation
Asfaraspossible, avoid co-administration of QTprolonging drugs oranyother drugs with 
thepotential toincrease therisk o fdrug-related QTprolongation (e.g., viaapotential DDI 
that increases theexposure ofribociclib or theexposure of theQTprolonging drug). A 
definitive list of drugs w ithaknown risk, possible risk, or conditional risk of QTprolongation 
and/or Torsades de Pointes (TdP) is available online at www.qtdrug.org.and in Appendix 1.
Medications with a known risk for QT prolongation are prohibited during study  treatment .

[COMPANY_001] Confidential Page 104
Amended Protocol v03 ( clean ) CLEE011XUS29
6.6 Patient num bering, treatment assignment or randomization
6.6.1 Patient numbering
Each patient is identified in the study  by a Patient Number (Patient No.), that is assigned when 
the patient is first enrolled for screening (signs consent) and is retained as the primary  identifier 
for the patient throughout his/her entire participation in the trial. The Patient No. consists of a 
4 digit Center Number (Center No.) (as assigned by [CONTACT_141002]) with a 
sequential [ADDRESS_160050] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages prescribed to the patient and all dose changes during the study  must 
be recorded on the Do sage Administration Record CRF.
Ribociclib will be supplied as capsules or tablets for oral use. The capsules or tablets will be 
packaged in bottles. Everolimus and exemestane will be supplied as tablets for oral use. Refer 
to Table 6-1for ribociclib capsule /tablet and everolimus and exemestane tablet strengths. 
Ribociclib , everolimus and exemestane will be dosed on a flat scale ofmg/day and not adjusted 
to body  weight or body surface 
area. The dexamethasone mouthwash must be received by 
[CONTACT_121937], handled and stored safel y and properly , and kept in a 
secured location to which only  the investigator and designated site personnel have access. The 
dexamethasone mouthwash should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled 
Room Temperature]. Dispense in original, commercial container.
6.6.4 Study drug packaging and labeling
Ribociclib capsules /tablets are packaged in high density  polyethylene (HDPE) bottles with child 
resistant closures. Everolimus tablets are packaged in blister packs (4 blisters per pack per 
strength). Exemestane tablets are packaged in high density  polyethylene (HDPE) bottles with 
child resista nt closures.
Medication labels will be in the local language and comply  with the legal requirements of the 
[LOCATION_002]. They  will include storage conditions for the drug but no information about the 
patient. The medication will be supplied as open label supply to the sites in a wa y which allows 
the patien t to take medication at home.
Ribociclib capsules /tablets, Everolimus and Exemestane tablets, and dexamethasone 
mouthwash will be supplied by  [CONTACT_5343].

[COMPANY_001] Confidential Page 105
Amended Protocol v03 ( clean ) CLEE011XUS29
6.6.[ADDRESS_160051] access. Upon receipt, the study treatment should be stored according to the 
instructions specified on the drug labels, andin the (Investigator’s Brochure for LEE011) and 
the package insert for everolimus,exemestane , and dexamethasone .
6.6.6 Study drug compliance and accountabi lity 
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit and 
information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each patient 
visit.
On days of PKsampling and scheduled ECG visits to the clinic, the patient will take their 
assigned combination of drugs at the clinic. For all other study  days, the patient will take their 
assigned combination at home. The time of dose administrations taken in the clinic must be 
recorded in the Dosage Administration Record eCRF.
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_141003]. Patients will be asked to return all 
unused study  treatment and packaging on a regular basis, at the end of the study  or at the time 
of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , the investigator will return 
all used and unused study  treatment, packaging, drug labels, and a copy  of the completed drug 
accountability  log to the monitor or to the [COMPANY_001] address provided in the investigator folder 
at each site.
6.6.[ADDRESS_160052] party , as appropria te. Ifpre-arranged between 
[COMPANY_001] and stud y site, destruction of used and unused ribociclib, everolimus, exemestane and 
dexamethasone will be performed at the stud y site if permitted by [CONTACT_427]. 
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Below is alistall of theassessments andindicates with an “X ”thevisits when they are 
performed. All data obta ined from these assessments must be supported in the patient’s source 

[COMPANY_001] Confidential Page 106
Amended Protocol v03 ( clean ) CLEE011XUS29
documentation. The table indicates which assessments produce data tobe entered into the 
database (D) or remain in source documents only (S) (“Categor y” column).
The following are based on local lab results. Allowed visit windows are specified as follows:
Screening assessments, apart from those listed below, must occur within [ADDRESS_160053] dose of study  treatment as perTable 7 -1.
Vital signs, phy sical exam, l aborator y
assessments and ECOG performance status that
were completed withi n 3 days prior toDay 1ofeach cycle(e.g. C1D1) do not need tobe
repeated on day  1 of that respective cy cle.
For all other visits, a ±3 da
y window is permitted on assessments to take into account 
scheduling, if not explicitl yspecified otherwise. For efficac y assessments there isa±7
day window for those done within 12 months of C1D1. After 12 months, there is a ±[ADDRESS_160054] be performed as outlined in Table 7-2.

[COMPANY_001] Confidential Page 107
Amended Protocol v03 ( clean ) CLEE011XUS29
Table 7-[ADDRESS_160055] treatment follow -up phase Survival 
phase
Visit name [CONTACT_15102] 1 Cycle 2 Cycle 3
Subsequent 
cyclesEnd of 
study 
treatment 
(EOT) Safety 
follow -up Efficacy 
follow -upEnd of 
post-
treatment 
follow -upSurvival 
follow -up 
Study  days -[ADDRESS_160056] dose + 
30 daysEvery 8 
weeks (if 
applicable) Every 6 
months
Screening
Study Informed Consent D 7.1.1 X
IRT Screening (after ICF 
signature)S [IP_ADDRESS] X
Disposition Assessment
End of Phase Disposition D [IP_ADDRESS] X X X
Patient history
Demography D [IP_ADDRESS] X
Inclusion/exclusion 
criteriaD 5.2 X
Medical history and 
current medical 
conditionsD [IP_ADDRESS] X
HER2 status D [IP_ADDRESS] X
Pregnancy test (if GnRH 
antagonist required)D 5.3 X 

[COMPANY_001] Confidential Page 108
Amended Protocol v03 ( clean ) CLEE011XUS29Category
Reference to 
protocol 
sectionScreening phaseTreatment phase Post treatment follow -up phase Survival 
phase
Visit name [CONTACT_15102] 1 Cycle 2 Cycle 3
Subsequent 
cyclesEnd of 
study 
treatment 
(EOT) Safety 
follow -up Efficacy 
follow -upEnd of 
post-
treatment 
follow -upSurvival 
follow -up 
Study  days -[ADDRESS_160057] dose + 
30 daysEvery 8 
weeks (if 
applicable) Every [ADDRESS_160058] [IP_ADDRESS] X
Prior antineoplastic 
therapyD [IP_ADDRESS] X
Prior / concomitant 
medicationsD 6.5 Continuous –up to [ADDRESS_160059] dose
Assessments
Physical examination S [IP_ADDRESS] X X1X X X X
Performance status D [IP_ADDRESS] X X1X X X X
Height D [IP_ADDRESS] X
Weight D [IP_ADDRESS] X X1X X X X
Vital signs D [IP_ADDRESS] X X1X X XX X X
Laboratory  assessments
Hematology D [IP_ADDRESS].1 X X1X X XX X X
Chemistry D [IP_ADDRESS].2 X X1X X XX X X
Fasting Lipid PanelD [IP_ADDRESS].[ADDRESS_160060] 
cycleX

[COMPANY_001] Confidential Page 109
Amended Protocol v03 ( clean ) CLEE011XUS29Category
Reference to 
protocol 
sectionScreening phaseTreatment phase Post treatment follow -up phase Survival 
phase
Visit name [CONTACT_15102] 1 Cycle 2 Cycle 3
Subsequent 
cyclesEnd of 
study 
treatment 
(EOT) Safety 
follow -up Efficacy 
follow -upEnd of 
post-
treatment 
follow -upSurvival 
follow -up 
Study  days -[ADDRESS_160061] dose + 
30 daysEvery 8 
weeks (if 
applicable) Every 6 
months
Coagulation D [IP_ADDRESS] X As clinically indicated X
Urinalysis D [IP_ADDRESS].3 X X1X X
Tumor assessment
Tumor evaluation 
(RECIST 1.1)D [IP_ADDRESS] X CT/MRI Chest, Abdomen, Pelvis +/-whole body bone scan +/- X-ray
Every [ADDRESS_160062] 12 months, and then every 
12 weeks thereafter until disease progression
Cardiac assessment
ECG (standard 12 -lead)D [IP_ADDRESS].1 X (Must be
completed 
between days -7 
to -1)X X XX X X
For all 
cycles up 
to Cycle 6
As clinically indicated
ECHO or MUGA D [IP_ADDRESS].2 X As clinically indicated
Safety
Adverse events D 8.1 X Continuous X X
Pharmacokinetics
PK D 7.2.3 X X X XX

[COMPANY_001] Confidential Page 110
Amended Protocol v03 ( clean ) CLEE011XUS29Category
Reference to 
protocol 
sectionScreening phaseTreatment phase Post treatment follow -up phase Survival 
phase
Visit name [CONTACT_15102] 1 Cycle 2 Cycle 3
Subsequent 
cyclesEnd of 
study 
treatment 
(EOT) Safety 
follow -up Efficacy 
follow -upEnd of 
post-
treatment 
follow -upSurvival 
follow -up 
Study  days -[ADDRESS_160063] dose + 
30 daysEvery 8 
weeks (if 
applicable) Every 6 
months
Study  Drug administration
ribociclib D [IP_ADDRESS] Daily
everolimus D [IP_ADDRESS] Daily
exemestane D [IP_ADDRESS] Daily
dexamethasone D [IP_ADDRESS] TID through Cycle 2
Discontinuation
New antineoplastic 
therapi[INVESTIGATOR_140924] 7.1.6 X X

[COMPANY_001] Confidential Page 111
Amended Protocol v03 ( clean ) CLEE011XUS29Category
Reference to 
protocol 
sectionScreening phaseTreatment phase Post treatment follow -up phase Survival 
phase
Visit name [CONTACT_15102] 1 Cycle 2 Cycle 3
Subsequent 
cyclesEnd of 
study 
treatment 
(EOT) Safety 
follow -up Efficacy 
follow -upEnd of 
post-
treatment 
follow -upSurvival 
follow -up 
Study  days -[ADDRESS_160064] dose + 
30 daysEvery 8 
weeks (if 
applicable) Every 6 
months
Survival follow -up(phone 
call)D 7.1.[ADDRESS_160065] day of cycle . Use of the same value in 
screening and C1D1 is allowed if done within 3 days of cycle 1 day 1. 

[COMPANY_001] Confidential Page 112
Amended Protocol v03 ( clean ) CLEE011XUS29
7.1.1 Screening
TheStudy IRB/IECapproved Informe d Consent Form (ICF) must besigned anddated before 
anyscreening procedures areperformed (procedures thatarepartoftheclinical routine during 
theinitial diagnostic work -up of thepatient maybeperformed before signing theICF).A 
copy oftheICFmust begiventothepatien t ortotheperson signing theform. The Investigator
ordesignee must recor dthedate when thestudy informed consent wassigned in the medical 
records of the patient.
After signing thestudyInformed Consent Form, thescreening assessments willbe done within
21daysprior to day  one of study  treatment for selected assessments (Table 7 -1and Table 7-2 )
for the list of assessments to be performed).
Anyimaging assessments alrea dycompleted during theregul arwork -up of thepatient within 
28days prior tostarting study  treatment
,including before signing themainstudy ICF canbe 
considered as the baseline images for this study.
Re-screening ofpatients isallowed once perpatient ifthepatient was not registered as entering
thetreatment phase . Inthiscase theSubject Number assigned tothepatien tinitiall y will be
usedandthepatient will be identifie dwiththisnumber throughout his/her entire participation 
to the stud y
.
Forlaborator y evaluations used todetermine eligibilit y,repeated evaluation within the 
screening window arepermitted forscreening result s out of thedefined range. If therepeated 
laboratory  result meets thecriteria, that result may beused todetermine eligibilit y. In c ase
rescreening occurs, allevaluations re-assessed should meet the eligibility  criteria
[IP_ADDRESS] Eligibility  screening
Following registration intheIRT forscreening, patient eligibility  willbechecked once all 
screening procedures ar
e completed. The eligibilit y check will be embedded in the IRT system. 
Please refer and compl ywith detailed guidelines in the IRTmanual.
[IP_ADDRESS] Information to be collected on screening failures
Patients who sign aninformed consent butfailtostart treatment forany reason will be 
considered a screen failure. The reason for not being started on treatment will be entered on the
Screening Phase Disposition Page . The demographic information, informed consent, and 
Inclusion/Exclusion pages must also becompleted for Screen Failure patients. Noother data 
will be entered into the clinical database for patients who are screen failures, unless the patient 
experienced aSerious Adverse Event during the Screening Phase (Section 8.2for SAE 
reporting details).
[IP_ADDRESS] Patient demographics and other baseline characteristics
The data that will be collected on patient characteristics at screening includes:
Demograp hy(Date of birth andinitials, sex, race,ethnicit y,source of patient referral)
Diagnosis and exte nt of cancer (including staging at study entryandhistolog y/cytolog y)

[COMPANY_001] Confidential Page 113
Amended Protocol v03 ( clean ) CLEE011XUS29
Medical history (e.g., important medical, surgical, andallergic conditions from the 
patient’s medical history which could have animpact on th e patient’ s evaluation ) / current 
medical conditions (e.g.,allrelevant current medical conditions which are present at 
the 
time ofsigning informed consent). Ongoing medical conditions, symptom sanddisease 
which are recorded on the Medical History eCRF should include the toxicity grade.
ER, PgR and HER2 status
Rb status
Allprior antineoplastic therapi[INVESTIGATOR_140925] ,
biologi c, immunologi cand radiation therapi[INVESTIGATOR_140926].
All medications and significant non-drug therapi[INVESTIGATOR_14939] [ADDRESS_160066] be recorded in the Prior and Concomitant medication or 
Surgicalandmedical procedures eCRF page andupdated ona continual basis ifthere are 
anynew changes to the medications.
Furthermore 
the following assessments will be performed:
Vital signs
Height, weight
Physical examination
Performance status (ECOG)
Laboratory evaluations (hematolog
y, PT/PTT , INR, chemistr y (including LFTs) , lipid 
panel, HBV -DNA, HBsAg, HB Ag, HBc Ab, HCV -RNA -PDC, urinaly sis, and FSH, LH 
and/or estradiol (if necessary ) 
ECG
ECHO/MUGA
Radiological assessments (e.g. CT /MRI /bone scan)
PK 
7.1.[ADDRESS_160067] follow theInvestigator ’sinstructions with regards 
to contraception, concomitant medications, and dosing regimen (see Section 6). Patients willbe 
treated with ribociclib + everolimus + exemestane
until disease progression, unacceptable
toxicit y,withdrawal ofconsent by [CONTACT_15619], patient islostto follow up,death, discontinuation
from thestudy treatment duetoany otherreason orthe sponsor terminates the study. For details 
of assessments, refer to Table 7 -2, and Table 7 - 3.
I
f apatient remains onstudy a fteradose interruption of >[ADDRESS_160068] bereported inthesource documentation and 
in a comment in the eCRF.

[COMPANY_001] Confidential Page 114
Amended Protocol v03 ( clean ) CLEE011XUS29
7.1.3 End of study  treatment visit including safety completion and study 
treatment discontinuation
Patients who discontinue study  treatment should be scheduled for an End of Treatment (EOT) 
visit within [ADDRESS_160069] determine the primary  reason for a patient’s premature withdrawal from 
the study  and record this information on the EOT eCRF page. The EOT visit is not considered 
the end of the stud y.
At a minimum, all patients who discontinue study  treatment, includi ng those who refuse to 
return for a final visit, will be contact[CONTACT_15025] y evaluations during the [ADDRESS_160070] dose of study  treatment.
If a patient discontinues study  treatment, but continues study  assessments, the patient remains
on study  until such time as 
he/she completes protocol criteria for ending study  assessments. At
that time, the reason for study  completion should be recorded on the End of Post Treatment
Phase Disposition CRF page.
The investigator must also contact [CONTACT_105253]’s discontinuation from study  
treatment.
7.1.[ADDRESS_160071] make every effort 
(e.g. telephone, e -mail, letter) to determine the primary  reason for this decision and record this 
information i n the patient’s chart and on the appropriate eCRF pages. They  may  beconsidered 
withdrawn if they state an intention to withdraw, fail to return for visits, or become lost to 
follow -up for an y other reason.
The investigator should discontinue study  treatme nt for a given patient if, on balance, he/she
believes that continuation would be detrimental to the patient’s well -being.
Patients may  be withdrawn from the study  treatment if an y of the following occur:
Adverse Event 
Lost to follow -up
Physician decision
Progressive Disease
Protocol deviation
Study  terminated by  [CONTACT_3211]
Technical problems
Patients must be withdrawn from the stud y treatment if an y of the following occur:
Pregnancy

[COMPANY_001] Confidential Page 115
Amended Protocol v03 ( clean ) CLEE011XUS29
Death
Subject/Guardian decision
In addition to the general withdrawal criteria, the following study  specific criteria will also 
require stud y treatment discontinuation:
Adjustments to study  treatment that result in discontinuation. Please refer to Section 6.4.
Use of prohibited medication. Please refer to Section 6.5 andAppendix 1 .
Patients who discontinue study  treatment should NOT be considered withdrawn from thestudy . 
They should return for the assessments indicated in Table 7-1. If they fail to return for these 
assessments for unknown reasons, every effort (e.g. telephone, email, letter) should be made to 
contact [CONTACT_141004] 7.1.8. 
Patients who discontinue study  treatment should undergo an End of Treatment (EOT) visit 
followed b y a 30 day safety follow -up.
7.1.5 Withdrawal of consent
Patients may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a patient:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data.
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the patient’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. Further attempts to 
contact [CONTACT_141005] -up.
All efforts should be made to complet e the assessments prior to study  withdrawal. A final 
evaluation at the time of the patient’s study  withdrawal should be made as detailed in the 
assessment table. [COMPANY_001] will continue to keep and use collected study information (including 
any data resulti ng from the analy sis of a patient’s samples until their time of withdrawal) 
according to applicable law.
7.1.[ADDRESS_160072] safety evaluations for30 days afterthelastdose ofstudy treatment. 
Information related toAEs (including concomitant medication taken for ongoing AEs) and 
ongoing anti-neoplastic treatments will becollected for30 days after thelastdose ofstudy 
drug. AllAEs suspected toberelated tostudy treatment should befollowed upasclinical ly 
indicated, until resolution or stabilization. Data collected should beadded t o the Adverse Events 
CRF, Concomitant Medications CR F, and Anti-neoplastic treatment CR F.

[COMPANY_001] Confidential Page 116
Amended Protocol v03 ( clean ) CLEE011XUS29
7.1.7 Efficacy  Follow -up
Patients enrolled in thisstudy who discontinue study treatment for any reason other than disease
progression willbefollowed upevery 8 (±1 weeks) weeks viaa phone call and CT/MRI  scans 
asdetailed in Table [ADDRESS_160073]. Antineoplastic therapi[INVESTIGATOR_140927]/U period must b
erecorded onthe Antineoplastic Therapi[INVESTIGATOR_140928].
7.1.[ADDRESS_160074] to Follow -up
Forpatientswhose statu s isunclear because they failtoappea rforstudyvisitswithou tstating 
anintention towithdraw consent, theinvestigator should show "due diligence" by[CONTACT_5368], familyorfamilyphysician as ag reed intheinformed consent andby [CONTACT_141006] 
i
nthesource docu mentssteps taken tocontact [CONTACT_15619], e.g.dates oftelephone calls, 
registered letters,etc.Apatientshould not be considered lostto follow -upuntil duediligence 
has bee ncompleted. Patients losttofollow upshould berecorded assuch ontheappropriate 
Disposition CRF.
7.2 Assessment types
7.2.1 Efficacy  assessments
[IP_ADDRESS] Imaging tumor assessments
Tumor response will beassessed local ly andcentrall y according toREC ISTVersion 1.1
(Eisenhauer et al 2009 ). The decision regarding patient management will remain with the local 
investigator. Patients should have at least one documented measurable lesion (per RECIST v1.1) 
or in the absence of measurable disease, have at least one lytic or mixed (blastic/ly tic) bone 
lesion at study  entry .
Imaging assessments will
beperformed at screening within 21dayspriortofirst dose 
of study  treatment and subsequent lyevery 8week s(+/- 1 week) from day one of study 
treatment durin gthefirst
12monthsandevery 12weeks (+/-2 weeks) thereafter. See Table 7-
2for details of assessments. The 8-week(or 12 week ) interval should be respected regardless 
of whether stud ytreatment is temporarily withheld or modified
.
After baseline, selected assessments should beperformed on cy cle 1 day  1(will not need to be 
repeated on day  of treatment if performed within 3 day s of C1D1) see Table [ADDRESS_160075]/MR I fortumor measurement wasperformed withi n 21 day s.Efficacy  

[COMPANY_001] Confidential Page 117
Amended Protocol v03 ( clean ) CLEE011XUS29
assessments should continue as per the scheduled visit perTable [ADDRESS_160076] with 
intravenous
(i.v.) contrast. However, if at baseline, apatient i sknown to have a contraindication
toCTi.v.contrast media ordevelops acontraindication during thetrial, a non -contrast CT
or PET CT is allowed. MRI  plus contrast is allowed, however not recommended of the chest 
due to respi[INVESTIGATOR_14943]. 
A whole body bone scanaccording toinstitutional guidelines (e.g. Tc-99 bone scan, whole 
body bone MRI ,FDG-PET orsodium fluoride positron emission tomograp hy (NaFPET) must
beacquired atscreenin g forallpatients. Skeletal lesions identified onthewhole body  bone
scan atbaseline, which are notvisible onthechest, abdomen andpelvis CT(orMRI) scan must
beimaged atbaseline andfollowed atscheduled visits using localized CT, MRI  or x-ray.If 
multiple bone lesions are identified, bone scans can be used to follow lesions throughout the 
study  instead of localized CT, MRI  or x-ray. They  should be repeated every  [ADDRESS_160077] or MRI, then bone scan need not be repeated unless 
clinically  indicated.
Positron Emission Tomograp hy(PET)/CT may beusedin place of bone scan and CT only if 
the CT component is of similar diagnostic qualit y as a CTperformed without PET. Atthe
discretion oftheInvestigators, FDG -PET scans may b eperformed to document progressive 
disease per REC IST1.[ADDRESS_160078] X -
rayor ultrasound should not be used to assess tumor lesions.
Partial Response (PR) and Complete Response (CR) must be confirmed by [CONTACT_141007] 4weeks andafter thecriteria for objective response arefirstmet. In case 
tumor assessment isperformed <[ADDRESS_160079] assessment ofanobjective response to
confirm PR/CR, subsequent tumor assessments should revert back tothe protocol schedule 
outlined in Table 7-2.
I
fpossible, asingle radiologist should perform alltumor response evaluations foran individual
patient. Any lesions inpreviously  irradiated areas should not be considered measurable unless
they have experienced progression since theradiotherap y.Anypre-existing radiographic
findings which may mimic metastatic disease andany prior radiotherap y should be recorded in 
the eCRF.

[COMPANY_001] Confidential Page 118
Amended Protocol v03 ( clean ) CLEE011XUS29
Anyimaging assessments already c ompleted during theregular work -up of thepatient within 
28days prior toregistration for treatment ,including before signing themainstudy
ICFcanbe 
considered as the baseline images for this study.
Results from tissue or bod y fluid collection should be recor ded intheeCRF tocomplement 
radiographic findings.
Allstudy imaging performed, (e.g., tofulfill a progression or response criterion), should
besubmitted tothe designated imaging CROwithin 2 weeks. 
Ifanoff-schedule imaging assessment isperformed to confirm response or ifprogression is
suspected, subsequent imaging assessments should be performed in accordance with the 
original imaging schedule.
Physicalexam tumor assessments, photography, pathology /histolog y and cy tolog y results, as 
well as,information regardin g prior interventions, pre-existing radiographic findings that mimic
metastatic disease atbaseline/screening andon-study interventions should becaptured inthe
appropriat eeCRF ’sand will be transmitte d totheimagin gCRO forrevie w by a medical 
oncologist.
Table 7-2 Imaging assessments
Procedure Screening:
Day −21to
Day 1Treatment phase* End of treatment* Post -Treatment
Phase
CT or MRI 
(Chest, 
Abdomen, 
Pelvis)1Mandated Every 8 weeks (±1 
week) during the 
first 12 months and 
every 12 weeks 
thereafter (± 2 
weeks)Mandated Every 8 weeks (±1 week) 
during the first 12 months 
and every 12 weeks 
thereafter (± 2 weeks) until 
disease progression, 
withdrawal of consent, loss 
to follo w-up,or 
subject/guardian decision
(±1 wee k). In the absence 
of disease progression, 
continue the assessment 
even if a new ant i-
neoplastic therapy is started 
until disease progression , 
only in this case a ±[ADDRESS_160080] or 
MRIMandated at 
screening if 
history of 
existing or 
suspected 
brain 
metastasesIf brain lesion is 
present at 
screening: every 8 
weeks (±1 week)
during the first 12 
months and every 
12 weeks thereafter 
(± 2 weeks)Mandated only if 
brain lesion at 
screeningIf brain lesion at screening:
every 8 weeks (±1 week)
during the first 12 months 
and every 12 weeks 
thereafter (± 2 weeks) until 
disease progression, 
withdrawal of consent, loss 
to foll ow-up,or 
subject/guardian decision
(±1 week). In the absence 
of disease progression, 
continue the assessment 

[COMPANY_001] Confidential Page 119
Amended Protocol v03 ( clean ) CLEE011XUS29
Procedure Screening:
Day −21to
Day 1Treatment phase* End of treatment* Post -Treatment
Phase
even if a new anti-
neoplastic therapy is started 
until disease progression, 
only in this case a ±14 days 
window is allowed
Whole body 
bone scan1,2Mandated If multiple bone 
lesions at 
screening and 
cannot be followed 
by X-ray, MRI or 
CTthen bone 
scans should be 
done every 8 
weeks (±1 week)
during the first 12 
months and every 
12 weeks thereafter 
(± 2 weeks) If any  
new le sions are 
identified, then 
confirm with X -ray, 
CT or MRIMandated only if 
multiple bone 
lesions identified 
at screening
Or as clinically 
indicated. If multiple bone lesions at 
screening and cannot be 
followed by X -ray, MRI or 
CTthen bone scans should 
be done every 8 weeks (±1 
week) during the first 12 
months and every 12 weeks 
thereafter (± 2 weeks) until 
disease progression, 
withdrawal of consent,
loss to follo w-up,or 
subject/guardian
decision (±1 week). In the 
absence of disease 
progression, continue the 
assessment even if
a new ant i-neoplastic 
therapy is started until 
disease progression, only 
as clinically indicated
Bone X-ray,
CT
orMRI1Only if 
skeletal 
abnormalitie
s identified 
at screening 
or by [CONTACT_141008], 
abdom en, 
pelvis 
CT/MRI.If new bone lesion 
is identified with 
bone scan, confirm 
metastasis with 
bone X -ray, CT or 
MRI, if not visible in 
the chest, 
abdomen, pelvis 
CT/MRI.Mandated
only if bone
lesion at
screeningIf bone lesion at screening, 
every 8weeks (±1 week)
during the first 12months 
and every 12 weeks 
thereafter (±2 weeks ) until 
disease progression, 
withdrawal of consent, loss 
to follow -up, or
subject/guardian
decision (±1 week ). Inthe 
absence of disease
progression, continue the 
assessment even if
a new anti -neoplastic
therapy is started until
disease progression,
only in this case a ±[ADDRESS_160081] 
Abdomen 
PelvisOnly if 
suspected 
lesion at 
screeningEvery 8 weeks if 
lesion identified at 
screening .
Of note, If multiple 
bone lesions at 
screening and 
cannot be followed Mandated if lesion 
at screeningIf lesion s are identified at 
screening, every 8 weeks 
(±1 week) during th e first 12 
months and every 12 weeks 
thereafter (± 2 weeks) until 
disease progression, 
withdrawal of consent,

[COMPANY_001] Confidential Page 120
Amended Protocol v03 ( clean ) CLEE011XUS29
Procedure Screening:
Day −21to
Day 1Treatment phase* End of treatment* Post -Treatment
Phase
by X-ray, MRI or 
CTthen bone 
scans should be 
done every 8 
weeks (±1 week)
during the first 12 
months and every 
12 weeks thereafter 
(± 2 weeks) If any  
new le sions are 
identified, then 
confirm with X -ray, 
CT or MRIloss to follo w-up,or 
subject/guardian
decision (±1 week). In the 
absence of disease 
progression, continue the 
assessment even if
a new ant i-neop lastic 
therapy is started until 
disease progression, only 
as clinically indicated
Skin Color 
PhotographyOnly if
lesions at 
screeningEvery 8 weeks if 
lesion at screeningMandated if lesion 
at screeningIf lesion s are identified at 
screening, every 8 weeks 
(±1 week) during the first 12 
months and every 12 weeks 
thereafter (± 2 weeks) until 
disease progression, 
withdrawal of consent,
loss to follo w-up,or 
subject/guardian
decision (±1 week). In the 
absence of disease 
progression, continue the 
assessment even if
a new ant i-neoplastic 
therapy is started until 
disease progression, only 
as clinically indicated
1Positron Emission Tomography (PET)/CT may  be used in place of bone scan and CT only if the CT 
component is of similar diagnostic quality as a CT performed without PET. At the discretion of the 
Investigators, FDG -PET scans may  be performed to document progressive disease per RECIST 1.1
2A whole body bone scan according to institutional guidelines (e.g. Tc -99 bone scan, whole body 
bone MRI, FDG -PET or sodium fluoride positron emission tomography (NaF PET)
All scans will beacquired and analyzed locally. For primary endpoint ,scans should be 
sent centrally to the CRO designated by [CONTACT_141009] 
2 weeks .
7.2.2 Safetyand tolerability assessments
Safety will be monitored by [CONTACT_141010]. Allsafety  assessments should beperformed pre-dose unless 
specified otherwise.

[COMPANY_001] Confidential Page 121
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Physical examination
A complete physical examination thatevaluates allmajor organ systems willbe performed at 
Screening/baseline. Subsequent ph ysicalexam smaybelimited andshould be focused on sites 
of disease to explore clinical signs and symptoms.
Significant findings thatwere present prior tothe signing ofinformed consent must be included
intheRelevant Medical Histor y/Current Medical Conditions page onthepatient’s eCRF.
Significan t new finding s that begin or worse n after informe d consen t must be recorded on the
Adverse Event page of the patient’s eCRF.
Physical exams to be performed are outlined in Table 7 -
1.
[IP_ADDRESS] Vital signs
Vital signs (heart rate, blood pressure and temperature) will be obtained in the sitting position, 
or as appropriate prior toanyblood collection.
Vital signs to be performed per Table 7 -
1.
[IP_ADDRESS] Performance status
Assessment of ECOG Performance Status will be performed atscreening and regular ly 
throughout the w hole study p
eriod irrespective of the time of dosing 
Performance status to be performed per Table 7 -1and Table 7-3.
Table 7
-3 ECOG performance status
Grade ECOG status
0 Fully active, able to carry on all pre -disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or
sedentary nature e.g., light house work, office work
2 Am bulatory and capable of all self -care but unable to carry out any work activities. Up and about
more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair
5 Dead
[IP_ADDRESS] Height and Weight
Height incentimeters (cm) andbody weight inkilogram (kg).Height and weight to be performed per
Table 7-1.
[IP_ADDRESS] Laboratory  evaluations
Sites willusetheir local laboratories fortheanalysisofallsafety labsamples, collected atthe
time points indicated asperTable 7-1. More frequent assessments may b eperformed if
clinical ly indicated, or at the investigator’s discretion and these should be recorde d onthe 
Unscheduled Visit 
eCRF’s.
Abnormal laboratory values thatareclinical lyrelevant (e.g., require aninterruption ordelay 
tostudy treatment, leadtoclinical symptoms, orrequire therapeutic intervention) must be 
documented intheAdverse Event eCRF.

[COMPANY_001] Confidential Page 122
Amended Protocol v03 ( clean ) CLEE011XUS29
[COMPANY_001] will beprovide d with a copy ofthesite’slocallaborator y certification andtabulation 
ofthenormal range
sforeachparameter required atstudystart andshould bekept up to date 
onanongoing basis. In a ddition, ifatany time apatient has l aborator y parameters obtained 
from a differen t outsid e laborator y,[COMPANY_001] must beprovide dwith acopy of the certification 
and a tabulation of the normal ranges for that laboratory.
Table 7-[ADDRESS_160082] Name
[CONTACT_141045] (W BC) with differential 
(neutrophils, ly mphocytes, monocy tes, 
eosinophils, and basophils ), hemo globin (Hgb) 
and platelet count.
Biochemistry  with fasting glucose Sodium, potassium, urea or BUN, creatinine, 
fasting glucose, calcium (or corrected calcium), 
magnesium, phosphorou s, total protein and 
albumin.
AST (SGOT), ALT (SGPT), total bilirubin, direct 
bilirubin, GGT and alkaline phosphatase, 
Amylase, lipase and LDH.
Fasting Lipid Panel Total cholesterol, LD L-cholesterol, HD L-
cholesterol and triglycerides
Coagulation PT/PTT, International normalized ratio [INR]
Urinalysis Macroscopic Panel (Dipstick) (Color, Bilirubin, 
Blood, Glucose, Ketones, Leukocy tes est erase, 
Nitrite, pH, Protein, Specific Gravity, 
Urobilinogen)
If there are any significant findings on the dipstick 
then a microscopic evaluation should be 
measured: Microscopic Panel (WBC and RBC 
sediments, Casts, Crystals, Bacteria, Epi[INVESTIGATOR_15129])
[IP_ADDRESS].1 Hematology
Complete blood count (CBC) with differential -white blood count (WBC), neutrophil count 
(including bands], lymphoc yte,monoc yte,eosinophil, and basophil counts, hemoglobin, and 
platelet count. Hematology collections to be performed per Table 7 -1.Hematology tests areto
beperformed according totheVisit Schedules outlined inTable 7-1. For details of the 
Hematology
panel refer to Table 7-4.
[IP_ADDRESS].2 Clinical chemistry
Sodium, potassium, chloride, bicarbonate, urea or BUN, creatinine, glucose, fasting glucose (at
least 2hours fasting), AST (SGOT), ALT(SGPT), total bilirubin (ifatotal bilirubin elevation 

[COMPANY_001] Confidential Page 123
Amended Protocol v03 ( clean ) CLEE011XUS29
≥Grad e [ADDRESS_160083] bilirubin should be measured), LDH, albumin, calcium 
(corrected for serum albumin), magnesium, phosphate, alkaline phosphatase and fasting lipid 
panel (at least 8 hours) . Clinical chemistry visit schedules are outlined in Table 7 -1.For details 
of the Chemistry panel refer to Table 7
-4.
[IP_ADDRESS].3 Urinalysis
Urinal ysisis
tobeperformed according totheVisit Schedules outlined inTable 7 - 1.For 
details of the urina l
ysis panel refer to Table 7-4.
[IP_ADDRESS].4 HBV testing
Prior to enrollment, thecategories o
f patients listedin Section 5.1.1 should betested for
hepatiti s B serologic markers and viral load: HBV -DNA HBsAg, HBc Ab, and HBs Ab. 
HBV DNA monitoring should be done depending onresults from serologic markers and viral 
load as listed in HCV testing.
Patients with hepatitis C risk factors and additional patients atthediscretion ofthe investigator
should betested forHCVRNA -PCRtestatscreenin g .Foralistofhepatitis C risk factors,
refer toSection 5.1.2. Follo w -up testing will be performed, asperthevisitschedule, only i f the
patient hasahistor y orispositive atbaseline, or both.
[IP_ADDRESS].5 Hepatic safety markers
Anadditional blood sample isrequested from patients inresponse toriseinALT/AST orin 
total bilirubin (as described below) if this rise occurs outside of the scheduled collection dates:
In patients with normal AST and ALT and total bilirubin at baseline that present a rise of 
AST or ALT ≥ grade 2 with total bilirubin >[ADDRESS_160084] without evidence of cholestasis 
(defined as: A LPelevation >2.0 x UL N with R value [A LT/ALP in x UL N] <2 in patients 
without bone metastasis, or elevation of ALP liver fraction in patients with bone 
metastasis).
OR
For patients with elevated baseline AST or ALT or total bilirubin that present [AST or 
ALT >2 x baseline AND >3.0x U LN] OR [AST or A LT 8.0x ULN ]-whichever is lowe r-
combined with [total bilirubin 2xbaseline AND >2.[ADDRESS_160085]]
OR
ALT or AST > 8 x UL N without bilirubin increase
Anal ysisofsamples willbe performed based onresults of ALT/AST and totalbilirubin, with 
theaimtobetter understand theunder l
yingmechanism of any observed hepatotoxicit y. 
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
Standard triplicate 12-lead ECGs will be performed after the patient hasbeen resting for 5 -10 
minutesprior to each time point indicated in Table 7 -5.
Triplicate ECGs should betaken approximately 2-minute s apart .The combined QTcF values 
from 
these 3 ECGs will be averaged to provide a single value for each time point. Eligibility  

[COMPANY_001] Confidential Page 124
Amended Protocol v03 ( clean ) CLEE011XUS29
will be based on the average of the triplicate ECG conducted at screening. In order for accurate 
evaluation ofbaseline QTcF, a total ofthree 12-lead ECGs will be performed within 7 days 
prior to registration (at screening between Day  -7 and Day  -1).
Note: All study ECGs, should be submitted tothe designated CRO immediately.
Note: Toensure ECG evaluation is received for eligibility assessment, it is advisable to
perform theECG atleast 24hours priorthescheduled enrollment date as it takes at least 24 
hours to receive central read.
Ifanabnormal ECG orQTcFvalue of ≥[ADDRESS_160086] ECG assessment may beperformed atany time during thestudy atthe 
discretion of the investigator.
Intheevent that aQTcF value of ≥[ADDRESS_160087]-dose (± 15 
min)Triplicate [ADDRESS_160088]-dose (± 15 
min)Triplicate [ADDRESS_160089]-dose (± 15 
min)Triplicate [ADDRESS_160090]-dose (± 15 
min)Triplicate [ADDRESS_160091]-dose (± 15 
min)Triplicate [ADDRESS_160092]-dose (± 15 
min)Triplicate [ADDRESS_160093] 
cyclecFor patients
with QTcF ≥481 ms 
at any time prior to 
cycle 7Day 1 pre-dose Single 12 Lead

[COMPANY_001] Confidential Page 125
Amended Protocol v03 ( clean ) CLEE011XUS29
Cycle Patients Day Sampling Timea, 
bECG Type
Unscheduled As clinically 
indicatedTriplicate [ADDRESS_160094] doseTriplicate 12 Lead
a. All measurement times are relative to dose of ribociclib unless otherwise specified.
b. If both ECG and PK sample are scheduled at the same time, the PK sample should be taken immediately 
(within 1 hour) after ECG assessment
c. Pre-dose ECG on the first day of every cycle. Additionally, [ADDRESS_160095] cycle (i.e. Cycle 9, 12, 15, 
18, etc.).
d. The exact date and time of dosing must be recorded on the appropriate eCR F.
All ECGs including unscheduled triplicate ECGs with clinically  relevant findings, collected 
during thestudyshould be transmitted toacentral laboratory andwill becentral lyreviewed 
by [CONTACT_15034]. EachECG tracing should belabeled with thestudy number ,patient
number, date, andkept inthesource documents atthestudysite. Clinically  significant ECG
abnormalities present atscreening when thepatient signsinformed consent shoul
dbe recorded
ontherelevant medical histor y/current medical conditions eCRF page. Newor worsened 
clinicall y significant findings occurring after informed consent must be recorded on the Adverse 
Events CRF page
[IP_ADDRESS].2 Cardiac imaging -ECHO (echocardiogram) or MUGA (multiple gated 
acquisition) scan
Theleftventricular heartfunction willbeevaluate d
by [CONTACT_141011].The same procedure should be used th roughout the stud y.
7.2.3 Pharmacokinetics
The blood sampling regimens for determining thePKofribociclib (and itsactive metabolite, 
LEQ803 )and everolimus after oral administration aregiven in the table below ( Table 7 -6).
Anunscheduled PKblood sample may
becollected atany time formeasurement ofplasma 
drugconcentrations if clinicall y indicated or at theInvestigator’s discretion. I f apatient 
discontinues from thestudy treatment due totoxicities related tostudy treatment, an 
unscheduled PKblood sample ma y beobtained assoon aspossible afterthelastdose andthe 
date andtime oflastdose recorded. Inaddition, anunscheduled blood sample may be collected 
if additional ECG measurements are conducted.
 
 
 
 

[COMPANY_001] Confidential Page 126
Amended Protocol v03 ( clean ) CLEE011XUS29
[IP_ADDRESS] Pharmacokinetic blood sample collection and handling
[IP_ADDRESS].1 Blood collection plan
Phase I and II: PKsampling willbeperformed inallsubjects treated inthePhase I  and Phase 
IIparts of this study . Blood for PKprofiling ofribociclib (and its metabolite) and everolimus
willbe collected on 
Cycle1 Day 15,Cycle 2 Day s 1 and Day  15 and Cy cle 3 Day  1(see Table 
7-6).
For subjects who were previously  treated with a CDK 4/6 inhibitor within 30 day s of starting 
study  drug will require PK sample on Cy cle 1 Day 1
Table 7
-6 Schedule of blood sam ple collection for PK in phase I and II 
Cycle Day Scheduled Time Point Relative to Dosing Blood Volume
(mL)
1 1 Pre-dose (if previously treated with a CDK 4/6 i) [ADDRESS_160096] -dose (± 30 min) [ADDRESS_160097] -dose (± 30 min) [ADDRESS_160098] -dose (± 15 min) [ADDRESS_160099] -dose (± 15 min) [ADDRESS_160100] Pre-dose PK sample immediately before drug administration (approximately [ADDRESS_160101] dose and immediately before the next dose)
b.Unscheduled PK blood samples may  be collected at any time for measurement of plasma drug 
concentrations if clinically indicated or at the Investigator’s discretion and will be uniquely, sequentially 
numbered .
[IP_ADDRESS].2 Additional guidelines for P K sampling/ECG
On days with PK sampling and/or ECG testing (collection day s are outlined in Table 7-6), the 
following additional guidelines must be followed
:
Pre-dose ECGs and/or PK samples should be collected before dosing of the study  
treatment.
ECGs should be done prior to PK sampling.

[COMPANY_001] Confidential Page 127
Amended Protocol v03 ( clean ) CLEE011XUS29
The time of PK collection and the time the study  medication was taken must be precisel y
recorded in the eCRF.
Sites must record t he precise date and time of the last study  treatment prior to PK
collection in the eCRF.
Post-dose ECGs and/or PK samples should be collected after dosing of the study 
treatment.
The date and exact time of dosing on PK collecti ondays, as well as the date and actual time of 
blood sampling must berecorded ontheappropriate eCRF pages. Inaddition, theexacttime 
of dosing on the previous day must be precise lyrecorded.
If vomiting occurs during thecourse oftreatment, nore-dosing of thepatient isallowed, and 
medication should resume onthenext day. The occurrence andfrequency of any vomiting 
must benoted intheadverse events section oftheeCRF. Inaddition, thedate andexact time 
ofvomiting should only berecorded if itoccurs within 4hours ofdosin g on thedays of PK 
samplin g
. If a vomiting epi[INVESTIGATOR_140929] 4hours post- dosing during theday of 
the last dose prior to trough PK samples theexact time (whenever possible) must be noted on 
the eCRF.
PKparameters (eg.Cmax, Tmax,AUC 0-6h,etc.) willbeestimated (whe nfeasible) from individual 
plasma concentration -time profiles using appropriate methods and software; a detailed 
description of the planned ana lyses is given in Table 7-6.
[IP_ADDRESS]   Pharmacokinetic blood sample collection and handling
Blood samples will beobtained from allpatients either by [CONTACT_141012] (e.g., inserted ina forearm vein, orcentral venous line) fortheanalysisof 
plasma concentrations ofribociclib (and any relevant metabolites such asLEQ803), when 
feasible. At the specified time points described in Table 7-1and Table 7-5, one single 3mL 
blood draw will be collected into a tube containing EDTA and gentl yinverted several times to 
thorough ly mixtheanticoagulant. Theblood tube
will becentrifuged toseparate theplasma. 
Plasma will immediatel y be split and transferre d into separat e pre-labele d tube s for ribociclib. 
Plasma sample
s will be stored frozen in an upright position until shipment.
Any sampling problem s(e.g., patient took study drugbefore bloodsample, scheduled sampling 
time is missed, sample is not draw naccording to the schedule) should be noted as a 
comment on the eCRF. Refer to the Laboratory  Manual for detailed instructions for the 
collection, handling, and shipment of PK samples

[COMPANY_001] Confidential Page 128
Amended Protocol v03 ( clean ) CLEE011XUS29

[COMPANY_001] Confidential Page 129
Amended Protocol v03 ( clean ) CLEE011XUS29

[COMPANY_001] Confidential Page 130
Amended Protocol v03 ( clean ) CLEE011XUS29

[COMPANY_001] Confidential Page 131
Amended Protocol v03 ( clean ) CLEE011XUS29
8 Safety monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) undesirable 
sign(s), s ymptom(s), or medical condition(s) that occur after patient’s signed informed consent 
has been obtained.
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormality  that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Advers e 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  page of the patient’s CRF. Adverse event monitoring should 
be continued for at least 30 days (or 5 half -lives, whichever is longer) following the last dose 
of study  treatment. Adverse events (including lab abnormalities that constitute AEs) should be 
described using a diagnosis whenever possible, rather than individual underly ing signs and 
symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate Adverse Event.
Adverse events will be assessed according to the Common Terminology  Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an adverse event, the 
severit y of mild, moderate, severe, and life-threatening, corresponding to Grades 1 -4, will be 
used. CTCAE Grade 5 (death) will not be used in this study ; rather, information about deaths 
will be collected through a Death form.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive questioning of the patient 
(subject) during the screening process after signing 
informed consent and at each visit during 
the study . Adverse events also may be detected when they are volunteered by [CONTACT_102] 
(subject) during the screening process or between visits, or through physical examination, 
laboratory  test, or other assessments. As far as possible, each adverse event should be eva luated 
to determine:
1.The severit y grade (CTCAE grade 1 -4)
2.Its duration (Start and end dates )or Ongoing at End of Study .
3.Its relationship to the study  treatment (Reasonable possibility  that AE is related: No, Yes)

[COMPANY_001] Confidential Page 132
Amended Protocol v03 ( clean ) CLEE011XUS29
4.Action taken with respect to study  or investigational treatment (none, dose adjusted, 
temporaril y interrupted, permanentl y discontinued, unknown, not applicable)
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
concomitant medication/non -drug therap y)
6.Outcom e (not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequalae, fatal, unknown)
7. Whether it is serious, where a SAE is defined as in Section 8.2.
Iftheevent worsened theevent should be reported asecond time
intheCRF noting thestart
date when the even worsens in toxicity .For Grade 3 and 4 adverse events only, if improvement 
to a lower grade is determined a new entry  for this event should be reported in t he CRF noting  
the start date when the event improved from having been Grade 3 orGrade 4.
All adverse events should be treated appropriately. If a concomitant medication or non-drug 
therap y is given, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is judged 
to be permanent, and assessment should be made at each visit (or more frequently, if necessary ) 
of any changes in severity, the suspected relationship to the study  treatment, the interventions 
required to treat it, and the outcome.
Progression of malignancy  (including fatal outcomes), if documented by [CONTACT_5371] (for example, as per RECIST 1.1 criteria), should not be reported as a serious adverse 
event.
Adverse events separate from the progression of malignancy  (example, deep vein thrombosis 
at the time of progression or hemopty sis concurrent with finding of disease progression) will be 
reported as per usual guidelines used for such 
events with proper attribution regarding 
relatedness to the drug.
8.1.[ADDRESS_160102] abnormalities
[IP_ADDRESS] Definitions and reporting
Laboratory  abnormalities that constitute an adverse event in their own right (are considered 
clinically significant, induce clinical signs orsymptoms, require concomitant therapy or require
changes instudy treatment), should berecorded ontheAdverse Events CRF. Whenever 
possible, a diagnosis, rather than a symptom should be provided (e.g. anemia instead of low 
hemoglobin). Laboratory abnormalities that meet the criteria for adverse events should be 
followed until they have returned to normal or an adequate explanation of the abnormality  is 
found. When an abnormal laboratory or test result corresponds to a sign/s ymptom of an already 
reported adverse event, it is not necessary  to separately  record the lab/test result as an additional 
event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 event (severe) as per CTCAE does not automatically 
indicate a SAE unless it meets the definition of serious as defined below and/or as per 
investigator’s discretion. A dose hold or medication for the lab abnormality may be required b y 
the protocol in which case the lab abnormality  would still, by [CONTACT_108], be an adverse event 
and must be reported as such.

[COMPANY_001] Confidential Page 133
Amended Protocol v03 ( clean ) CLEE011XUS29
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening .
Results in persistent or significant disability /incapacity .
Constitutes a congenital anomaly /birth defect .
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above .
Requires inpatient hospi[INVESTIGATOR_1081],
Note that hospi[INVESTIGATOR_14944]:
1.Routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition
2.Elective or pre -planned treatment for a pre -existing condition that is unrelated to 
the indication under study  and has not worsened since signing the informed 
consent
3.Social reasons and respi[INVESTIGATOR_140930]’s 
general condition
Note that treatment on an emergency outpatient basis that does not result in hospi[INVESTIGATOR_5317] y of the definitions of a SAE given 
above is not a serious adverse event
8.2.[ADDRESS_160103] be reported to [COMPANY_001] within 24 
hours of learning of its occurrence.
Any SAEs experienced after this 30 days period (or 5 half-lives, whichever is longer ) should 
only be reported to [COMPANY_001] if the investigator suspects a causal relationship to the study  
treatment. Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE must be reported 
as follow -up to the original epi[INVESTIGATOR_5319] [ADDRESS_160104] ed and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinicall y 
thorough report. The investigator must assess and record the relationship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and send the completed, signed form by  [CONTACT_87109] 24 hours to the oncology 
[COMPANY_001] Drug Safety  and Epi[INVESTIGATOR_623]  (DS&E) department.
The telephone and fax number of the contact [CONTACT_141013] y 
and Epi[INVESTIGATOR_623]  (DS&E), specific to the site, are listed in the investigator folder provided to 

[COMPANY_001] Confidential Page 134
Amended Protocol v03 ( clean ) CLEE011XUS29
each site. The original copy  of the SAE Report Form and the fax confirmation sheet must be 
kept wi th the case report form documentation at the study site.
Follow -up information is sent to the same contact(s) to whom the original SAE Report Form 
was sent, using a new SAE Report Form stating that this is a follow -up to the previously  
reported SAE and giving the date of the original report. Each re-occurrence, complication, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated, whether the blind was broken or not, and whether the 
patient continued or withdrew from study  participation.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrenc e) and is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] 
Drug Safet y and Epi[INVESTIGATOR_623]  (DS&E) department associate may urgently  require further 
information from the investigator for Health Authority  reporting. [COMPANY_001] may need to issue an 
Investigator Notification (IN), to inform all investigators involved in any study with the same 
drug that this SAE has been reported. Suspected Unexpected Serious Adverse Reactions 
(S[LOCATION_003]Rs) will be collected and reported to the competent author ities and relevant ethics 
committees in accordance with Directive 2001/20/EC or as per national regulatory  requirements 
in participating countries.
8.[ADDRESS_160105] -menopausal women (chemical ovarian suppression 
allowed).
If a female subject, or a female partner of a male subject should become pregnant, to ensure 
safet y, each pregnancy  occurring while the patient is on study  treatment must be reported to 
[COMPANY_001] within 24 hours of learning of its occurrence. The pregnan cy should be followed up to 
determine outcome, including spontaneous or voluntary  termination, details of the birth, and 
the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregnancy  Form and reported by [CONTACT_141014][INVESTIGATOR_18540] (DS&E).
Pregnancy  follow -up should be recorded on the same form and should include an assessment
of the possible re lationship to the investigational treatment any  pregnancy  outcome. Any SAE
experienced during pregnancy  must be reported on the SAE Report Form. Warnings and 
precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the pr ovided I nvestigator’s 
Brochure for ribociclib and the approved package inserts for everolimus and exemestane.
Additional safet y information collected between IBupdates will be communicated in the form 
of INs. This information will be included in the patient informed consent and should be 
discussed with the patient during the stud y as needed .
8.4 Data Monitoring Committee
An independent data monitoring committee (IDMC) will be established to assess the safet y 
efficacy  of ribociclib. The IDMC will be responsible for reviewing the efficacy and safet y data 

[COMPANY_001] Confidential Page 135
Amended Protocol v03 ( clean ) CLEE011XUS29
accruing in the trial at regular intervals of approximately  every three months or when 25%, 50%, 
75% and 100% of the patients are enrolled whichever occurs first. Also, if requested by [CONTACT_141015], additional safet y reviews may be performed.
The IDMC will consist of at least oneoncologist, one hepatologist and one statistician and will 
be formed prior to the study  treatment of the first patient. Detailed recruitment status and interim 
safet y reports will be provided to the IDMC on a regular basis. Recruitment will not be 
interrupted during IDMC anal ysis. Details will be provided in the IDMC charter.
8.[ADDRESS_160106] of the following:
What p rotected health information (PHI) will be collected from subjects in this study
Who will have access to that information and w hy
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PH I.
Inthe event that a subject revokes authorization tocollect or use PHI,theinvestigator, by 
[CONTACT_5151], retains theabilit y touseallinformatio ncollecte dprior totherevocatio n ofsubject 
authorization. For subjects that have revoked authorization tocollect o
ruse PHI, attempts 
should bemade to obtain permission tocollect follow-up safety information (e.g. has the 
subject experienced a nynew or worsened AEs) at the end of their scheduled study period.
Thedata collection systemforthisstudy usesbuilt-insecurity features toencry ptalldata for 
transmission inboth directions, preventing unauthorized access toconfidential participant 
information. Access tothesystem will becontrolled by [CONTACT_141016], made available only toauthorized personnel who 
have completed prerequisite training.
9.2 Site monitoring
Before study initiation, atasite initiation visit
orat an investigator’s meeting, [COMPANY_001] 
personnel (ordesignated CRO) willreviewtheprotocol andeCRF’s with the investigators and 
their staff. During thestudy,thefield monitor will visit thesite regularl y tocheck the 
completeness ofpatient records, theaccurac y ofentries ontheeCRF’s ,theadherence tothe 

[COMPANY_001] Confidential Page 136
Amended Protocol v03 ( clean ) CLEE011XUS29
protocol toGood Clinical Practice, theprogress of enrollment, and toensure that study 
treatment isbeing stored, dispensed, andaccounted foraccording tospecifications. Key stu dy 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each
patient inthestudy,consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and theresults ofany other tests or 
assessments. All information recorded on eCRF’s must be traceable to source documents in the 
patient's file. The investigator must also keeptheoriginal signed informed consent form (a 
signed co py is given to the patient).
The investigator must g
ivethe monitor access toallrelevant source documents toconfirm 
their consistency with the eCRF entries. [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria 
anddocumentation ofSAEs. Additional checks oftheconsistency  ofthesource data with the 
eCRF’s are performed according to the stu dy-specific monitoring plan.
9.3 Data collection
This study  will use Electronic DataCapture (EDC). Thedesignated investigator staff willenter
thedata required by [CONTACT_141017] (eCRF). The eCRF’s
have been built using fullyvalidated secur e web- enabled software thatconforms to21CFR
Part 11 requirements. I nvestigator site staff will not be givenaccess totheEDC systemuntil
they havebeen trained. Autom atic validation programs check for data discrepancies inthe 
eCRF’s and, allow modification or verification of the entered data b y the investigator staff.
The Principal Investigator [INVESTIGATOR_140931], accurate, and that entry and updates are performed in a timely manner.
Blood andtumor samples for  PK assessments will be collected by [CONTACT_141018]. The laboratory  results and
IRTdata willbesentelectronicall y to[COMPANY_001]. Imaging andECG data willbecollected atthe
sitesandthedata willbe transmitted toa designated CRO for centralized analysis,as well as 
further processing and data reconciliation.
Designated investigational sitestaff will enter theinformation required by [CONTACT_141019]/or designated laborator y requisiti onforms. Field monitors will 
review theeCRF’s andlaborator y paper requisition forms foraccuracy andcompleteness and 
will instruct sitepersonnel tomake any required corrections oradditions. One copy of the 
requisition form willbeforwarded toeachanal
ytical laboratory  withtherespective sample(s) 
by [CONTACT_141020] o r by[CONTACT_141021], andonecopy willbe retained 
at the investigational site.
9.4 Data management and quality  control
[COMPANY_001] personnel (ordesignated CRO) will review thedata entered by [CONTACT_49432]. Electronic data queries stating the nature of theproblem and 
requesting clarification will be create d for discrepancies and missing values and sent to the 

[COMPANY_001] Confidential Page 137
Amended Protocol v03 ( clean ) CLEE011XUS29
investigational site via the EDC sy stem. Designated investigator site staff is required to respond 
promptly to queries and to make any necessar ychanges to the data.
Concomitant treatments andprior medications entered into thedatabase will becoded using
theWHO Drug Reference List, which emplo ystheAnatomical Therapeutic Chemical 
classification system . Medical histor y/current medical conditions and adverse events will be 
coded using the Medical dictionary forregulatory activities (MedDRA) terminology.
Samples and/or data collected forallthird party datasuch asECG, PK willbe 
processed centrally andtheresults willbesentelectronical ly to[COMPANY_001] (oradesignated CRO).
The occurrence of an y protocol violations will bedetermined. After these actions have been 
completed andthedata hasbeen verified tobecomplete andaccurate, thedatabase will be 
declared locked anddata made available for dataanal
ysis. Authorization isrequired prior to 
making any database changes tolocked data, by[CONTACT_141022]. 
After database lock, theinvestigator will receive a CD- ROM orpaper copi[INVESTIGATOR_140932].
10 Statistical methods and data analy sis
Data will beanalyzed
by[CONTACT_64105]/or designated CRO. Any data analysiscarried out 
independent ly by [CONTACT_141023].
I
tis planned that thedata from participating centers in this protocol will becombined, so that 
anadequate number ofpatients will beavailable foranalysis.Data will be summarized with 
respect todemographic and baseline characteristics, efficacy  and safety observations and 
measurements using descriptive statistics (quantitative data) and contingency tables (qualitative 
data).
Thestudydata willbeanalyzedandreported based onallpatients’ data uptothetime when 
allpatients have potentially  completed atleast sixcyclesoftreatment or discontinued the study.
Any additiona ldataforpatient scontinuin g toreceiv estudytreatmen tpastthedatacutof fdate 
fortheprimar y Clinical Study Report willbereported once allpatients have discontinued the 
studyor at the end of the study ,whichever occurs first.
Data will be summarized and listed by [CONTACT_141024].
For safetyendpoin t, all patients will be analy zed for each phase and may be pooled for analysis.
The efficacy  data tha t will be anal yzed for Phase I andPhase II of this study separately  
Categorical data will be pr esented asfrequencies andpercentages. Forcontinuou s data, mean, 
standard deviation, median, 25th and 75th percentiles, minimum, and maximum will be 
presented.
Screen failure patients ar
e those who signed the informed consent, butneve r started the study 
treatment forany reason. Forthese patients, theeCRF data collected, will not be included in 
anyanalysis, but will be reported in the CSR as separate listings.

[COMPANY_001] Confidential Page 138
Amended Protocol v03 ( clean ) CLEE011XUS29
Thereason fordiscontinuation from study will be summarized andlisted, along with dates of 
first andlaststudy drugtreatment, duration ofexposure tostudy drugtreatment anddate of 
discontinuation foreachpatient. Other missing data will simpl y benoted asmissing on 
appropriate tables/listings.
10.1 Analysis sets
10.1.1 Full analy sis set
The Full AnalysisSet(FAS) comprises all patients who received at least one dose ofthe
assigned combination ofstudy drugs (ribociclib+ everolimus + exemestane).
10.1.[ADDRESS_160107]-baseline safety  assessment. 
Investigational treatment/ grouprefers tothe tripletcombination ofribociclib +
everolimus +exemestane. The statemen t that a patient had noAEs (on theA
EeCRF)
constitutes asafety assessment.
10.1.3 DLT- determining analy sis set
The DLT- determining set(DDS) includes allpatients from thesafety setin the dose escalation 
partwho either completed a minimum exposure requirement and have sufficient safet y 
evaluations in the first c ycle or discontinued premature ly due to a dose limiting toxicity (DLT).
Apatient isconsidered tohave mettheminimum exposure requirement ifhaving received at 
least 75% of theplanned combination doses (i.e.21 out of 28 planned daily doses) for all 
compounds administered together (same day):ribociclib, everolimus and exemestane. The 
length of a c ycleis28 day s.
Patients who do not experien ce a DLT during thefirstcyclewillbeconsidered tohave sufficient
safety evaluation s ifthey havebeenobserve dfor ≥[ADDRESS_160108] enough safet y data to conclude that 
a DLT did not occur.
10.1.4 Pharmacokinetic analy sis set
The PKanalysisset (PAS) consists of allpatients who have at least one blood sample providing 
evaluable PK data. The PAS willbe used for summaries of PKdata (tables and figures) as well 
as for listings of derived parameters.
10.1.5 Per-protocol set
A subset of Full Anal ysis Set (FAS) excluding major protocol violations
10.2 Patient demographics/other baseline characteristics
Demographic andother baseline data including age, gender, height, weight, medical condition,
and disease characteristics will besummarized descriptivel y.Treatmen ts(stud ytreatment,
concomitant therapi[INVESTIGATOR_014], compliance) .

[COMPANY_001] Confidential Page 139
Amended Protocol v03 ( clean ) CLEE011XUS29
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], 
compliance)
10.3.1 Study treatment
The actual dose and duration indays of ribociclib, everolimus and exemestane as well as the 
dose intensity  
(based onactual dose received andactua lduration) andthe relative dose intensity
(computed astheratio ofdose intensity  and planned dose intensity  based on planned dose and 
planned duration), will belisted and summarized by [CONTACT_141025]. The
summary  datawillbepresented foreachtreatment c
ycleindividuall y, as well asforall study 
days as a single categor y . Thetotal daily doses ofribociclib, everolimus andexemestane for 
each patient will be summarized using descriptive statistics (e.g. mean, median, maximum and 
minimum doses).
10.3.2 Concomitant therapi[INVESTIGATOR_140933]-drug therapi[INVESTIGATOR_140934] (Anatomical Therapeutic 
Chemical Classification Sy stem) term. These summaries will include medications starting on
or after thestart of studytreatment ormedications starting prior tothestart ofstudytreatment
and continuing after thestart ofstudy treatment. A
nyprior concomitant medications or
significant non-drug therapi[INVESTIGATOR_140935] .
10.3.3 Compliance
Compliance totheprotocol will be
assessed by [CONTACT_141026]. These will be identified prior to database lock and will be listed and 
summarized by [CONTACT_1570]/study arm.Compliance tothestudydrug willbeassessed by 
[CONTACT_141027] r eductions and dose interruptions).
10.4 Statistical hy pothesis, model, and method of analy sis
10.4.1 Study  Design
This isamulti- center, open -label, Phase I/IIstudy consisting ofboth Phase I dose escalation
and dose de-escalation, and aPhase II. The dose escalatio
nand de-escalation part ofthetrial
will be conducte d 
in men and postmenopausal women with HR+ HER2- negativ e advanced
breast cancer that is endocrine resistant. Phase II will evaluat e theantitumor activity  ofthe
combination of ribociclib +everolimus + exemestane combination in men and postmenopausal 
women with HR+HER2
- advanced breast cancer that progressed on a CDK4/6 inhibitor . 
10.4.2 Sample size and accrual
Phase I: In the phase I of the study , there will be 3-6 patients per dose level cohort (for a total 
of 3cohorts) . A RP2D will be based on safet yprofile of the dose escalation (cohort A &B) and 
the dose de
-escalation (cohort C).RP2D will be defined as the optimal dose level at which 33% 
or less experience DLTs.   Thus, including confirmation, at least 3-6 patients will be required 
for Phase I for each cohort.

[COMPANY_001] Confidential Page 140
Amended Protocol v03 ( clean ) CLEE011XUS29
Phase II:
The sample size is based on an exact test for single proportion to test the null hy pothesis H 0: p 
≤ 0.10 where p is the clinical benefit rate in24 weeks. If the true rate is p ≥ 30%, then with 
one-sided alpha level of 0.05% and a power of 80%, a minimum of approximately  60(30 per 
group ) evaluable patients are required for the study .
Including drop out rate of 10%, to get 60evaluable patients, a total of approximately  66 
pateints (33 patients per group ) will be enrolled for the phase 2 of the study for each group
(group 1 and group 2 ). Thus, if fewer than [ADDRESS_160109] 66 patients (33 patients per group (group 1&2) ) will be required to be 
enrolled for the Phase II of the study
10.5 Objectives
10.5.1 Primary  objectives
Phase I:The primar y objective ofthisdose escalation part ofthestudy is
toestimate the 
MTD(s) and/or RP2D ofribociclib incombination with everolimus and exemestane in 
postmenopausal women with HR+ HER2− advanced breast cancer .
Phase II:The primar y objective is
toevaluate efficacy  measured by [CONTACT_141028] 
(CBR) at 24 weeks for thetriple combination of ribociclib +everolimus + exemestane among 
patients with HR+HER2 -advanced breast cancer following the progression of CDK 4/6 
inhibitors.
Demonstration of significant Clinical Benefit Rate (CBR) will be based on thisstudy  with at 
least an80% power to test the null hypothesis that the clinical benefit ratein 24weeks is at least 
10% or less with an alternative hy pothesis that this rate is above 1 0%.
The Clinical benefit rate will be presented together with an exact 9 5% Clopper -Pearson 
confidence interval. The null hy pothesis will be rejected and successful clinical benefit w ill be 
demonstrated if the lower limit of the 9
5% confidence interval is great er than at least 0.10.
Thus, if [ADDRESS_160110] CDK 4/6completing 24 weeks or 
discontinue earl y will also be inc luded in the final phase II analysis.
10.5.2 Secondary  objective(s)
Progression -free survival (PFS), defined as the time from date of treatment to the date of first 
documented progression or death due to an y cause.
PFS will be analyzed using the Kaplan -Meier Prod
uct-Limit method. Patients who do not 
progress will be censored at the last adequate assessment. Estimates of the 25th, median and 
75th percentile of the PFS and their 95% confidence intervals will be provided, if applicable. 

[COMPANY_001] Confidential Page 141
Amended Protocol v03 ( clean ) CLEE011XUS29
Overall response rate (ORR) defined as the proportion of patients whose best overall response 
is either complete response (CR) or partial response (PR) according to RECI ST 1.1 . ORR will 
be calculated based on FAS according to the IIT principle ; however, patients with only non-
measurable disease at baseline will be included in the numerator if they achieved a complete 
response.
ORR will be summarized by [CONTACT_7237]. Disease Control Rate (DCR)
in Phase I  will be summarized by  [CONTACT_141029] 4/6 inhibi tor treatment status with accompany ing 
95% confidence intervals. 
Overall survival (OS) is defined as the time from date of first treatment to the date of death due 
to any  cause. If a patient is not known to have died, survival will be censored at the last date of 
contact. OS will also be summarized by  [CONTACT_5263]-Meier Product- Limit method .
Duration of Overall Response (DOR) applies only to patients whose best overall response is 
CR or PR according to RECI ST 1.1. The start date is the date of first documented response (CR 
or PR) and the end date is the date defined as first documented progression or death due to 
underly ing cancer. In other words, the start date should be determined using the time that the 
response was first determined and not using the time the response was confirmed. If a patient 
had not had an event, duration will be censored at the date of the last adequate tumor assessment. 
DOR will be listed and summarized by  [CONTACT_2939]. 
ECOG performance scale as described in Table 7-3will be used to assess physical health of 
patients. An anal ysis of time to definitive deterioration of the ECOG PS by [CONTACT_141030]. Deterioration is considered definitive if no
improvements in ECOG PS status is observed at a subsequent time of measurement during 
treatment period following the time point where the deterioration is observed.
Adverse Events (AEs), serious AE (SAEs), changes in hematology  and chemistry  values, vita l 
signs, electrocardiograms (ECGs), dose interruptions, reductions and dose intensity  
To determine the PK profile of ribociclib and everolimus in the triplet combination. PK 
parameters including, but not limited to, AUC 0-6h,Ctrough, Cmax, accumulation ra tio (R acc) 
[IP_ADDRESS] Adverse events (A Es)
Summary  tables foradverse events (AEs) have to include onl y AEsthatstarted orworsened 
during theon-treatment period, thetreatmen t -emergent AEs. However, allsafety data 
(including those from thepreandpost- treatment periods) will belisted andthose collected 
during the pr e-treatment and post- treatment period are to be flagged.
The incidence of treatment- emergent adverse events (new or worsening from baseline) will be 
summarized by [CONTACT_141031],severit y (based onCTCAE grades), 
relation to study treatment by [CONTACT_1570].
Deaths reportable asSAEs andnon-fatal serious adverse events will belisted by [CONTACT_5380] b
y type of adverse event and treatment group.
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  testscovered by [CONTACT_30828] 4.03, thestudy’sbio statistical andreporting 
team wil
lgradelaborator y dataaccording ly.Forlaborator ytestscovered by C TCAE, aGrade
0willbe assigned for allnon-missing values not graded as 1or higher .Grad e 5willnotbe used.

[COMPANY_001] Confidential Page 142
Amended Protocol v03 ( clean ) CLEE011XUS29
Forlaborator y testswher eGrades arenotdefined by [CONTACT_3989], results will begraded by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges.
Ifthelowe rlimit s ofnorma lrange sused inCTCA Edefinition saremissing ,thentheyhaveto 
be replaced b y a clinical meaningful limit.
The following summa rieswill begenerated separate ly forhematology, biochemistry  and 
urinary laboratory tests:
Frequency table for newly occurring o n-treatment Grades 3 or 4.
Shift tables using CTCAE Grades to compare baseline to the worst o n-treatment value.
For laboratory tests where CTCAE Grades are not defined, shift tables using the 
low/normal/high/ (low and high) classification to compare baseline to the worst on-
treatment value.
Listing ofalllaboratory  datawith values flagged toshow thecorresponding CTCAE Grades 
and the classifications relative to the laboratory normal ranges.
I
naddition totheabove mentioned tables andlistings, other analyses,for example 
figures plotting time course ofraw or change inlaboratory  testsover time or box plots might 
be specified in the Report and Anal ysis Plan (RAP) .
[IP_ADDRESS] Other safety  data
Vital sign and ECG data will be summarized descriptively .
Allsafety information collected willbelisted andnotable values willbeflagged . Any statistical
tests performed toexplore thedata willbeused only tohighlight anyinteresting comparisons
thatmay warrant further consideration.
[IP_ADDRESS] Supportive analy sis for secondary  objectives
Anysupportive analysesthat areconsidered appropriate forsecondary variables will be 
described in the RAP Module 3 prior to DBL.
[IP_ADDRESS] Tolerability
Tolerability  of study  drug treatment will be assessed by  [CONTACT_141032]. Reasons for dose interruption and dose reductions will 
be listed by [CONTACT_111895]. Cumulative dose, dose intensity  and relative dose intensity  
of ribociclib, everolimus and exemestane will be listed by  [CONTACT_111895]. Categories
forrelative dose intensity forribociclib, everolimus andexemestane willbe specified as <0.5, 
≥0.5 - <0.75, ≥0.75 - < 0.9, ≥ 0.9 - < 1.1 and ≥1.1. The number and proportion of patients within 
each category  will be presented .
10.5.3 Pharmacokinetics
Ribociclib and everolimus concentrations for all PK-evaluable patients will be summarized 
based on time points (listed in Table 7-6).The LLO Qforribociclib (and LEQ803 ) inplasma
isapproximately 1.00 ng/mL .The LLOQ foreverolimus in whole blood is approximately 
0.3ng/mL .The LLOQ forexemestane in plasma isapproximately 0.0200 ng/mL . All
concentrations below theLLOQ or missing data will be labeled as such in the concentration 

[COMPANY_001] Confidential Page 143
Amended Protocol v03 ( clean ) CLEE011XUS29
data listings.  
Table 10-1 Non-compartmental pharmacokinetic parameter s
Parameter Definition
Cmax Maximu m observed drug concentration after drug administration (mass x volum e-1)
Ctrough Minimum drug concentration at the end of a dosing interval (taken directly before next 
administration) (mass x volume-1)
Tmax Time to reach maximum plasm a/blood/s erum drug concentration (time)
AUC 0-6h Area under the drug concentratio n-time curve during a dosing interval (mass x time x 
volume-1)
Racc Accumulation ratio calculated as AUC τ,ss / AUC τ,sd
T1/2 Effective elimination ha lf-life (time)
CL Apparent total body clearance of drug (volume x time-1)
[IP_ADDRESS] Data handling principals
[IP_ADDRESS].1 Basic tables, figures amd listings
Descriptive statistics (mean, standard deviation, CV% ormedian (range)) will bepresented 
forallPK parameters by [CONTACT_141033]. When ageometric mean ispresented,
it will be stated as such. Only median values and ranges will be given for Tmax.
Descriptive graphical plots ofindividual plasm aconcentration by [CONTACT_141034], as 
will mean concentration -time profiles forribociclib (and LEQ803) and everolimus. Details of 
PKanalysispresented will be givenintheReporting andAnal ysisPlan (RAP).  

[COMPANY_001] Confidential Page 144
Amended Protocol v03 ( clean ) CLEE011XUS29

[COMPANY_001] Confidential Page 145
Amended Protocol v03 ( clean ) CLEE011XUS29
10.7 Interim analy sis
No formal interim analy sis is planned  One interim statistical analysis will be done after 
completing Phase I  part of the study . The final analy sis will be after completing Phase II  of the 
study .
11 Ethical considerations and administrative procedures
11.1 Regulatory  and ethical compliance
This clinical studywas designed, shall beimplemente dandreported inaccordance with the 
ICHHarmonized Tripartite Guidelines for Good Clinical Practice, wit
happlicable local 
regulations (including European Directive 2001/20/EC andUSCode of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol andtheproposed informed consent form must bereviewed andapproved by a 
proper ly constituted Institutional Review Board/ Independent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study start. Prior tostudystart, theinvestigator is required
tosign aprotocol signature [CONTACT_5389]/her agreement toconduct thestudy  in
accordance with these documents and allofthe instructions andprocedures found inthis 
protocol and togive access toallrelevant data and records to[COMPANY_001] monitors, auditors, 
[COMPANY_001] Clinical Quality  Assurance representatives, designated agents of[COMPANY_001], 
IRBs/IECs/REBs and regulatory authorities as required.
11.3 Informed consent procedures
Eligible patients may onlybeincluded inthestudy afterproviding written, IRB/IEC/RE B -
approved informed consent.
Informed consent must beobtained before conducting anystudy-specific procedures (i.e. all 
oftheprocedures described intheprotocol). The process of obtaining informed consent 
should bedocumented inthepatient source documents. The date when a subject’s Informed 
Consent was actual ly obtained will be captured in their eCRFs.
[COMPANY_001] will provide toinvestigators, inaseparate document, a proposed Informed Consent 
Form (ICF) thatisconsidered appropriate forthis study and complies with theICH GCP 
guideline andregulator y requirements. Any changes tothisICFsuggested by [CONTACT_141035] N ovartis befor esubmission totheIRB/IEC/REB, andacopy ofthe 
appr
oved version must be provided to the [COMPANY_001] monitor after IRB/ IEC/REB approval.
Women ofchild bearing potential should beinformed thattaking thestudy medication may 
involve unknown risks tothefetus ifpregnancy  weretooccur during thestudy and ag reethat 
inorder toparticipate inthestudy they must adhere tothecontraception requirement forthe 
duration ofthestudy. If there isany question thatthepatient will notreliabl ycomply, they 
should not be entered in the study.

[COMPANY_001] Confidential Page 146
Amended Protocol v03 ( clean ) CLEE011XUS29
11.4 Discontinuation of the study
[COMPANY_001] reserves theright todiscontinue this study under theconditions specified inthe 
clinical study agreement. Specific conditions forterminating thestudy are outlined inSection 
4.4.
11.5 Publication of study  protocol and results
[COMPANY_001] assures that thekey designelements ofthisprotocol will beposted inapublic ly 
accessible database such asclinicaltrials.gov. Inaddition, upon study  completion and 
finalizatio n ofthestudyrepor t theresults ofthisstudy will be eithe rsubmitte dforpublication 
and/or posted in a publicly accessible database of clinical study results.
11.[ADDRESS_160111] keepi[INVESTIGATOR_140936], in 
compliance with Section 4.9 of theICH E6 GCP, andregulator yandinstitutional requirements 
fortheprotection of confidentiality  of subjects. Aspart ofparticipating ina [COMPANY_001] -sponsored
study
,each site willpermit authorized representatives ofthesponsor(s) andregulator y 
agencies toexamine (and when required by [CONTACT_1289], tocopy) c linical records forthe
purposes ofquali tyassurance reviews, audits and evaluation ofthe study  safetyand
progress.
Source data are allinformation, original records of clinical findings, observations, or other 
activities inaclinical trialnecessary  forthereconstruction andevaluation ofthe trial. Examples 
of these original documents and data records include, butare not limited to, hospi[INVESTIGATOR_1097],
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation
checklists, pharmacy dispensing records, recorded datafrom automated instruments, copi[INVESTIGATOR_140937], microfiches,
photographic negatives, microfilm ormagnetic media, x -rays,and subject files and records kept 
at thepharmac y,at the laboratories, and medico- technical departments involved in the clinical 
trial.
Data collection is the responsibility of the clinical trial staff at the site un der the supervision of 
thesitePrincipal Investigator. Thestudy caserepor tform(CRF ) istheprimar ydata collection 
instrument forthestudy.Theinvestigator should ensure theaccurac y,completeness, legibilit y,
and timeliness of thedata reported in the CRFs and all other required reports. Data reported on 
the CRF, thatare derived from source documents, should beconsistent with the source
documents orthediscrepancies should beexplained. Alldata requested ontheCRF must
berecorded. A
nymissing data must beexplained. Any change orcorrection toapaper CRF
should bedated, initialed, andexplained (ifnecessar y)andshould notobscure the original
entry.Forelectronic CRFs anaudit trail will bemaintained by [CONTACT_5382]. The investigator 
should retain records of the changes and corrections to paper CRFs.
The investigator/institution should maintain the trial documents asspecified inEssential 
Documents fortheConduct ofa Clinical Trial (ICH E6Section 8) andasrequired by [CONTACT_5383]/or guidelines. The investigator/institution should take 
measures to prevent 
accidental or premature destruction of these documents.

[COMPANY_001] Confidential Page 147
Amended Protocol v03 ( clean ) CLEE011XUS29
Essential documents (written and elect ronic) should be retained for a period of not lessthan 
fifteen (15) yearsfrom thecompletion of theClinical Trial unless Sponsor provides written 
permission todispose of them or,requires their retention foran additional period of time 
because of applicable laws, regulations and/or guidelines 
11.[ADDRESS_160112] ensure anonymity ofthe patients; patients must not be identified by 
[CONTACT_141036]. Signed informed consent forms andpatient 
enrollment log must be kept strictly confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must beavailable toinspections by[CONTACT_141037].
11.[ADDRESS_160113] be 
considered a protoco lamendment, and unless such a
namendment isagreed upon by [CONTACT_141038]/IEC/REB itcannot beimplemented .
Allsignificant protocol 
deviations will be re corded and reported in the CSR.
12.[ADDRESS_160114] beapproved by N ovartis, Health Authorities where required, and theIRB/IEC/REB. 
Only amendments thatarerequired forpatient safet y may beimplemented prior to 
IRB/IEC/REB approval. Notwithstanding theneed forapproval offormal protocol amendments,
theinvestigator isexpected totake any immediate action required forthesafety ofany patient
included inthisstudy
,even ifthisaction represents adeviation from the protocol. In such cases, 
[COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed
according to local regulations but not later than 10 working day s.
13 References (avail able upon request)
Afinitor®(package insert). East Hanover, NJ : [COMPANY_001] Pharmaceuticals Corp; 2012.
Aromasin (package insert). [LOCATION_001], NY : [COMPANY_007]- Pharmacia; 2013.

[COMPANY_001] Confidential Page 148
Amended Protocol v03 ( clean ) CLEE011XUS29
Bachelot T, et al (2012). Randomized phase II trial of everolimus in combination with 
tamoxifen in patie nts with hormone receptor -positive, human epi[INVESTIGATOR_13392] 2- negative metastatic breast cancer with prior exposure to aromatase inhibitors: a 
GINECO study . J Clin I nvest. 30(22):2718- 24. doi: 10.1200/JCO.2011.39.0708
Bardia A, et al (2015) Triplet therapy  with ribociclib, everolimus, and exemestane in women 
with HR+/HER2– advanced breast cancer. [abstract]. I n: Proceedings of the Thirty -Eighth 
Annual CTRC -AACR San Antonio Breast Cancer Sy mposium [poster] : 2015 Dec 8- 12; San 
Antonio, TX. Phi ladelphia (PA): AACR; Cancer Res 2016;76([ADDRESS_160115]):Abstract nr P6 -13-01.
Baselga J, Campone M, Pi[INVESTIGATOR_94899] M, Burris HA et al (2012) Everolimus in postmenopausal 
hormone -receptor -positive advanced breast cancer. N Engl J Med. Feb 9;366(6):520
-9.
Beslija S, Bonneterre J, Burstein HJ, et al (2009). Third consensus on medical treatment of 
metastatic breast cancer. Ann Oncol; 20: 1771-85.
Beslija S, et al (2009) for the Central European Cooperative Oncology  Group (CECOG).
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 
20(11):1771-85. 
Beroukhim R, Mermel CH, Porter D, et al (2010) The landscape of somatic copy -number 
alteration across human cancers. Nature. 463(7283):899-905.
Burstein HJ (2011). Novel agents and future directions f or refractory  breast cancer. Semin
Oncol. 38 S2:S17 -24.
Buzdar A (2003) Pharmacology  and Pharmacokinetics of the Newer Generation Aromatase
Inhibitors. Clinical Cancer Research 9, 468s -472s, (Suppl.).
Buzdar AU, Jonat W, Howell A, et al (1998) Anastrozol e versus megestrol acetate in the 
treatment of postmenopausal women with advanced breast carcinoma: Results of a survival 
update based on a combined anal ysis of data from two mature phase III trials. Arimidex Study  
Group. Cancer 83:1142 -1152.
Capparelli C , et al (2012) Autophagy  and senescence in cancer -associated fibroblasts 
metabolically  supports tumor growth and metastasis via gl ycolysis and ketone production. 
Cell Cy cle. 2012 Jun 15;11(12):2285 -302. doi: 10.4161/cc.[ZIP_CODE].
Carlson RW, Theriault R, Schu rman CM, et al. Phase II trial of anastrozole plus goserelin in
the treatment of hormone recepto r-positive, metastatic c arcinoma of the breast in 

[COMPANY_001] Confidential Page 149
Amended Protocol v03 ( clean ) CLEE011XUS29
premenopausal women. J Clin Oncol 2010;28(25):3917–21Chano T, Kontani K, Teramoto K, 
et al (2002) Truncating m utations of RB1CC1 in human breast cancer. Nat Genet; 31: [ADDRESS_160116] cancer in pr e-menopausal women. Eur J Cancer 2010;46(16):2936–42
Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ -RAD using a human
intestinal cell line (Caco -
2) and a single pass perfusion model in rats: comparison with
rapam ycin. Pharm R es. 15(11):1666-72. 
de Oliveira M, et al (2011). Clinical presentation and management of mTOR inhibitor
associated stomatitis. Oral Oncology ; 47:998 -1003.
Demers, L M, Lipton A, Harvey  H A et al. (1993). The efficacy  of CGS [ADDRESS_160117] cancer. J Steroid Biochem Mol
Biol 44: 687
–691.
Divers J (2013). Management of Stomatitis Associated With mTOR I nhibitors in Hormone
Receptor –Positive/HER2 -Negative Advanced Breast Cancer: Clinical Experiences From a
Single Center. 38th Annual Oncology  Nurses’ Society  Congress 2013; Poster 315.
Efey an A, Sabatini DM (2010) mTOR and cancer: many  loops in one pathway . Curr Opin
Cell Biol. 22:169 -76. 
Eisenhauer et al (2009) New response evaluation cr iteria in solid tumours: Revised RECI ST 
guideline (version 1.1). European Journal of Cancer ; 45:)228- 247
 
 
Everolimus (Investigator’s Brochure). [COMPANY_001] Pharmaceutical.
Finn RS, et al (2012) Results of a randomized phase 2 study  of PD 0332991, a cy clin
dependent kinase (cdk) 4/[ADDRESS_160118] 
linetreatment of ER+/HER2- advanced breast cancer (BC). Cancer Research. 72(24): S3, 
doi:10.1158/0008 -
5472.

[COMPANY_001] Confidential Page 150
Amended Protocol v03 ( clean ) CLEE011XUS29
Finn RS, et al (2015) The cy clin-dependent kinase 4/[ADDRESS_160119] cancer (PALOMA -1/TRIO -18): a randomized phase 2 study .
The Lancet. 16(1):25 -35, doi: 10.1016/S1470
-2045(14)[ADDRESS_160120] cancer. Br J Cancer 2004;90(3):590 –4
Guba M, von Breitenbuch P, Steinbauer M, et al (2002) Rapam ycin inhibits primary  and
metastatic tumor growth by  [CONTACT_36939]: involvement of vascular endothelial growth
factor. Nat Med. 8(2):[ADDRESS_160121] cancer cell lines and
tumors. Clin Cancer Res. 2005 Jun 15;11(12):4357-64. 
Hurvitz S, et al (2017) Ribociclib in Combination With Everolimus and Exemestane in Men 
and Postmenopausal Women With HR+/HER2 − Advanced Breas t Cancer Following
Progression on a CDK4/6 I nhibitor: Safet y, Tolerability , and Pharmacokinetic Results From 
Phase [ADDRESS_160122] T, et al (2005) Effect of Exemestane on Tamoxifen
Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer; Clin Cancer Res.
11(24) 8722-8727.
Infante JR ASCO (2014) A phase I stud y of the single -agent CDK4/6 inhibitor L EE011 in pt s 
with advanced solid tumors and ly mphomas. ASCO 2014; abstract 2528
Johnston SR (2006) Targeting downstream effectors of epi[INVESTIGATOR_140938]/HER2 in breast cancer with either farnesy ltransferase inhibitors or mTOR
antagonists. I nt J Gy necol Cancer. [ADDRESS_160123] 2:543 -8. 
Kovarik et al (2002) Effect of rifampin on apparent clearance of everolimus. Ann 
Pharmacother. 2002 Jun;36(6):981 -5.
Kovarik et al (2005a) Rapid concerted evolution of nuclear ribosomal DNA in two 
Tragopogon allopol yploids of r ecent and recurrent origin. Genetics. 2005;169:931–944. 

[COMPANY_001] Confidential Page 151
Amended Protocol v03 ( clean ) CLEE011XUS29
Kuhn et al (2001). Metabolism of sirolimus and its derivative everolimus by [CONTACT_141039] P450 
3A4: I nsights from docking, molecular dy namics, and quantum chemical calculations. J Med 
Chem; 44(12);2027-34. 
Lane HA, Wood JM, McSheehy  PM, et al (2009) mTOR inhibitor RAD001 (everolimus) has
antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin
Cancer Res; 15(5):1612 -1622.
Laplante A, Demeule M, Murphy  GF, et al (2002) Interaction of immunosuppressive agents
rapam ycin and its analogue sdz -rad with endothelial p -gp. Transplant Proc. 34:3393-5.
LEE011 (Inve stigator’s Brochure). [COMPANY_001] Pharmaceutical.
Loomba R, Rowley  A, Wesley  R, et al (2008). Sy stematic review: the ef fect of preventive
lamivudine on hepatitis B reactivation during chemotherapy . Ann Intern Med 148(7): 519 -28.
Mabuchi S, Altomare DA, Cheung M et al. (2007b) RAD001 inhibits human ovarian cancer
cell proliferation, enhances cisplatin -induced apoptosis, and prolongs survival in an ovarian
cancer model. Clin Cancer Res; 13(14):4261 -70.
Mabuchi S, Altomare DA, Connolly  DC, et al. (2007a) RAD001 (Everolimus) delays tumor
onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 
67:2408-2413.
Marangoni E, Vincent -Salomon A, Auger N, et al (2007) A new model of patient tumor
derived breast cancer xenografts for preclinical assay s. Clin Cancer Res. 13(13):3989 -98.
Miller TW, et al (2010) Hy peractivation of phosphatidy linositol- [ADDRESS_160124].
120(7): 2406-13.
Musgrove EA, et al (2011) Cy clin D as a therapeutic target in cancer. Nature Rev Cancer.
11(8):558-72.
Montagna E, Cancello G, Coll eoni M. The aromatase inhibitors (plus ovarian function 
suppression) in premenopausal breast cancer patients: Ready  for prime time? Cancer Treat 
Rev. 2013 Dec;39(8):886 -90.
NCCN (2012) Clinical Practice Guidelines for NSCL C Version 2.

[COMPANY_001] Confidential Page 152
Amended Protocol v03 ( clean ) CLEE011XUS29
Nicolatou- Galitis O et al (2013). Oral ulcers in patients with advanced breast cancer receiving 
everolimus: a case series report on clinical presentation and management. Surg Oral Med Oral 
Pathol Oral Radiol (Article in press):e1 -e7)
Nishimura R, Anan K, Yamamoto Y. A multi center phase II trial of the LH -RH analogue and
an aromatase inhibitor combination in premenopausal patients with advanced or recurrent 
breast cancer refractory  to an LH -RH analogue with tamoxifen: JMTO BC08- 01. J Clin Oncol 
2012;30. Suppl.; abstr 588.
Park IH, Ro J, Lee KS, et al. Phase II parallel group study showing comparable efficacy
between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin 
and postmenopausal patients treated with letrozole alone as firs t-line hormo ne thera py. J Clin
Oncol 2010;28(16):270 5–11
Perez A, et al (2013). Clinical management and resolution of stomatitis in BOLERO -
2. 2013
ASCO Annual Meeting; Poster 558.
Perou CM, Sorlie T, Eisen MB, et al (2000) Molecular portraits of human breast tumours.
Nature; 406 (6797):747 -752. 
Sotiriou and Pusztai (2009) Gene -Expression Signatures in Breast Cancer. N Engl J Med 
2009; 360:790- 800. DOI : 10.1056/NEJMra0801289
Pagani (2014) Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast 
Cancer. N Engl J Med 2014; 371:[ADDRESS_160125] KI, et al (2012) Everolimus for postmenopausal
women with advanced breast cancer: Updated results of the BOLERO -2 phase III trial. J Clin
Oncol 30: (suppl; abstr 559).
Plourde PV, Dy roff M, Dowsett M, et al (1995) ARI MIDEX: a new oral, once -a-day
aromatase inhibitor. J Steroid Biochem Mol Biol 53: [ADDRESS_160126] cancer: a phase II trial. 
JClin Oncol 2009;27:15s. Suppl.; abstr 1079.
Rugo H, et al (2013). Everolimus- Related Adverse Events: Safet y Insights From BOLERO - 2.
St. Gallen I nternational Breast Cancer Conference 2013; P oster 274.

[COMPANY_001] Confidential Page 153
Amended Protocol v03 ( clean ) CLEE011XUS29
Schiff R, Massarweh SA, Shou J, et al (2004) Cross -talk between estrogen receptor and
growth factor pathway s as a molecular target for overcoming endocrine resistance. Clin
Cancer Res. 10(1 Pt 2):331S- 6S.
Tobin NP et al (2011) Molecular subt ype and tumor characteristics of breast cancer 
metastases as assessed by  [CONTACT_141040] -relapse 
survival. Ann Oncol. 2015 Jan;26(1):81 -8. doi: 10.1093/annonc/mdu498.
Tsutsumi N, Yonemitsu Y, Shikada Y, et al (2004) Esse ntial role of PDGFRalpha -p70S6K
signaling in mesench ymal cells during therapeutic and tumor angiogenesis in vivo: role of
PDGFR alpha during angiogenesis. Circ Res. 94(9):1186-1194.
Turner N.C. et al (2015) Palbociclib in Hormone- Receptor –Positive Advance d Breast Cancer.
N Engl J Med 373:209
-219 
Urva et al (2013) A phase I study  evaluating the effect of everolimus on the pharmacokinetics 
of midazolam in healthy  subjects. J Clin Pharmacol.2013;53:444–450.
USPI ; Aromasin SmPC August (2008) ([LOCATION_006] as RMS for EU MRP). 
Yamnik RL , Digilova A, Davis DC, et al (2009) S6 kinase [ADDRESS_160127] cancer cell proliferation. J. Biol. Chem. 284:6361 -9.
Yamnik RL , Holz MK (2010) mTOR/S6K1 and MAPK/RSK signaling pathways coordinat ely
regulate estrogen receptor alpha serine 167 phosphory lation. FEBS Lett. 584:124- 8. Epub.
Yu Q, Sicinska E, Geng Y, et al (2006) Requirement for CDK4 kinase function in breast
cancer: Cancer Cell. Jan; 9(1):23-32.
Yu Y, Sato JD (1999) MAP kinases, phosphatidy linositol 3 -kinase, and p70 S6 kinase
mediate the mitogenic response of human endothelial cells to vascular endothelial growth
factor. J Cell Phy siol 178: 235 –246.

[COMPANY_001] Confidential Page 154
Amended Protocol v03 ( clean ) CLEE011XUS29
14 Appendices
14.1 Appendix 1 -Concomitant medication
In general, the use of any concomitant medication deemed necessary  for the care of the patient 
is permitted in this study , except as specifically  prohibited below. Combination administration 
of study  drugs could result in drug-drug interactions (DDI) that could potentially  lead to reduced 
activity  or enhanced toxicity  of the concomitant medication and/or ribociclib .
The following lists are based on the Oncology  Clinical Pharmacology  Drug-Drug Interaction 
and Co-Medication Considerations (v05 release date: 2015), which was compi[INVESTIGATOR_140939] y School of Medicine’s “Clinically Relevant” Table 
(http://medicine.iupui.edu/clinpharm/ddis/main -table/) and supplemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Analy sis, and 
Implications for Dosing and Labeling (February  2 012) 
(http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/u
cm292362.pdf), and the University  of Washington’s Drug Interaction Database 
(.druginteractioninf o.org/). For current lists of medications that may cause QT prolongation 
and/or 
torsade’s de pointes (TdP), refer to the CredibleMeds® website (www.qtdrugs.org/).
These lists are not comprehensive and are onl y meant to be used as a guide. Please contact [CONTACT_3433] e 
medical monitor with any questions.
Table 14-[ADDRESS_160128] of prohibited medications during study  drug treatment
Category Drug Name
[CONTACT_15105]3A4/5 inhibitors Atazanavir/ritonavi r, boceprevir, clarithromycin, cobicistat, conivaptan, 
danoprevir/ritonavir , elvitegravir /ritonavir, grapefruit juice, indinavir /ritonavir, 
itraconazole, ketoconazole, lopi[INVESTIGATOR_054] /ritonavir , mibefradil, nefazodone, 
nelfinavir, posaconazole, ritonavir, saquinavir, saquinavir/ritonavir, telaprevir, 
telithromycin, tipranavir /ritonavir , troleandomycin, voriconazole
Strong CYP3A 4/5inducers Carbamazepi[INVESTIGATOR_050], lumacaftor ,mitotane, phenobarbital, phenytoin, rifabutin, 
rifampin (rifampi[INVESTIGATOR_2513])3, St. John's wort (hypericum perforatum)3, enzalutamide
CYP3A substrates with NTI1Alfentanil , astemizole, cisapride, cyclosporine, diergotamine 
(dihydroergotamine), ergotamine, fentany l, lomitap ide5, lovastatin, 
nicardipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], pi[INVESTIGATOR_3924], quinidine, simvastatin, sirolimus, 
tacrolimus
Medications with a known risk 
for QT prolongation4Amiodarone, anagrelide, arsenic trioxide, astemizole, azithromycin,bepridil
chloroquine, cocaine chlorpromazine, cilostazol, ciprofloxacin, cisapride, 
citalopram, clarithromycin, disopyramide, dofe tilide, domperidone, donepezil, 
dronedarone, droperidol, erythromycin, escital opram, flecainide, fluconazole, 
gatifloxacin, grepafloxacin, halofantr ine, halope ridol, ibutilide, levofloxacin, 
levomepromazine, levosulpi[INVESTIGATOR_14956], levome thadyl, mesoridazine methadone, 
moxifloxacin, ondansetron, oxaliplatin, p apaverine HCl (intra -coronary), 
pentamidine, pi[INVESTIGATOR_3924], probucol, procainamide, propofol, quinidine, 
roxithromycin, sevoflurane, sotalol, sparfloxacin, sulpi[INVESTIGATOR_14956], sultopr ide, 
terlipressin, terodiline, terfenadine, thioridazine, vandetanib,
Herbal preparations/ 
medicationsHerbal preparations/medications known as strong inducers or inhibitors of
CYP3A4/5 or those with a known risk of QT prolongation are prohibited 
throughout the study. These herbal medications include, but are not limited 
to: St. John’s wort, Kava, ephedra (ma huang), gingko biloba, 
dehydroepi[INVESTIGATOR_2119] (DHEA), yohimbe, saw palmetto, and g inseng. 
Patients should stop using these herbal medications [ADDRESS_160129] dose 
of study drug.

[COMPANY_001] Confidential Page 155
Amended Protocol v03 ( clean ) CLEE011XUS29
Category Drug Name
[CONTACT_141046][INVESTIGATOR_140940]. Anticancer therapy (chemotherapy, hormonal therapy, including but 
not limited to all SERMS [inclduing raloxifene], biologic or radiation therapy
[except for palliative radiotherapy as outlined in the protocol], and surgery) 
other than the study treatments must not be given t o patients while the 
patient is on the study medication. If such agents are required for a patient 
then the patient must discontinue study drug.
1NTI = narrow therapeutic index drugs whose exposure -response indicates that increases in their exposure 
levels by [CONTACT_64128] (e.g., Torsades de 
Pointes), or drugs which have <[ADDRESS_160130] provided is as of January 2018.Check https www crediblemeds.org/healthcare -providers/drug -list for
the most updated list.
As far as possible, avoid co -administration of QT prolonging drugs or any other drugs with the potential to 
increase the risk of drug -related QT prolongation (e.g., via a potential DDI that increases the exposure of 
ribociclib or the exposure of the QT pro longing drug). A definitive list of drugs with a known risk, possible risk, 
or conditional risk of QT prolongation and/or Torsades de Pointes (TdP) is available online at www.qtdrugs.org . 
Source: [COMPANY_001] PK Sciences Memorandum: Drug -Drug Interactions (DDI) and Co-medication Considerations
for [COMPANY_001] Clinical Trials (January 2018), which is compi[INVESTIGATOR_140941] U niversity “Clinically Relevant” 
Flockhart Table™, University of Washington Drug Interaction Database, an d FDA Drug Development and Drug 
Interactions: Table of Substrates, Inhibitors and Inducers.
Table 14-[ADDRESS_160131] of medications to be used with caution during study  drug 
treatment
Category Drug Name
[CONTACT_15106]3A4/5 inhibitors Aprepi[INVESTIGATOR_053], amprenavir, asafoetida resin (Ferula asafoetida) cimetidine,
crizotinib, diltiazem, faldaprevir, imatinib, isavuc onazole, netupi[INVESTIGATOR_053], nilotinib, 
tofisopam, Schisandra sphenanthera (nan wu wei zi), verapamil
Moderate CYP3A4/5 inducers Bosentan, dabrafenib, efavirenz, etravirine, genistein, modafinil, nafcillin, 
telotristat, lopi[INVESTIGATOR_054]5
Sensitive CYP3A 4/5
substrates1Alpha -dihydroergocryptine, api[INVESTIGATOR_3822], aprepi[INVESTIGATOR_053], atorvastatin, avanafil,
bosutinib,brotizolam, budesonide, buspi [INVESTIGATOR_5331], cobimetinib, darifenacin, 
dasatininb, ebastine, eletriptan, eplerenone, everolimus, felodipi[INVESTIGATOR_050], 
fluticasone, grazoprevir, ibrutnib, isavuconazole, ivabradine, ivacaftor, 
lumefantrine, lurasidone, maraviroc, midazolam, mido staurin, naloxegol, 
neratini b, perospi[INVESTIGATOR_5331], quetiapi[INVESTIGATOR_050], ridaforolimus, rivaroxaban, sildenafil, 
simeprevir, ticagrelor, tilidine, tolvaptan, triazolam, ulipristal, vardenafil, 
venetoclax, vicriviroc, voclosporin -
BSEP inhibitors Alectinib, atorvastatin, bromocriptine, candesartan, clobetasol, clofaziminie, 
dabigatran, dipyridamole, glyburide, grazoprevir, ledipasvir, mifepristone, 
pi[INVESTIGATOR_051], reserpi[INVESTIGATOR_050], rifamycin, simeprevir, telmisartan, timcodar, 
troglitazone, valinomycin, velpatasvir

[COMPANY_001] Confidential Page 156
Amended Protocol v03 ( clean ) CLEE011XUS29
Category Drug Name
[CONTACT_141047] a 
possible risk for Q T 
prolongation2Alfuzosin, apomorphine, aripi[INVESTIGATOR_4253], artenimol+pi[INVESTIGATOR_14961] , asenapi[INVESTIGATOR_050],
atazanavir, atomoxetine, bedaquiline, bendamustine, bortezomib, bosutin ib, 
buprenorphine, cabozantinib, capecitabine, cerit inib, clomipramine, crizotinib, 
clozapi[INVESTIGATOR_050], cyamemazine (cyamepromazine), da brafenib, dasatinib, degarilix, 
delamanid, desipramine, dexmedetomidine, dol asetron, efavirenz, eliglustat, 
epi[INVESTIGATOR_14962], eribulin mesylate, ezogabine(reti gabine), famotidine, felbamate, 
fingolimod, flupentixol, gemifloxaci n, granisetron, hydrocodone-ER, 
iloperidone, imipramine (melipramine), isradipi[INVESTIGATOR_050], ketanserin, lapatinib, 
lenvatinib, leuprolide, loperamide, lithium, melperone, midostaurin, 
mifepristone, mirabegron, mirtazapi[INVESTIGATOR_050], moexipril/HCTZ, necitumumab, , 
nilotinib, nor floxacin, nortriptyline, nusinersen, ofloxacin, lanzapi[INVESTIGATOR_14963], 
oxytocin, paliperidone, palonosetron, panabinostat, pasireotide, pazopanib, 
perflutren lipid microspheres, perphenazine, pi[INVESTIGATOR_14959], pi[INVESTIGATOR_4256], 
pi[INVESTIGATOR_14964], promethazine, prothipendyl, quetiapi[INVESTIGATOR_050], ranolazine rilpi[INVESTIGATOR_12979], 
risperidone, romidepsin, sertindole, sorafenib, sunitinib, tamoxifen, 
telavancin,tetrabenazine, tipi[INVESTIGATOR_14965]/trifluridine, tizanidine, 
tolterodine, oremifene,trimipramine, tropi[INVESTIGATOR_14960], vardenafil, vemurafenib, 
venlafaxin e, vorinostat, ziprasidone
MATE1/2 substrates3Acyclovir, cephalexin, cimetidine, fexofenadine, ganciclovir, glycopyrronium,
metformin, pi[INVESTIGATOR_8405], plisicainide, ranitidine, topotecan, varenicline
OCT2 substrates4Amantadine, 6 -beta-hydroxycortisol, carboplatin, cisplatin, cephalexin,
cephradine, ipratropi[INVESTIGATOR_1890], lamivudine, lin agliptin, metformin, oxyplatin, 
oxybutynin, phenformin, pi[INVESTIGATOR_14958], pi[INVESTIGATOR_14959], p indolol, ranitidine, sorafenib, 
tropi[INVESTIGATOR_14960], trospi[INVESTIGATOR_1890], umeclidinium,, and zidovudineAcyclovir,
BCRP substrates Daunorubicin, dolutegravir, doxorubicin, hematoporphyrin, imatinib,
methotrexate, mitoxantrone, pi[INVESTIGATOR_2830], rosuvastatin, irinotecan,
ethinyl estradiol, sulfasalazine, sofosbuvir, tenofovir, topotecan, venetoclax..
1Sensitive substrates: Drugs whose plasma AUC values have been shown to increase [ADDRESS_160132] provided is as of Januar y 2018. Check https www crediblemeds.org/healthcare-
providers/drug -list for the most updated list
3MATE1 and MATE2 share considerable substrate specificity.
4OCT1 and OCT2 share considerable substrate specificity.
5 Lopi[INVESTIGATOR_140942]: [COMPANY_001] PK Sciences Memorandum: Drug -Drug Interactions (DDI) and Co -medication 
Considerations for [COMPANY_001] Clinical Trials (January 2018), which is compi[INVESTIGATOR_14957] 
“Clinically Relevant” Flockhart Table™, University of Washington Drug Interaction Database, and 
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.2

[COMPANY_001] Confidential Page 157
Amended Protocol v03 ( clean ) CLEE011XUS29
14.2 Appendix 2 -Guidelines for response, duration of overall 
response, TTF, TTP, progression-free survival and overall 
survival (based on RECIST 1.1)
Harmonization of Efficacy  Analysis of Solid Tumor Studies
Document type: TA Specific Guideline
Document status: Version 3.1: 29-Nov-2011
Version 3:0: 19-Oct-2009
Version 2: 0: 18- Jan-2007
Version 1: 0: 13- Dec- 2002
Release date: 29-Nov-2011
Authors (Version 3.1):
 
Authors (Version 3):  
Authors (Version 2):
Authors (Version 1):

[COMPANY_001] Confidential Page 158
Amended Protocol v03 ( clean ) CLEE011XUS29
Glossary
CR Complete response
CRF Case Report Form
CSR Clinical Study Report
CT Computed tomography
DFS Disease -free survival
eCRF Electronic Case Report Form
FPFV First patient first visit
GBM Glioblastoma multiforme
MRI Magnetic resonance imaging
LPLV Last patient last visit
OS Overall survival
PD Progressive disease
PFS Progression -free survival
PR Partial response
RAP Reporting and Analysis Plan
RECIST Response Evaluation Criteria in Solid Tumors
SD Stable disease
SOD Sum of Diameter
TTF Time to treatment failure
TTP Time to progression
UNK Unknown
14.2.[ADDRESS_160133] criteria for tumor responses (Therasse et al 2000 ) and the revised 
RECI ST 1.1 guidelines ( Eisenhauer et al 2009 ).
The efficacy  assessments described in Section 14.2.[ADDRESS_160134] response. Section 14.2.18 is summarizing the “time to event” 
variables and rules which are mainly  derived from internal discussions and regulatory 
consultations , as the RECI ST criteria do not define these variables in detail. 
Section 14.2.28 of 
this guideline describes data handling and programming rules. This section is to be referred to
in the RAP (Reporting and Analy sis Plan) to provide further details needed for programming.
14.2.[ADDRESS_160135] criteria (Therasse et al 2000 ), New Guidelines 
to Evaluate the Response to Treatment in Solid Tumors, Journal of National Cancer Institute, 
Vol. 92; 205-[ADDRESS_160136] guidelines (version 1.1) (Eisenhauer et al 2009 ) European 
Journal of Cancer; 45:228 -247.

[COMPANY_001] Confidential Page 159
Amended Protocol v03 ( clean ) CLEE011XUS29
14.2.3 Definitions
14.2.4 Disease measurability
In order to evaluate tumors throughout a study , definitions of measurability  are required in order 
to classify  lesions appropriately  at baseline. In defining measurability , a distinction also needs 
to be made between nodal lesions (pathological l ymph nodes) and non -nodal lesions.
Measurable disease -the presence of at least one measurable nodal or non -nodal lesion. 
If the measurable disease is restricted to a solitary  lesion, its neoplastic nature should be 
confirmed b y cytology /histology .
For patients without meas urable disease see Section 14.2.26.
Measurable lesions (both nodal and non -nodal)
Measurable non- nodal -As a rule of thumb, the minimum size of a measurable non -nodal 
target lesion at baseline should b e no less than double the slice thicknes s or 10mm 
whichever is greater -e.g. the minimum non-nodal lesion size for CT/MRI  with 5mm cuts 
will be 10 mm, for 8 mm contiguous cuts the minimum size will be 16mm.
Lytic bone lesions or mixed ly tic-blastic lesions with identifiable soft tissue components, 
that can be evaluated b y CT/MRI , can be considered as measurable lesions, if the soft 
tissue component meets the definition of measurability .
Measurable nodal lesions (i.e. ly
mph nodes) -Lymph nodes 15 mm in short axis can be 
considered for selection as target lesions. Lymph nodes measuring 10 mm and <15 mm 
are considered non -measurable. Ly mph nodes smaller than 10 mm in short axis at 
baseline, regardless of the slice thickness, are normal and not conside red indicative of 
disease.
Cystic lesions:
Lesions that meet the criteria for radiographicall y defined simple cy sts (i.e., spherical 
structure with a thin, non -irregular, non -nodular and non
-enhancing wall, no 
septations, and low CT density  [water -like] co ntent) should not be considered as 
malignant lesions (neither measurable nor non -measurable) since they  are, by  
[CONTACT_108], simple cy sts.
‘Cystic lesions’ thought to represent cy stic metastases can be considered as 
measurable lesions, if they meet the definition of measurability described above. 
However, if noncy stic lesions are present in the same patient, these are preferred for 
selection as target lesions.
Non-measurable lesions - all other lesions are considered non -measurable, including small 
lesions (e.g. longest diameter <[ADDRESS_160137]/MRI  or pathological ly mph nodes with 
10 to <15 mm short axis), as well as trul y non -measurable lesions e.g., blastic bone 
lesions, leptomeningeal disease, ascites, pleural/pericardial effusion, inflammatory  breast
disease, l ymphangitis cutis/pulmonis, abdominal masses/abdominal organomegaly  
identified by  [CONTACT_15072].

[COMPANY_001] Confidential Page 160
Amended Protocol v03 ( clean ) CLEE011XUS29
14.2.5 Eligibility  based on measurable disease
If no measurable lesions are identified at baseli ne, the patient may  be allowed to enter the study 
if she/he has bone only disease (if l ytic or mixed) See section [ADDRESS_160138] non-measurable disease at baseline will be evaluated for response and 
also handled in the statistical anal yses is given in Section 14.2.26.
14.2.6 Methods of tumor measurement -general guidelines
In this document, the term “contrast” refers to intravenous (i.v
.) contrast.
The following considerations are to be made when evaluating the tumor:
All measurements should be taken and recorded in metric notation (mm) , using a ruler or 
calipers. All baseline evaluations should be performed as closel y aspossible to the 
beginning of treatment and never more than 4 weeks before the beginning of the 
treatment.
Imaging- based evaluation is preferred to evaluation by [CONTACT_111910] a trea tment.
For optimal evaluation of patients, the same methods of assessment and technique should 
be used to characterize each identified and reported lesion at baseline and during follow-
up. Contrast
-enhanced CT of chest, abdomen and pelvis should preferably be performed 
using a [ADDRESS_160139]/MRI  scan 
slice thickness should not exceed [ADDRESS_160140] or 
develops a contraindication during the trial, the following change in imaging modalit y will 
be accepted for follow up: a non- contrast CT of chest (MRI  not recommended due to 
respi[INVESTIGATOR_14943]) plus contrast- enhanced MRI of abdomen and pelvis.
A change in methodology  can be defined as either a change in contrast use (e.g. keepi[INVESTIGATOR_14967], like CT, but switching from with to without contrast use or vice -versa, 
regardless of the justification for the change) or a change in t echnique (e .g. from CT to 
MRI , or vice -versa), or a change in an y other imaging modality . A c hange in methodology  
will r esult by [CONTACT_15074] a UNK overall lesion response assessment . However ,another 
response assessment than the [COMPANY_001] calculated UNK resp onse may  be accepted from the 
investigator or the central blinded reviewer if a definitive response assessment can be 
justified, based on the available information.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). New lesions on the basis of FDG -PET imaging can be identified according 
to the following algorithm:
Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.
No FDG -PET at baseline with a positive F DG-PET at follow -up:
If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by  
[CONTACT_4654], this is PD.
If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, 
additional follow -up CT are needed to determine if there is trul y progression occurring at 
that Site (if so, the date of PD will be the date of the initial abnormal CT sc an).

[COMPANY_001] Confidential Page 161
Amended Protocol v03 ( clean ) CLEE011XUS29
If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT 
that is not progressing on the basis of the anatomic images, this is not PD.
Chest x -ray: Lesions on chest x -ray are acceptable as measurable lesions when they  are 
clearl y defined and surrounded by [CONTACT_6776]. However, CT is preferable.
Ultrasound : When the primary  endpoint of the study  is objective response evaluation, 
ultrasound (US) should not be used to measure tumor lesions. I t is, however, a possible 
alternative to clinical measurements of superficial palpable l ymph nodes, subcutaneous 
lesions and thy roid nodules. US might also be useful to confirm the complete 
disappearance of superficial lesions usually  assessed by  [CONTACT_12148].
Endoscopy and lapar oscopy : The utilization of endoscopy  and laparoscopy  for objective 
tumor evaluation has not y et been full y and widely validated. Their uses in this specific 
context require sophisticated equipment and a high level of expertise that may  only be 
available in some centers. Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in specialized centers. However, such 
techniques can be useful in confirming complete pathological response when biopsies are 
obtained.
Tumor markers : Tumor markers alone cannot be used to assess response. However, 
some disease specific and more validated tumor markers (e.g. CA -125 for ovarian cancer, 
PSA for prostate cancer, alpha -FP, LDH and Beta-hCG for testicular cancer) can be 
integrated as non -target disease. If markers are initially  above the upper normal limit they  
must normalize for a patient to be considered in complete clinical response when all 
lesions have disappeared.
Cytology and histology: Cy tology  and histology  can be used to differentiate between PR 
and CR in rare cases (i.e., after treatment to differentiate between residual benign lesions 
and residual malignant lesions in tumor ty pes such as germ cell tumors). Cytologic 
confirmation of neoplastic nat ure of an y effusion that appears or worsens during treatment 
is required when the measurable tumor has met the criteria for response or stable disease. 
Under such circumstances, the cy tologic examination of the fluid collected will permit 
differentiation b etween response and stable disease (an effusion may  be a side effect of the 
treatment) or progressive disease (if the neoplastic origin of the fluid is confirmed).
Clinical examination : Clinical lesions will only  be considered measurable when they  are 
superficial (i.e., skin nodules and palpable l ymph nodes). For the case of skin lesions, 
documentation by  [CONTACT_6775] , including a ruler to estimate the size of the lesion, is 
recommended.
14.2.7 Baseline documentation of target and non -target lesions
For the evaluation of lesions at baseline and throughout the study , the lesions are classified at 
baseline as either target or non-target lesions:
Target lesions
: All measurable lesions (nodal and non-nodal) up to a maximum of five 
lesions in total (and a maximum o f two lesions per organ), representative of all involved 
organs should be identified as target lesions and recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter) and 
their suitabi lity for accurate repeated measurements (either by  [CONTACT_15078] ). Each target lesion must be uniquely  and sequentially  numbered on the CRF 
(even if it resides in the same organ).

[COMPANY_001] Confidential Page 162
Amended Protocol v03 ( clean ) CLEE011XUS29
Minimum target lesion size at baseline
Non-nodal target : Non-nodal target lesions identified by [CONTACT_15079] (e.g. clinical examination, photograph y) should be at least [ADDRESS_160141] diameter. See Section 14.2.4 .
Nodal target : See Section 14.2.4 .
A sum of diameters (long axis for non- nodal lesions, short axis for nodal) for all target lesions 
will be calculated and reported as the baseline sum of diameters (SOD). The baseline sum of 
diameters will be used as reference by [CONTACT_14218]. Each 
target lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCRF .
Non-target lesions: All other lesions are considered non-target lesions , i.e. lesions not 
fulfilling the criteria for target lesions at baseline.
Presence or absence or worsening of 
non-target lesions should be assessed throughout the study ; measurements of these lesions
are not required. Mult iple non-target lesions involved in the same organ can be assessed as 
a group and recorded as a single item (i.e. multiple liver metastases). Each non -target 
lesion identified at baseline must be followed at each subsequent evaluation and 
documented on eCR F.
14.2.8 Follow -up evaluation of target and non -target lesions
To assess tumor response, the sum of diameter sfor all target lesions will be calculated (at 
baseline and throughout the study ). At each assessment response is evaluated first separatel y 
for the target (Table 14-3) and non - target lesions (Table 14-4) identified at baseline. These 
evaluations are then used to calculate the overall lesion response considering both the target and 
non-target lesions together ( Table 14 - 5) as well as the presence or absence of new lesions.
14.2.[ADDRESS_160142] to 
substantial “partial volume” effects (i.e., size may be underestimated because of the distance of 
the cut from the longest diameter; such lesions may appear to have responded or progressed on 
subsequent exami nations, when, in fact, they  remain the same size).
If the lesion has completely disappeared, the lesion size should be reported as [ADDRESS_160143] slice 
thickness (but should not be changed with varying CT slice thickness). Actual measurement 

[COMPANY_001] Confidential Page 163
Amended Protocol v03 ( clean ) CLEE011XUS29
should be given for all lesions larger than [ADDRESS_160144] diameter irrespective of slice 
thickness/reconstruction interval.
In other cases where the lesion cannot be reliably measured for reasons other than its size (e.g., 
borders of the lesion are confounded by [CONTACT_15081]), no measurement 
should be entered and the lesion cannot be evaluated.
14.2.11 Nodal lesions
A nodal lesion less than 10 mm in size by [CONTACT_15082]. Lymph nodes are not 
expected to disappear completely , so a “non- zero size” will alway s persist.
Measurements of nodal target lesions that become [ADDRESS_160145] slice thickness (but 
should not be changed with varying CT slice thickness).Actual measurement should be given 
for all lesions larger than 5 mm in short axis irrespective of slice thickness/reconstruction 
interval.
However, once a target nodal lesion shrinks to less than 10 mm in its short axis, it will be 
considered normal for response purpose determination. The lymph node measurements will 
continue to be recorded to allow the values to be included in the sum of diameters for target 
lesions, which may  be required subsequentl y for response determination.
14.2.12 Determination of target lesion response
Table 14-3 Response criteria for target lesi ons
Response Criteria Evaluation of target lesions
Complete Response (CR): Disappearance of all non -nodal target lesions. In addition, any pathological lymph 
nodes assigned as target lesions must have a reduction in short axis to <10 mm 1
Partial Response (PR): At least a 30% decrease in the sum of diameter of all target lesions, taking as 
reference the baseline sum of diameters.
Progressive Disease (PD): At least a 20% increase in the sum of diameter of all measured target lesions, 
taking as refe rence the smallest sum of diameter of all target lesions recorded at 
or after baseline. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm2.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions 
which would qualify for PD.
Unknown (UNK) Progression has not been documented and one or more target lesions have not 
been assessed or have been assessed using a different method than baseline.3
1. SOD for CR may  not be zero when nodal lesions are part of target lesions
2. Following an initial CR, a PD cannot be assigned if all non- nodal target lesions are still not present 
and all nodal lesions are <10 mm in size. In this case, the target lesion response is CR
3. Methodology change See Section 14.2.6 .
Notes on target lesion response
Reappearance of lesions: If the lesion appears at the same anatomical location where a target 
lesion had previously disappeared, it is advised that the time point of lesion disappearance (i.e., 
the “0 mm” recording) be re-evaluated to make sure that the lesion was not actually  present 

[COMPANY_001] Confidential Page 164
Amended Protocol v03 ( clean ) CLEE011XUS29
and/or not visualized for technical reasons in this previous assessment. If it is not possible to 
change the 0 value, then the investigator/radiologist has to decide between the following three 
possibilities:
The lesion is a new lesion, in which case the overall tumor assessment will be considered 
as progressive disease
The lesion is clearl y a reappearance of a previously  disappeared lesion, in which case the 
size of the lesion has to be entered in the CRF and the tumor assessment will remain based 
onthe sum of tumor measurements as presented in Table 14-3 above (i.e., a PD will be 
determined if there is at least 20% increase in the sum of diameters of allmeasured target 
lesions, taking as referen ce the smallest sum of diameters of all target lesions recorded at or 
after baseline with at least 5 mm increase in the absolute sum of the diameters). Proper 
documentation should be available to support this decision. This applies to patients who 
have not achieved target response of CR. For patients who have achieved CR, please refer 
to last bullet in this section.
For those patients who have onl y one target lesion at baseline, the reappearance of the 
target lesion which disappeared previousl y, even if sti ll small, is considered a PD.
Missing measurements : In cases where measurements are missing for one or more target 
lesions it is sometimes still possible to assign PD based on the measurements of the 
remaining lesions. For example, if the sum of diameters for [ADDRESS_160146] -baseline visit 
is 140 mm (with data for 2 other lesions missing) then a PD should be assigned. However, 
in other cases where a PD cannot defini tely be attributed ,the target lesion response would 
be UNK.
Nodal lesion decrease to normal size : When nodal disease is included in the sum of target 
lesions and the nodes decrease to “normal” size they  should still have a measurement 
recorded on scans. T his measurement should be reported even when the nodes are normal 
in order not to overstate progression should it be based on increase in the size of nodes.
Lesions split : In some circumstances, disease that is measurable as a target lesion at 
baseline and appears to be one mass can split to become two or more smaller sub- lesions. 
When this occurs, the diameters (long axis -
non-nodal lesion, short axis -nodal lesions) of 
the two split lesions should be added together and the sum recorded in the diameter f ield on 
the case report form under the original lesion number. This value will be included in the 
sum of diameters when deriving target lesion response. The individual split lesions will not 
be considered as new lesions, and will not automatically  trigger a PD designation.
Lesions coalesced : Conversel y, it is also possible that two or more lesions which were 
distinctly  separate at baseline become confluent at subsequent visits. When this occurs a 
plane between the original lesions may  be maintained that would aid in obtaining diameter 
measurements of each individual lesion. I f the lesions have trul y coalesced such that they 
are no longer separable, the maximal diameters (long axis 
- non- nodal lesion, short axis -
nodal lesions) of the “merged lesion” should be used when calculating the sum of 
diameters for target lesions. On the case report form, the diameter of the “merged lesion” 
should b
e recorded for the size of one of the original lesions while a size of “0”mm should 
be entered for the remaining lesion n umbers which have coalesced.
The measurements for nodal lesions , even if less than [ADDRESS_160147]  with slight modifications.

[COMPANY_001] Confidential Page 165
Amended Protocol v03 ( clean ) CLEE011XUS29
Since lesions less than [ADDRESS_160148] disappeared.
Once a CR target lesion response has been assigned a CR will continue to be 
appropriate (in the ab sence of missing data) until progression of target lesions.
Following a CR, a PD can subsequently  only be assigned for target lesion response if 
either a non
-nodal target lesion “reappears” or if any  single nodal lesion is at least [ADDRESS_160149] 20% increase in sum of the diameters of all nodal target 
lesions relative to nadir with at least 5 mm increase in the absolute sum of the 
diameters.
14.2.13 Determination of non -target lesion response
Table 14-4 Response criteria for non-target lesions
Response Criteria Evaluation of non -target lesions
Complete Response (CR): Disappearance of all non -target lesions. In addition, all lymph nodes assigned a 
non-target lesions must be non -pathological in size ( <10 mm short axis)
Progressive Disease (PD): Unequivocal progression of existing non -target lesions.1
Non-CR/Non-PD: Neither CR nor PD
Unknown (UNK) Progression has not been documented and one or more non-target lesions have 
not been assessed or have been assessed using a different method than baseline.
1. Although a clear progression of non -target lesions only is exceptional, in such circumstances, the opi[INVESTIGATOR_140943] (or 
study chair).
Notes on non -target lesion response
The response for non- target lesions is CRonly if all non- target non- nodal lesions which 
were evaluated at baseline are now all absent and with all non- target nodal lesions 
returned to normal size (i.e. <10 mm). If any  of the non -target lesions are still present, or 
there are an y abnormal nodal lesions (i.e. 10 mm) the response can onl y be ‘ Non-
CR/Non -PD’ unless an y of the lesions was not assessed (in which case response is UNK ) 
or there is unequivocal progression of the non -target lesions (in which case response is 
PD).
Unequivocal progression :To achieve “unequivocal progression” on the basis of non-
target disease there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of CR, PR or SD in target disease, the overall tumor burden 
has increased sufficiently to merit discontinuation of therap y. A modest “incr ease” in the 
size of one or more non- target lesions is usually  not sufficient to qualify  for unequivocal 
progression status. The designation of overall progression solely  on the basis of change in 
non-target disease in the face of CR, PR or SD of target disease is therefore expected to be 
rare. I
n order for a PD to be assigned on the basis of non- target lesions, the increase in the 
extent of the disease must be substantial even in cases where there is no measurable 
disease at baseline. If there is unequivoc al progression of non- target lesion (s),then at least 
one of the non -target lesions must be assigned a status of “Worsened”. Where possible, 
similar rules to those described in Section 14.2.12 for assign ing PD following a CR for the 
non-target lesion response in the presence of non -target lesions nodal lesions should be 
applied.

[COMPANY_001] Confidential Page 166
Amended Protocol v03 ( clean ) CLEE011XUS29
14.2.[ADDRESS_160150] s associated with Progressive Disease (PD) and has to 
be recorded as a new le sion in the New Lesion CRF page.
If a new lesion is equivocal , for example because of its small size, continued therap y and 
follow -up evaluation will clarify  if it represents truly  new disease. If repeat scans confirm 
there is definitel y a new lesion, then progression should be declared using the date of the 
first observation of the lesion.
If new disease is observed in a region which was not scanned at baseline or where the 
particular baseline scan is not available for some reason, then this should be considered as 
a PD. The one exception to this is when there are no baseline scans at all available for a 
patient in which case the response should be UNK, as for a ny of this patient's assessment 
(see Section 14.2.15).
A lymph node is considered as a “new lesion” and, therefore, indicative of progressive 
disease if the short axis increases in size to 
[ADDRESS_160151] time in the study plus 5 
mm absolute increase.
FDG -PET : can complement CT scans in assessing progression (particularly  possible for 
‘new’ disease). See Section 14.2.6 .
14.2.15 Evaluation of overall lesi on response
The evaluation of overall lesion response at each assessment is a composite of the target lesion 
response, non-target lesion response and presence of new lesions as shown below in
Table 14
-5.
Table 14-5 Overall lesion response at each assessment
Target lesions Non-target lesions New Lesions Overall
lesion response
CR CR No CR1
CR Non-CR/Non-PD3No PR
CR, PR, SD UNK No UNK
PR Non-PD and not UNK No PR1
SD Non-PD and not UNK No SD1, 2
UNK Non-PD or UNK No UNK1
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
1. This overall lesion response also applies when there are no non -target lesions identified at baseline.
2. Once confirmed PR was achieved, all these assessments are considered PR.
3. As defined in Section 14.2.8 .
If there are no baseline scans available at all ,then the overall lesion respons e at each assessment 
should be considered Unknown (UNK).
If the evaluation of any of the target or non-target lesions identified at baseline could not be 
made during follow -up, the overall status must be ‘unknown’ unless progression was seen.

[COMPANY_001] Confidential Page 167
Amended Protocol v03 ( clean ) CLEE011XUS29
In some circu mstances it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of complete response depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy ) to confirm the CR.
14.2.[ADDRESS_160152] response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). In general, the patient's best response assignment will depend on 
the achievement of both measurement and confirmation criter ia.
The best overall response will usually  be determined from response assessments undertaken 
while on treatment. However, if an y assessments occur after treatment withdrawal the protocol 
should specificall y describe if these will be included in the determ ination of best overall 
response and/or whether these additional assessments will be required for sensitivity  or 
supportive analyses. As a default, any assessments taken more than [ADDRESS_160153] overall response determination. If response assessments taken after 
withdrawal from study  treatment and/or alternative therap y are to be included in the main 
endpoint determination, then this should be described and justified in the protocol.
Where a study  requires confirmation of response (PR or CR ), changes in tumor measurements 
must be confirmed by [CONTACT_15085] [ADDRESS_160154] be clearl y stated in the protocol. 
The main goal of confirmation of objective response is to avoid overestimating the response 
rate observed. In cases where confirmation of response is not feasible, it should be made clear 
when reporting the outcome of such studies that the responses are not confirmed.
For non -randomized trials where response is the primary  endpoint, confirmation is needed.
For trials intended to support accelerated approval, confirmation is needed
For all other trials, confirmation of response may  be considered optional.
The best overall response for each patient is determined from the sequence of overall (lesion) 
responses according to the following rules:
CR = at least two determinations of CR at least 4 weeks apart before progression where 
confirmation required or one determination of CR prior to progression where confirmation 
not required
PR = at least two determinations of PR or better at least 4 weeks apart before progression 
(and not qualify ing for a CR) where confirmation required or one determination of PR 
prior to progression where confirmation not required

[COMPANY_001] Confidential Page 168
Amended Protocol v03 ( clean ) CLEE011XUS29
SD = at least one SD assessment (or better) >6 weeks after randomization/start of 
treatment (and not qualifying for CR or PR).
PD = progression  12 weeks after randomization/ start of treatment (and not qualify ing for 
CR, PR or SD).
UNK = all other cases (i .e. not qualify ing for confirmed CR or PR and without SD after 
more than [ADDRESS_160155] 12 weeks)
Overall lesion responses of CR must stay the same until progression sets in, with the exception 
of a UNK status. A patient who had a CR cannot subsequently  have a lower status other than a 
PD, e.g. PR or SD, as this would imply  a pro gression based on one or more lesions reappearing, 
in which case the status would become a PD.
Once an overall lesion response of PR is observed (whic h may have to be a confirmed PR 
depending on the study) this assignment must stay the same or improve over time until 
progression sets in, with the exception of an UNK status. However, in studies where 
confirmation of response is required, if a patient hasa single PR (30% reduction of tumor 
burden compared to baseline) at one assessment, followed by  a <30% reduction from baseline 
at the next assessment (but not 20% increase from previous smallest sum), the objective status 
at that assessment should be SD. Once a confirmed PR was seen, the overall lesion response 
should be considered PR (or UNK) until progression is documented or the lesions totally  
disappear in which case a CR assignment is applicable. In studies where confirmation of 
response is not requ ired after a single PR the overall lesion response should still be considered 
PR (or UNK) until progression is documented or the lesion totally  disappears in which case a 
CR assignment is applicable.
Example: In a case where confirmation of response is required the sum of lesion diameters is 
200 m m at baseline and then 140 mm - 150 m m -140 m m - 160 m m - 160 m m at the subsequent 
visits. Assuming that non -target lesions did not progress, the overall lesion response would be 
PR -SD 
-PR -PR -PR. The second assessment with 140 m m confirms the PR for this patient. 
All subsequent assessments are considered PR even if tumor measurements decrease only by 
20% compared to baseline (20 0 mm to 16 0 mm) at the following assessments.
If the patient progressed but conti nues study  treatment , further assessments are not considered 
for the determination of best overall response.
Note : these cases may be described as a separate finding in the CSR but not included in the 
overall response or disease control rates.
The best overall response for a patient is alway s calculated, based on the sequence of overall 
lesion responses. However, the overall lesion response at a given assessment may  be provided 
from different sources:
Investigator overall lesion response
Central Blinded Rev iew overall lesion response
[COMPANY_001] calculated overall lesion response (based on measurements from either 
Investigator or Central Review)
The primary  analysis of the best overall response will be based on the sequence of 
investigator/central blinded revie w/calculated (investigator)/calculated (central) overall lesion 
responses.

[COMPANY_001] Confidential Page 169
Amended Protocol v03 ( clean ) CLEE011XUS29
Based on the patients’ best overall response during the study , the following rates are then 
calculated:
Overall response rate (ORR) is the proportion of patients with a best overall response of CR 
or PR. This is also referred to as ‘Objective response rate’ in some protocols or publications.
Disease control rate (DCR) is the proportion of patients with a best overall response of CR or 
PR or SD.
Another approach is to summarize the progression rate at a certain time point after baseline. In 
this case, the following definition is used:
Early progression rate (EPR) is the proportion of patients with progressive disease within 
8weeks of the start of treatment.
The protocol should defin e populations for which these will be calculated. The timepoint for 
EPR is study  specific. EPR is used for the multinomial designs of Dent and Zee (2001) and 
counts all patients who at the specified assessment (in this example the assessment would be at 
8 weeks ± window) do not have an overall lesion response of SD, PR or CR. Patients with an 
unknown (UNK) assessment at that time point and no PD before, will not be counted as early 
progressors in the ana lysis but may  be included in the denominator of the EPR rate, depending 
on the analy sis population used. Similarly  when examining overall response and disease control, 
patients with a best overall response assessment of unknown (UNK) will not be regarded as 
“responders” but may be included in the denominator for ORR and DCR calculation depending 
on the anal ysis population (e.g. populations based on an ITT approach).
14.2.18 Time to event variables
The protocol should state which of the following variables is used in that study .
14.2.19 Progression -free survival
Progression -free survival (PFS) is the time from date of randomization/start of treatment to 
the date of event defined as the first documented progression or death due to any cause. If a 
patient has not had an event , progression- free survival is censored at the date of last adequate 
tumor assessment.
14.2.[ADDRESS_160156] seen alive / last known date patient alive , the date of death and the reason of 
death (“Stud y indication” or “Other”).
Overall survival (OS) is defined as the time from date of randomization/start oftreatment to 
date of death due to an y cause. If a patient is not known to have died, survival will be censored 
at the date of last known date patient alive.
14.2.21 Time to progression
Some studies might consider only death related to underly ing cancer as an even t which indicates 
progression. In this case the variable “Time to progression” might be used. TTP is defined as 
PFS except for death unrelated to underl ying cancer.

[COMPANY_001] Confidential Page 170
Amended Protocol v03 ( clean ) CLEE011XUS29
Time to progression (TTP) is the time from date of randomization/start of treatment to the 
date of event defined as the first documented progression or death due to underly ing cancer. If 
a patient has not had an event, time to progression is censored at the date of last adequate tumor 
assessment.
14.2.[ADDRESS_160157] of disc ontinuation 
reasons to be considered or not as treatment failure may be adapted according to the specificities 
of the study  or the disease.
Time to treatment failure (TTF) is the time from date of randomization/start of treatment to 
the earliest of date ofprogression, date of death due to any cause, or date of discontinuation due 
to reasons other than ‘Protocol violation’ or ‘Administrative problems’. The time to treatment 
failure for patients who did not experience treatment failure will be censored at last adequate 
tumor assessment.
14.2.[ADDRESS_160158] been reports where 
a treatment with asignificantly  higher response rate had a significantl y shorter duration of 
response but where this probabl y primarily  reflected selection bias which is explained as 
follows: I t is postulated that there are two groups of patients: a good risk group and a p oor risk 
group. Good risk patients tend to get into response readily  (and relatively  quickly ) and tend to 
remain in response after they  have a response. Poor risk patients tend to be difficult to achieve
a response, may have a longer time to respond, and tend to relapse quickl y when they do respond. 
Potent agents induce a response in both good risk and poor risk 
patients. Less potent agents 
induce a response mainly in good risk patients only. This is described in more detail by [CONTACT_15088] 
(1988)
It is recommended that an analy sis of all patients (both responders and non-responders) be 
performed whether or not a 
“responders onl y”descriptive analy sis is presented. An anal ysis of 
responders should onl y be perfo rmed to provide descriptive statistics and even then interpreted 
with caution by [CONTACT_15089]. If an 
inferential comparison between treatments is required this should only be performed on all 
patients (i.e. not restricting to “responders” onl y) using appropriate statistical methods such as 
the techniques described in Ellis et al (2008) . It should also be stated in the protocol if duration 
of respons e is to be calculated in addition for unconfirmed response.
For summary  statistics on “responders” only the following definitions are appropriate. (Specific 
definitions for an all-patient analysis of these endpoints are not appropriate since the status of 
patients throughout the study  is usuall y taken into account in the anal ysis).
Duration of overall response (CR or PR) : For patients with a CR or PR (which may  have to 
be confirmed the start date is the date of first documented response (CR or PR) and the end date 
and censoring is defined the same as that for time to progression.

[COMPANY_001] Confidential Page 171
Amended Protocol v03 ( clean ) CLEE011XUS29
The following two durations might be calculated in addition for a large Phase III study  in which 
a reasonable number of responders is seen.
Duration of overall complete response (CR ): For patients with a CR (which may  have to be 
confirmed) the start date is the date of first documented CR and the end date and censoring is 
defined the same as that for time to progression.
Duration of stable disease (CR/PR/SD) : For patients with a CR or PR (which may have to be 
confirmed) or SD the start and end date as well as censoring is defined the same as that for time 
to progression.
14.2.24 Time to response
Time to overall response (CR or PR) is the time between date of randomization/start of 
treatment u ntil first documented response (CR or PR). The response may need to be confirmed 
depending on the ty pe of study  and its importance. Where the response needs to be confirmed 
then time to response is the time to the first CR or PR observed.
Although an analysis on the full population is preferred a descriptive analysis may be performed 
on the “responders ” subset only, in which case the results should be interpreted with caution 
and in the context of the overall response rates, since the same kind of selection bias may be 
introduced as described for duration of response in Section 14.2.23. It is recommended that an 
analysis of all patients (both responders and non-responders) be performed whether or not a 
“responders only” descriptive anal ysis 
is presented. Where an inferential statistical comparison 
is required, then all patients should definitely  be included in the analysis to ensure the statistical 
test is valid. For analysis including all patients, patien ts who did not achieve a response (which 
may have to be a confirmed response) will be censored using one of the following options.
at maximum follow -up (i.e. FPFV to LPLV used for the anal ysis)for patients who had a 
PFS event (i.e. progressed or died due to an y cause). In this case the PFS event is the worst 
possible outcome as it means the patient cannot subsequently  respond. Since the statistical 
analysis usually  makes use of the ranking of times to response it is sufficient to assign the 
worst possible censoring time which could be observed in the study  which is equal to the 
maximum follow -up time (i.e. time from FPFV to L PLV)
at last adequate tumor assessment date otherwise . In this case patients have not y et 
progressed so they  theoretically  still have 
a chance of responding
Time to overall complete response (CR) is the time between dates of randomization/start of 
treatment until first documented CR. Similar analy sis considerations including (if appropriate) 
censoring rules apply  for this endpoint descri bed for the time to overall response endpoint.
14.2.25 Definition of start and end dates for time to event variables
Assessment date
For each assessment (i.e. evaluation number), the assessment date is calculated as the latest of 
all measurement dates (e.g. X -ray,CT-scan) if the overall lesion response at that assessment is 
CR/PR/SD/UNK. Otherwise -if overall lesion response is progression -the assessment date is 
calculated as the earliest date of all measurement dates at that evaluation number.

[COMPANY_001] Confidential Page 172
Amended Protocol v03 ( clean ) CLEE011XUS29
Start dates
For all “time to event” variables, other than duration of response, the randomization/ date of 
treatment start will be used as the start date.
For the calculation of duration of response the following start date should be used:
Date of first documented respons e is the assessment date of the first overall lesion 
response of CR (for duration of overall complete response) or CR / PR (for duration of 
overall response) respectively , when this status is later confirmed.
End dates
The end dates which are used to calcu late ‘time to event’ variables are defined as follows:
Date of death (during treatment as recorded on the treatment completion page or during 
follow -up as recorded on the study  evaluation completion page or the survival follow -up 
page).
Date of progression is the first assessment date at which the overall lesion response was 
recorded as progressive disease.
Date of last adequate tumor assessment is the date the last tumor assessment with overall 
lesion response of CR, PR or SD which was made before an event or a censoring reason 
occurred. In this case the last tumor evaluation date at that assessment is used. If no post -
baseline assessments are available (before an event or a censoring reason occurred) the 
date of randomization/start of treatment is used.
Date of next scheduled assessment is the date of the last adequate tumor assessment plus 
the protocol specified time interval for assessments. This date may  be used if back-dating 
is considered when the event occurred bey ond the acceptable time window for th e next 
tumor a ssessment as per protocol (see Section 14.2.26).
Example (if protocol defined schedule of assessments is 3 months): tumor assessments at 
baseline - 3 months - 6 months -missing -missing -PD. Date of next scheduled assessment 
would then correspond to 9 months.
Date of discontinuation is the date of the end of treatment visit.
Date of last contact [CONTACT_15090]. This 
corresponds to the latest date for either the visit date, lab sample date or tumor assessment 
date. If available, the last known date patient alive from the survival follow- up page is 
used. If no survival follow- up is available, the date of discontinuation is used as last 
contact [CONTACT_568].
Date of secondary  anti- cancer therap y is defined as the start date of an y additional 
(secondary ) antineoplastic therap y or surgery .
14.2.26 Handling of patients with non -measurable disease only  at baseline
It is possible that patients with only non- measurabl e disease present at baseline are entered into 
the study , either because of a protocol violation or by [CONTACT_8345] (e.g. in Phase III studies with PFS 
as the primary  endpoint). In such cases the handling of the response data requires special 
consideration with respect to inclusion in any analysis of endpoints based on the overall 
response evaluations.

[COMPANY_001] Confidential Page 173
Amended Protocol v03 ( clean ) CLEE011XUS29
It is recommended that any patients with only non-measurable disease at baseline should be 
included in the main (ITT) anal ysis of each of these endpoints.
Although the text of the definitions described in the previous sections primarily  relates to 
patients with measurable disease at baseline, patients without measurable disease should also 
be incorporated in an appropriate 
manner. The overall response for patients with measurable 
disease is derived slightly differentl y according to Table 14-6.
Table 14
-6 Overall lesion response at each assessment : patients with non -target 
diseas e only
Non-target lesions New Lesions Overall lesion response
CR No CR
Non-CR/Non-PD1No Non-CR/non -PD
UNK No UNK
PD Yes or No PD
Any Yes PD
1As defined in Section 14.2.8 .
In general, the non-CR/non -PD response for these patients is considered equivalent to an SD 
response in endpoint determination. In summary  tables for best overall response patients with 
only non-measurable disease may  be highlighted in an appropriate fashion e.g. in parti cular by 
[CONTACT_141041]- CR/non -PD category .
In considering how to incorporate data from these patients into the analy sis the importance to 
each endpoint of being able to identify  a PR and/or to determine the occurrence and timing of 
progression needs to be taken into account.
For ORR it is recommended that the main (ITT) analysis includes data from patients with only 
non-measurable disease at baseline, handling patients with a best response of CR as “responders” 
with respect to ORR and all othe r patients as “non -responders”.
For PFS, it is again recommended that the main ITT analy ses on these endpoints include all 
patients with only non-measurable disease at baseline, with possible sensitivity analyses which 
exclude these partic
ular patients. Endpoints such as PFS which are reliant on the determination 
and/or timing of progression can incorporate data from patients with only non-measurable 
disease.
14.2.[ADDRESS_160159] to follow- up? I t is important that the protocol and RAP specify  the primary  
analysis in detail with respect to the definition of event and censoring dates and also include a
description of one or more sensitivity  anal yses to be performed.
Based on definitions outlined in Section 14.2.25, and using the draft FDA guideline on 
endpoints (Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, April 2005) 
as a reference, the following analy ses can be considered:

[COMPANY_001] Confidential Page 174
Amended Protocol v03 ( clean ) CLEE011XUS29
Table 14-7 Options for event dates used in PFS, TTP, duration of response
Situation Options for end -date (progression or 
censoring)1
(1) = default unless specified differently  in 
the protocol or RAPOutcome
A No baseline assessment (1) Date of randomization/start of treatment3Censored
B Progression at or before next scheduled 
assessment(1) Date of progression
(2) Date of next scheduled assessment2Progressed
Progressed
C1 Progression or death after exactly  one
missing assessment(1) Date of progression (or death)
(2) Date of next scheduled assessment2Progressed
Progressed
C2 Progression or death after two or more
missing assessments(1) Date of last adequate assessment2
(2) Date of next scheduled assessment2
(3) Date of progression (or death)Censored
Progressed
Progressed
D No progression (1) Date of last adequate assessment Censored
E Treatment discontinuation due to ‘Disease 
progression’ without documented 
progression, i.e. clinical progression based 
on investigator claim(1) N/A
(2) Date of discontinuation (visit date at which 
clinical progression was determined)Ignored
Progressed
F New anticancer therapy given (1) Date of last adequate assessment
(2) Date of secondary anti -cancer therapy
(3) Date of secondary anti -cancer therapy
(4) N/ACensored
Censored
Event
Ignored
G Deaths due to reason other than 
deterioration of ‘Study indication’(1) Date of last adequate assessment Censored 
(only TTP and 
duration of 
response)
1.=Definitions can be found in Section 14.2.25
2.=After the last adequate tumor assessment. “Date of next scheduled assessment” is defined in 
Section 14.1.25 .
3.=The rare exception to this is if the patient dies no later than the time of the second scheduled 
assessment as defined in the protocol in which case this is a PFS event at the date of death.
The primary  analysis and the sensitivity  analyses must be specified in the protocol. Clearl y 
define if and why options (1) are not used for situations C, E and (if applicable) F.
Situation s C (C1 and C2): Progression or death after one or more missing assessments: The 
primary  anal ysis is usually  using option s(1) for situations C 1 and C2, i.e.
(C1) taking the actual progression or death date , in the case of only  one missing 
assessment .
(C2) censoring at the date of the last adequate assessment, in the case of two or more 
consecutive missing assessments.
In the case of two or missing assessments (situation C2), option (3) may be c onsidered jointly  
with option (1) in situation C1 as sensitivity analy sis. A variant of this sensitivity  analysis 
consists of backdating the date of event to the next scheduled assessment as proposed with 
option (2) in situations C1 and C2.
Situation E: Treatment discontinuation due to ‘Disease progression’ without doc umented 
progression :By [CONTACT_15094], option (1) is used for situation E as patients without documented PD 
should be followed for progression after discontinuation of treatment .However, option (2) may 
be used as sensitivity  analy sis.If progression is claimed based on clinical deterioration instead 
of tumor assessment by e.g. CT-scan, option (2) may be used for indications with high early 
progression rate or difficulties to assess the tumor due to clinical deterioration.

[COMPANY_001] Confidential Page 175
Amended Protocol v03 ( clean ) CLEE011XUS29
Situation F: New cancer therapy given : the handling of this situation must be specified in 
detail in the protocol. However, option (1), i.e. censoring at last adequate assessment may be 
used as a default in this case.
Additional suggestions for sensitivity analyses
Other suggestions for addition al sensitivity  analyses may include analyses to check for potential 
bias in follow -up schedules for tumor assessments, e.g. by [CONTACT_141042]. The latter could be handled b y replacing in Table 14 -7the
“Date of last adequate assessment” by [CONTACT_941] “Date of previous scheduled assessment (from 
baseline)”, with the following definition:
Date of previous scheduled assessment (from baseline) is the date when a tumor 
assessment would have taken place, if the protocol assessment scheme was strictly  
followed from baseline, immediately  before or on the date of the last adequate tumor 
assessment.
In addition, anal yses could be repeated using the Investigators’
assessments of response rather 
than the calculated response. The need for these types of sensitivity  analyses will depend on the 
individual requirements for the specific study  and disease area and have to be specified in the 
protocol or RAP documentation.
14.2.28 Data handling and programming rules
The following section should be used as guidance for development of the protocol, data 
handling procedures or programming requirements (e.g. on incomplete dates).
14.2.29 Study/project specific decisions
For each study  (or proj ect) various issues need to be addressed and specified in the protocol or 
RAP documentation. Any  deviations from protocol must be discussed and defined at the latest 
in the RAP documentation.
The proposed primary  analysis and potential sensitivity  analysesshould be discussed and agreed 
with the health authorities and documented in the protocol (or at the latest in the RAP 
documentation before database lock).
14.2.[ADDRESS_160160] to follow -
up, the investigator or designee should show "due diligence" by [CONTACT_141043], e.g., dates of telephone calls, registered letters, etc.
The end of treatment visit and its associated assessments should occur within 15days of the last 
study  treatment.
Patients may  discontinue study  treatment for an y of the following reasons:
Adver se event(s)
Lost to follow -up
Physician decision

[COMPANY_001] Confidential Page 176
Amended Protocol v03 ( clean ) CLEE011XUS29
Pregnancy
Protocol deviation
Technical problems
Subject/guardian decision
Death
Progressi ve disease
Study  terminated by  [CONTACT_456]
Non-compliant with study  treatment
No longer requires treatment
Treatment d uration completed as per protocol (optional, to be used if only  a fixed number 
of cy cles is given)
14.2.[ADDRESS_160161] -treatment follow -up (study  phase completion)
End of post-treatment follow -up visit will be completed after discontinuation of study  treatment 
andpost-treatment evaluations but prior to collecting survival follow-up.
Patients may  provide study  phase completion information for one of the following reasons:
Adverse event
Lost to follow -up
Physician decision
Pregnancy
Protocol deviation
Technical prob lems
Subject/guardian decision
Death
New therap yfor stud y indication
Progressi ve disease
Study  terminated by  [CONTACT_456]
14.2.[ADDRESS_160162] regarding measurement methods (i.e. any assessment with more or 
less sensitive method than the one used to assess the lesion at baseline is considered UNK) and 
not available evaluations (i.e. if any target or non-target lesion was not evaluated the whole 
overall lesion response is UNK unless remaining lesions qualified for PD), these UNK 
assessments may  be re -evaluated by  [CONTACT_111916]. I n addition, data 
review reports will be available to identify  assessments for which the investigators’ or central 
reader’s opi[INVESTIGATOR_140944]. 
This may be queried for clarification. However, the investigator or central reader’s response 
assessment will never be overruled.
If [COMPANY_001] elect to invalidate an overall lesion response as evaluated by [CONTACT_15099], the calculated overall lesion response 
at that specific assessment is to be kept in a dataset. This must be clearl y documented in the 

[COMPANY_001] Confidential Page 177
Amended Protocol v03 ( clean ) CLEE011XUS29
RAP documentation and agreed before database lock. This dataset should be created and stored 
as part of the ‘raw’ data.
Any discontinuation due to ‘Disease progression’ without documentation of progression by
[CONTACT_141044]. Only  patients with documented deterioration of 
symptoms indicative of progression of disease should have this reason for discontinuation of 
treatment or stud y evaluation.
14.2.33 Programming rules
The following should be used for programming of efficacy  results:
14.2.34 Calculation of ‘time to event’ variables
Time to event = end date -start date + 1 (in day s)
When no post-baseline tumor assessments are available, the date of randomization/start of 
treatment will be used as e nd date (duration = 1 day) when time is to be censored at last tumor 
assessment, i.e. time to event variables can never be negative.
14.2.35 Incomplete assessment dates
All investigation dates (e.g. X -ray, CT scan) must be completed with day , month and y ear.
If one or more investigation dates are incomplete but other investigation dates are available, 
this/these incomplete date(s) are not considered for calculation of the assessment date (and 
assessment date is calculated as outlined in Section 14.2.25
).If all measurement dates have no 
day recorded, the 1stof the month is used.
If the month is not completed, for any of the investigations, the respective assessment will be 
considered to be at the date which is exactly  between previous and following assessment. If a 
previous and following assessment is not available, this assessment will not be used for any 
calculation.
14.2.[ADDRESS_160163].
14.2.37 Non- target lesion response
If no non- target lesions are identified at baseline (and therefore not followed throughout the 
study), the non-target lesion response at each assessment will be considered ‘not applicable 
(NA)’.
14.2.38 Study/project specific programming
The standard anal ysis programs need to be adapted for each study
/project .
14.2.39 Censoring reason
In order to summarize the various reasons for censoring, the following categories will be 
calculated for each time to event variable based on the treatment completion page, the study 
evaluation completion page and the survival page.

[COMPANY_001] Confidential Page 178
Amended Protocol v03 ( clean ) CLEE011XUS29
For survival the following censoring reasons are possible :
Alive
Lost to follow -up
For PFS and TTP (and therefore duration of responses) the following censoring reasons 
are possible:
Ongoing without event
Lost to follow -up
Withdrew consent
Adequate assessment no longer available*
Event documented after two or more missing tumor assessments (optional, see Table 14 -7)
Death due to reason other than underl ying cancer (only used for TTP and duration of 
response)
Initiation of new an ti
-cancer therapy
*Adequate assessment is defined in Section 14.2.25 . This reason is applicable when adequate 
evaluations are missing for a specified period prior to data cut-off (or prior to any other 
censoring reason) corresponding to the unavailability  of two or more planned tumor 
assessments prior to the cut-off date. The following clarifications concerning this reason should 
also be noted:
This may be when there has been a definite decision to stop evaluation (e.g. reason=“Sponsor 
decision” on study  evaluation completion page), when patients are not followed for progression 
after treatment completion or when only  UNK assessments are available just prior to data cut -
off).
The reason "Adequate assessme nt no longer available" also prevails in situations when 
another censoring reason (e.g. withdrawal of consent, loss to follow -up or alternative anti -
cancer therap y) has occurred more than the specified period following the last adequate 
assessment.
This reason will also be used to censor in case of no baseline assessment.
14.2.40 References (available upon request)
Dent S, Zee(2001) application of a new multinomial phase II stoppi[INVESTIGATOR_14974] y progression, J Clin Oncol; 19: 785-791
Eisenhauer E, et al (2009) New response evaluation criteria in solid tumors: revised RECI ST 
guideline (version 1.1). European Journal of Cancer, Vol.45: 228 -47
Ellis S, et al (2008) Analysis of duration of response in oncology  trials. Contemp Clin Trials 
2008; 29: 456-465
FDA Guidelines: 2005 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, April 2005
FDA Guidelines: 2007 Clinical Trial Endpoints for the Approval of Cancer Drugs and 
Biologics, May 2007
Morgan TM (1988) Analy sis of duration of res ponse: a problem of oncology  trials. Cont Clin 
Trials; 9: 11-18

[COMPANY_001] Confidential Page 179
Amended Protocol v03 ( clean ) CLEE011XUS29
Therasse P, Arbuck S, Eisenhauer E, et al (2000 )New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors, Journal of National Cancer Institute, Vol. 92; 205 -16
14.3 Appendix 3 -Bone M arrow  Reserve in A dults
Adapted from R.E. ELLIS: The Distribution of Active Bone Marrow in the Adult, Phy. Med. 
Biol. 5, 255 -258, 1961
Table 14-8 Marrow distribution of the adult
SITEMARROW
wt.(g)FRACTION 
RED MARROW 
AGE 40RED MARROW 
wt.(g)
AGE 40%TOTAL RED 
MARROW
CRANIUM 
AND
MANDIBLEHead:
Cranium
Mandible165.8
16.40.75
0.[ZIP_CODE].6
124.3
12.313.1 13.1
HUMERI, 
SCAPULAE, 
CLAVICLESUpper Limb Girdle :
2 Humerus, head & 
neck
2 Scapulae
2 Clavicles26.5
67.4
21.60.75
0.75
0.7586.7
20.0
50.5
16.28.3 8.3
STERNUM AND
RIBSSternum
Ribs:
1pair
2
3
4
5
6
7
8
9
10
11
1239.0
10.2
12.6
16.0
18.6
23.8
23.6
25.0
24.0
21.2
16.0
11.2
4.60.6
All 0.423.4
82.6
4.1
5.0
6.4
7.4
9.5
9.4
10.0
9.6
8.5
6.4
4.5
1.82.3
7.910.2
PELVIC BONESSacrum
2 os coxae194.0
310.60.75
0.[ZIP_CODE].6
233.013.9
22.3 36.2
FEMUR 2 Femoral head
and neck53.0 0.75 40.0 3.8
